primari
immunodefici
diseas
heterogen
group
disord
caus
inherit
defect
immun
system
characteris
wide
spectrum
clinic
manifest
particularli
increas
suscept
infect
predisposit
autoimmun
diseas
malign
recurr
infect
infect
unusu
organ
commonli
present
primari
immunodefici
diseas
although
recurr
respiratori
tract
infect
gastrointestin
manifest
common
featur
diseas
especi
predominantli
antibodi
defici
combin
immunodefici
organ
involv
well
recurr
cutan
abscess
unusu
organ
deep
abscess
may
repres
infect
associ
immunodefici
particularli
phagocyt
defect
meningococc
infect
could
associ
complement
defici
meanwhil
bacteri
infect
mainli
streptococcu
pneumonia
staphylococcu
aureu
well
infect
virus
fungi
parasit
also
common
sever
primari
immunodefici
diseas
autoimmun
diseas
idiopath
thrombocytopen
purpura
autoimmun
haemolyt
anaemia
system
lupu
erythematosu
juvenil
arthriti
scleros
cholang
vascul
common
primari
immunodefici
diseas
whilst
syndrom
immunodefici
eg
wiskott
aldrich
syndrom
di
georg
syndrom
strong
associ
autoimmun
group
disord
eg
alp
apec
ipex
autoimmun
manifest
typic
first
signific
find
malign
also
common
primari
immunodefici
diseas
eg
cvid
alp
xlp
dna
repair
defect
manifest
dysmorph
featur
associ
anomali
skelet
dysplasia
oculocutan
hypopigment
uniqu
characterist
case
primari
immunodefici
diseas
clinic
manifest
diseas
often
help
guid
appropri
evalu
patient
prompt
precis
diagnost
laboratori
evalu
perform
patient
featur
wherea
earli
diagnosi
success
manag
patient
prevent
irrepar
organ
system
damag
improv
prognosi
immunodefici
specialist
europ
compos
multistag
diagnost
protocol
base
expert
opinion
order
increas
awar
pid
among
doctor
work
differ
field
protocol
start
clinic
present
patient
immunolog
skill
need
use
list
relev
symptom
sign
histori
physic
examin
alert
physician
potenti
pid
given
group
togeth
form
eight
typic
clinic
present
pid
recurr
ent
airway
infect
failur
thrive
earli
infanc
recurr
pyogen
infect
unusu
infect
unusu
sever
cours
infect
recurr
infect
type
pathogen
autoimmun
chronic
inflammatori
diseas
lymphoprolifer
characterist
combin
clinic
featur
eponym
syndrom
angioneurot
edema
present
lead
user
toward
differ
algorithm
fact
repres
tradit
divis
antibodi
complement
lymphocyt
phagocyt
defici
respect
algorithm
compris
sever
step
multistag
design
allow
costeffect
screen
pid
within
larg
pool
potenti
case
hospit
earli
phase
expens
test
reserv
definit
classif
collabor
immunologist
later
stage
g
geneva
ch
articl
suggest
male
circumcis
mc
decreas
risk
hiv
infect
appear
next
year
studi
two
epidemiolog
type
ecolog
observ
increasingli
support
content
ecolog
studi
show
strong
correl
preval
mc
hiv
eg
tribe
low
preval
mc
high
preval
hiv
infect
observ
crosssect
studi
show
uncircumcis
men
higher
rate
hiv
circumcis
men
observ
cohort
studi
confirm
weaker
studi
design
find
systemat
review
observ
studi
found
rel
risk
rr
ci
protect
effect
result
three
randomis
control
trial
subsaharan
africa
report
result
consist
pool
rr
ci
ident
observ
studi
protect
effect
three
trial
found
month
followup
extend
one
trial
protect
effect
month
followup
unaid
strongli
endors
mc
effect
hiv
prevent
strategi
generalis
hiv
epidem
mc
uncommon
europ
mc
uncommon
adult
male
preval
hiv
incid
low
enough
mc
hiv
prevent
purpos
unlik
much
impact
public
health
author
recommend
routin
neonat
circumcis
increasingli
howev
data
show
benefit
mc
addit
hiv
prevent
lessen
risk
urinari
tract
infect
infant
rr
ci
lifetim
avoid
phimosi
associ
condit
occur
mc
perform
neonat
benefit
occur
male
circumcis
age
mc
protect
acquir
sexual
transmit
infect
characteris
genit
ulcerssyphili
chancroid
herpesand
possibl
trichomoniasi
circumcis
men
may
less
like
acquir
hpv
like
clear
infect
protect
effect
hpv
mc
halv
risk
penil
cancer
rr
ci
partner
circumcis
men
lessen
risk
cervic
cancer
issu
must
consid
make
public
health
decis
mc
cultur
object
may
occur
mc
develop
world
readili
accept
noncircumcis
societi
studi
sexual
pleasur
function
found
relationship
circumcis
statu
mc
may
advis
subgroup
even
entir
popul
surgic
risk
cost
must
consid
mani
subsaharan
african
countri
scale
mc
servic
prevent
hiv
infect
public
health
agenc
mani
industrialis
countri
reconsid
mc
policiesth
outcom
effort
follow
interest
acut
otiti
media
aom
gener
consid
bacteri
infect
treat
antibiot
howev
despit
extens
use
broadspectrum
antibiot
condit
clinic
respons
treatment
often
poor
fact
togeth
vast
clinic
experi
connect
aom
viral
respiratori
infect
prompt
research
role
virus
aom
date
ampl
evid
studi
rang
anim
experi
larg
clinic
trial
support
crucial
role
respiratori
virus
aetiolog
pathogenesi
aom
case
viral
infect
upper
respiratori
mucosa
initi
whole
cascad
event
final
lead
develop
aom
complic
pathogenesi
aom
involv
complex
interplay
virus
bacteria
host
inflammatori
respons
recent
studi
indic
sensit
techniqu
virus
found
middleear
fluid
children
aom
either
alon
togeth
bacteria
virus
appear
enhanc
inflammatori
process
middl
ear
may
profoundli
impair
resolut
otiti
media
import
understand
howev
increas
knowledg
import
virus
etiopathogenesi
aom
diminish
central
role
bacteria
aom
therefor
virus
may
explain
mani
problem
encount
treat
aom
ultim
decis
whether
treat
aom
antibiot
base
sole
degre
viral
involv
aom
nonjudici
use
antibiot
lead
epidem
antimicrobi
resist
acut
otiti
media
aom
common
indic
use
antibiot
children
unit
state
us
despit
avail
evid
support
wait
see
approach
us
physician
immedi
prescrib
antibiot
treatment
aom
american
academi
pediatr
publish
guidelin
address
diagnosi
treatment
aom
guidelin
recommend
use
observ
potenti
strategi
treatment
aom
key
compon
publish
guidelin
discuss
well
evid
rational
support
use
observ
initi
strategi
treat
aom
otiti
media
om
common
bacteri
infect
children
age
year
antibiot
treatment
prescrib
worldwid
although
time
entiti
resolv
spontan
associ
morbid
famili
dysfunct
antibiot
use
burden
medic
system
effort
reduc
burden
om
vaccin
extrem
reward
progress
made
first
obviou
step
would
reduc
viral
infect
lead
secondarili
om
modern
era
viral
vaccin
proven
effect
aom
influenza
viru
vaccin
inactiv
live
viru
show
effect
sinc
influenza
viru
limit
season
yearli
effect
overal
om
rate
far
remark
haemophilu
influenza
hi
b
vaccin
reduc
om
sinc
hi
caus
om
nontyp
nthi
hib
newli
develop
pneumococc
conjug
vaccin
pcv
shown
reduc
om
caus
serotyp
includ
vaccin
replac
serotyp
includ
vaccin
non
pneumococc
organ
demonstr
reduc
overal
effect
pneumococc
vaccin
effect
pcv
reduct
recurr
om
om
effus
need
ventil
tube
frequent
visit
aom
suggest
real
impact
still
studi
aim
pcv
establish
recurr
om
prove
disappoint
pcv
reduc
om
caus
antibioticresist
pneumonia
continu
overus
antibiot
respons
increas
antibiot
resist
nonvaccin
serotyp
newli
develop
pcv
outer
membran
protein
hi
pnpd
suggest
reduc
also
om
caus
hi
confirm
studi
need
expans
serotyp
includ
current
licens
pcv
serotyp
may
add
prevent
om
near
futur
next
decad
om
continu
import
diseas
children
howev
expect
modifi
term
bacteriolog
aetiolog
antibiot
resist
hope
short
long
term
consequ
v
istanbul
tr
infecti
consequ
earthquak
mainli
involv
sever
type
communic
diseas
crush
relat
infect
waterborn
foodborn
ill
often
result
disrupt
public
water
sewag
system
contamin
water
suppli
overcrowd
poor
hygien
sanit
temporari
shelter
also
may
factor
type
infecti
diseas
associ
epidemiolog
communic
diseas
area
earthquak
occur
common
outbreak
associ
earthquak
gastroenter
infecti
hepat
pulmonari
infect
unvaccin
popul
report
increas
measl
tetanu
seen
popul
vaccin
coverag
level
low
risk
diarrhoeal
diseas
outbreak
follow
earthquak
higher
develop
countri
industrialis
countri
outbreak
acut
wateri
diarrhoea
involv
case
occur
camp
earthquak
pakistan
acut
respiratori
infect
hepat
e
cluster
measl
clinic
case
month
also
occur
among
displac
victim
earthquak
contamin
drink
water
led
outbreak
rotaviru
earthquak
kashmir
india
unusu
outbreak
coccidiomycosi
associ
exposur
increas
level
airborn
dust
occur
southern
california
earthquak
person
trap
rubbl
sever
hour
day
may
develop
compart
syndrom
requir
fasciotomi
amput
infecti
complic
common
renal
victim
marmara
earthquak
turkey
associ
increas
mortal
complic
sepsi
renal
victim
infecti
complic
mainli
sepsi
wound
infect
infect
nosocomi
origin
caus
gramneg
aerob
bacteria
staphylococcu
spp
multivari
analysi
riskfactor
nosocomi
infect
reveal
signific
associ
fasciotomi
length
hospit
stay
back
univers
hospit
frequent
pathogen
isol
pu
andor
wound
cultur
wenchuan
earthquak
survivor
aureu
e
coli
baumannii
e
cloaca
p
aeruginosa
disasterprepared
plan
focus
trauma
mass
casualti
manag
also
health
need
surviv
affect
popul
may
decreas
health
impact
earthquak
infect
disast
set
famin
experi
darfour
sudan
clinic
malnutrit
known
risk
factor
id
worldwid
subsaharan
africa
india
higher
risk
due
vegetarian
habit
absolut
absenc
anim
meat
protein
result
deplet
micronutriti
zinc
iron
selenium
respons
recoveri
postmalari
anaemia
addit
deplet
protein
result
immunoglobulinaemia
delay
respons
mani
bacteri
pathogen
caus
id
topic
pneumococci
salmonella
etc
third
problem
absenc
vitamin
dissolv
oil
fat
result
delay
phagocyt
activ
therefor
proteinocalor
malnutrit
result
signific
advers
outcom
hiv
tb
diarrhoea
pneumonia
major
killer
children
five
st
elizabeth
univers
tropic
programm
run
antimalnutrit
centr
sudan
darfour
kenya
amaong
upcountri
refuge
major
conflict
area
sudan
turrana
border
uganda
tri
rehabilit
malnourish
children
help
combat
diseas
respons
million
death
children
mean
year
malaria
mil
tb
mil
hiv
mil
pneumonia
mil
diarrhoea
mil
children
death
approxim
year
h
athen
gr
last
six
year
greec
face
larg
number
infect
mainli
intens
care
unit
icu
due
carbapenemsresist
klebsiella
pneumonia
proport
imipenemresist
k
pneumonia
increas
less
isol
hospit
ward
isol
icu
likewis
strain
identifi
three
hospit
wherea
isol
least
hospit
particip
greek
surveil
system
situat
due
spread
cassett
among
rapidli
evolv
multiresist
plasmid
multiresist
even
panresist
strain
mainli
k
pneumonia
also
enterobacteri
speci
howev
fact
strain
display
mic
valu
near
clsi
resist
breakpoint
creat
diagnost
therapeut
problem
possibl
obstruct
assess
real
incid
strain
emerg
kpcproduc
k
pneumonia
note
icu
greek
hospit
spread
hospit
throughout
countri
creat
countywid
outbreak
attikon
univers
hospit
recent
describ
icu
outbreak
kpcproduc
k
pneumonia
twentynin
patient
admit
februari
decemb
colonis
mainli
gi
tract
fifteen
patient
male
median
apach
ii
patient
alreadi
long
hospit
stay
preced
icu
admiss
median
day
twentytwo
patient
kpcproduc
k
pneumonia
colonis
definit
icuacquir
acquisit
ward
hospit
hypothes
five
patient
still
hospitalis
icu
remain
die
icu
mortal
ten
colonis
patient
clinic
infect
fifteen
infect
document
mostli
bsi
follow
vap
ssi
patient
die
infect
evidencebas
consensu
therapeut
strategi
infect
reach
keelpno
greek
ministri
health
propos
use
high
dose
meropenem
gday
combin
activ
aminoglycosid
colistin
strain
mic
mgml
wherea
strain
higher
mic
use
carbapenem
contraind
activ
altern
monotherapi
tigecyclin
colistin
aminoglycosid
aztreonambas
combin
could
use
antibiot
stewardship
great
import
dismal
situat
stringent
adher
infect
control
measur
probabl
even
greater
import
effect
contain
pandrugresist
strain
present
clostridium
difficil
infect
cdi
vari
mild
diarrhoea
potenti
fatal
pseudomembran
coliti
recent
emerg
type
c
difficil
associ
increas
virul
c
difficil
take
advantag
disrupt
normal
intestin
flora
caus
antibiot
therapi
antibiot
class
antimicrobi
resist
pattern
c
difficil
influenc
develop
diseas
netherland
significantli
patient
cdi
due
type
use
fluoroquinolon
ci
compar
infect
pcr
ribotyp
similar
type
cdi
patient
infect
type
also
frequent
receiv
fluoroquinolon
therapi
risk
develop
cdi
due
type
particularli
high
person
receiv
combin
cephalosporin
fluoroquinolon
associ
also
strongli
depend
durat
therapi
use
clindamycin
found
protect
factor
howev
recent
detect
clindamycinresist
c
difficil
type
strain
european
countri
import
worri
develop
sinc
associ
cdi
fluoroquinolon
investig
patient
level
studi
perform
investig
relationship
cdi
incid
preced
use
differ
antibiot
class
hospit
level
netherland
comparison
made
hospit
type
caus
epidem
hospit
isol
case
type
observ
hospit
outbreak
cdi
type
encount
preepidem
period
total
use
antibiot
compar
affect
unaffect
hospit
higher
use
secondgener
cephalosporin
macrolid
studi
antibiot
independ
associ
small
increas
cdi
incid
effect
small
predict
hospit
might
prone
outbreak
despit
fact
netherland
known
restrict
conserv
use
antibiot
outbreak
cdi
due
new
emerg
type
recogn
probabl
associ
use
antibiot
patient
level
hospit
depart
level
rather
use
antibiot
level
healthcar
institut
peiffer
j
bulitta
ha
haeberl
kinzigschipp
rodam
v
jakob
b
f
wa
trier
de
albani
us
tubingen
nuremberg
constanc
de
piperacillintazobactam
piptazo
broad
spectrum
antibiot
use
treatment
sever
infect
ventilatorassoci
pneumonia
vap
effect
betalactam
best
predict
durat
free
drug
concentr
minim
inhibitori
concentr
mic
infect
pathogen
anim
experi
suggest
mic
reach
continu
infus
ci
piptazo
may
enhanc
therapeut
perform
littl
data
pharmacokineticdynam
pkpd
paramet
ci
use
critic
ill
patient
object
aim
studi
determin
concentr
piptazo
plasma
bronchoalveolar
epitheli
line
fluid
elf
steadi
state
ci
base
result
penetr
ratio
plasmaelf
pkpd
paramet
piptazo
deriv
method
approv
ethic
committe
mechan
ventil
critic
ill
patient
enrol
treatment
intens
care
unit
patient
receiv
load
dose
g
piptazo
follow
ci
g
h
steadi
state
h
load
dose
total
blood
sampl
drawn
bronchoalveolar
lavag
bal
simultan
perform
case
sampl
discard
technic
reason
sampl
store
analysi
liquid
chromatographi
coupl
massspectrometri
lcm
elfconcentr
calcul
balsampl
use
relat
ureaplasma
ureab
dilut
factor
result
plasma
concentr
pip
tazo
n
pt
amount
mgml
mgml
respect
elflevel
n
mgml
mgml
elflevel
correspond
plasma
level
n
pip
tazo
respect
ratio
pip
tazo
plasma
elf
conclus
use
advanc
analyt
techniqu
elf
concentr
higher
compar
tradit
bolu
administr
ci
yield
steadi
state
plasma
concentr
excess
mic
suscept
bacteria
mgml
accord
eucast
measur
respect
elf
level
exceed
mgml
case
taken
togeth
data
provid
argument
ci
prefer
mode
administr
piptazo
critic
ill
patient
suspect
vap
object
staphylococcu
aureu
potenti
pathogen
microorgan
caus
agent
infect
intens
care
patient
optim
empir
choic
treatment
infect
result
reduct
morbid
mortal
therefor
essenti
provid
clinician
resist
data
bacteri
popul
treat
optimis
empir
choic
monitor
emerg
microbi
resist
nation
surveil
program
swab
start
netherland
studi
describ
result
resist
develop
aureu
icu
hospit
netherland
ten
year
period
method
first
month
year
particip
hospit
collect
clinic
isol
among
other
blood
respiratori
sampl
total
isol
collect
hospit
north
east
five
west
four
south
antimicrobi
suscept
determin
micro
broth
dilut
method
accord
clsi
guidelin
result
increas
resist
ciprofloxacin
observ
drop
resist
moxifloxacin
rather
constant
time
ie
resist
found
resist
clarithromycin
increas
decreas
level
resist
penicillin
clindamycin
tetracyclin
fluctuat
time
respect
studi
period
seven
methicillin
resist
aureu
isol
resist
vancomycin
teicoplanin
linezolid
observ
resist
gentamicin
rifampicin
sporadicli
found
region
differ
observ
ciprofloxacin
highest
western
southern
part
tetracyclin
lowest
northern
part
conclus
year
studi
period
increas
resist
ciprofloxacin
observ
data
present
justifi
empir
choic
flucloxacillin
rifampicin
gentamicin
depend
indic
case
infect
icu
patient
probabl
caus
aureu
jj
pr
hsueh
sy
lee
taichung
taipei
tw
object
investig
preval
visa
hospitalis
patient
mrsa
infect
colonis
teach
hospit
taiwan
evalu
possibl
clonal
spread
visa
hospit
method
septemb
august
consecut
mrsa
isol
collect
variou
clinic
specimen
patient
hospitalis
teach
hospit
taiwan
minimum
inhibitori
concentr
mic
vancomycin
mrsa
isol
determin
broth
microdilut
method
accord
clsi
guidelin
molecular
characterist
antimicrobi
suscept
visa
isol
investig
pulsedfield
gel
electrophoresi
use
evalu
clonal
isol
result
among
mrsa
isol
visa
visa
isol
vancomycin
mic
microgramml
vancomycin
mic
microgramml
isol
inhibit
tigecyclin
microgramml
linezolid
microgramml
ceftobiprol
microgramml
five
isol
reduc
suscept
daptomycin
mic
microgramml
six
visa
isol
decreas
suscept
autolysi
triton
visa
isol
recov
patient
patient
receiv
glycopeptid
treatment
prior
isol
visa
five
patient
die
despit
vancomycin
therapi
visa
isol
carri
sccmec
type
iii
agr
group
neg
pvl
gene
lukslukf
none
enterococc
van
gene
detect
visa
isol
result
pfge
analysi
reveal
one
major
clone
visa
isol
clone
exhibit
sccmec
type
iii
agr
group
absenc
pvl
gene
dissemin
hospit
conclus
retrospect
studi
demonstr
clonal
dissemin
visa
occur
hospit
rapid
correct
detect
visa
proper
use
antibiot
effect
approach
prevent
emerg
spread
x
c
qi
oleari
arrieta
shulman
chicago
us
object
vancomycin
remain
one
major
option
treat
methicillinresist
aureu
mrsa
relat
infect
studi
shown
increas
preval
mrsa
isol
elev
vancomycin
mic
valu
among
recent
clinic
isol
call
mic
creep
although
still
within
suscept
rang
higher
mic
may
associ
increas
chanc
treatment
failur
conflict
report
lack
publish
data
paediatr
patient
sought
assess
possibl
mic
chang
time
compar
result
gener
use
differ
methodolog
includ
etest
agar
dilut
broth
microdilut
microscan
method
method
studi
mrsa
isol
predominantli
commun
acquir
includ
blood
normal
steril
site
isol
collect
larg
children
hospit
molecular
bacteriolog
genom
sequenc
virul
methicillinsensit
staphylococcu
aureu
clinic
isol
encod
pantonvalentin
leukocidin
toxin
l
faraj
la
snyder
nj
loman
dp
turner
mj
pallen
alaaldeen
r
nottingham
birmingham
uk
object
determin
genom
sequenc
virul
meticillinsensit
staphylococcu
aureu
mssa
clinic
isol
method
roch
sequenc
determin
genom
sequenc
clinic
isol
time
coverag
newbler
sequenc
assembl
roch
gener
scaffold
annot
use
gendb
compar
aureu
genom
sequenc
result
asian
girl
present
fever
histori
knee
pain
follow
trivial
fall
mr
scan
reveal
larg
subperiost
abscess
around
upper
tibia
secondari
metaphys
osteomyel
pvlposit
mssa
isol
blood
cultur
pu
child
deterior
requir
repeat
debrid
develop
septic
shock
investig
reveal
aortic
valv
endocard
aortic
root
abscess
whole
genom
sequenc
reveal
first
sequenc
aureu
isol
determin
agr
type
iii
carri
three
code
region
found
aureu
genom
sequenc
amongst
uniqu
gene
present
region
dihydrofol
reductas
gene
dfrg
present
addit
usual
dfrb
gene
downstream
orfx
gene
kb
remnant
sccmec
type
ivc
found
sequenc
previous
found
genom
sequenc
locat
orfx
sccmec
type
ii
sequenc
uniqu
share
genom
region
aureu
strain
caus
agent
contagi
bovin
mastiti
one
genom
region
also
present
conclus
comparison
genom
sequenc
close
relat
hamrsa
isol
reveal
new
insight
evolut
camrsa
hamrsa
isol
link
aureu
pvlencod
mssa
strain
signific
pathogen
current
mandatori
surveil
uk
cost
whole
genom
sequenc
fall
becom
feasibl
use
technolog
monitor
evolut
mssa
mrsa
healthcar
set
reveal
clinic
relev
inform
help
improv
patient
outcom
object
camrsa
often
produc
pantonvalentin
leukocidin
pvl
leukocidin
encod
two
cotranscrib
gene
locat
lysogenis
phage
five
pvlencod
phage
describ
aureu
phipvl
phislt
singl
nucleotid
polymorph
snp
pvl
gene
tend
vari
lineag
may
structur
function
implic
examin
select
pvlposit
camrsa
report
hospit
determin
whether
sequenc
variat
pvlencod
phage
vari
lineag
method
twentytwo
pvlposit
isol
chosen
reflect
mlst
clonal
complex
identifi
hospit
isol
characteris
antimicrobi
resist
profil
sccmec
spa
type
pulsedfield
gel
electrophoresi
pfge
profil
multilocu
sequenc
type
mlst
oligonuleotid
array
clondiag
arraytub
use
detect
rang
toxin
antimicrobi
resist
gene
primer
design
amplifi
sequenc
luksfpv
gene
pvlencod
phage
characteris
use
recent
describ
pcrbase
assay
et
al
j
clin
microbiol
result
snp
identifi
seven
posit
luksfpv
gene
snp
profil
vari
lineag
three
snp
code
mutat
may
structur
function
implic
isol
found
carri
pvlencod
phage
definit
identifi
lineag
although
isol
carri
phage
isol
carri
elong
headtyp
phage
one
isol
unexpect
snp
pattern
compar
isol
isol
also
carri
novel
variant
phage
conclus
pvl
gene
sequenc
pvlencod
phage
vari
lineag
pvlposit
camrsa
isol
suggest
certain
lineag
suscept
infect
lysogeni
certain
phage
type
although
camrsa
commonli
carri
pvl
gene
strain
possibl
pvlneg
type
resist
infect
pvlencod
phage
perhap
via
restrict
modif
system
crucial
find
suggest
pvl
gene
coevolv
phage
freeli
transmit
differ
phage
work
requir
characteris
pvlencod
phage
isol
investig
whether
pvl
sequenc
variant
result
biolog
differ
object
communityassoci
mrsa
camrsa
mani
differ
mlst
clonal
complex
cc
harbour
lysogenis
bacteriophag
dna
prophag
encod
pantonvalentin
leukocidin
pvl
five
pvl
phage
phipvl
phislt
report
date
sought
determin
distribut
chromosom
integr
copi
lysogenis
pvlphage
amongst
domin
clone
pvl
mrsa
england
wale
method
seventi
isol
previous
characteris
pvlmrsa
analys
pcr
develop
et
al
jcm
identifi
discrimin
five
known
pvl
phage
maximis
underli
divers
repres
cc
select
base
upon
spa
staphylococc
cassett
chromosom
mec
sccmec
toxin
gene
pulsedfield
gel
electrophoresi
pfge
profil
includ
isol
intern
dissemin
pvlmrsa
lineag
cc
resembl
south
west
pacif
swp
european
clone
respect
addit
analys
pvlmrsa
cc
result
seven
isol
includ
repres
european
clone
possess
elongatedheadtyp
phage
posit
pcr
specif
phage
one
isol
possess
phage
four
swp
repres
elong
head
type
phage
whilst
remain
four
isol
harbour
icosahedralheadtyp
phage
one
posit
head
shape
includ
repres
eight
six
isol
isol
posit
elongatedheadtyp
phage
nine
isol
nontyp
phage
head
shape
specif
phage
pcr
three
four
isol
harbour
phage
unknown
head
type
isol
nontyp
isol
possess
icosahedralheadtyp
phage
posit
phipvl
phage
type
one
possess
type
determin
pvl
phage
present
divers
panel
distinct
pvlmrsa
clone
found
consider
interlineag
variat
pvl
prophag
present
also
evid
intra
lineag
variat
major
cc
cc
togeth
variat
mlst
cc
sccmec
data
suggest
pvlmrsa
evolv
multipl
occas
sometim
within
lineag
transcript
profil
klebsiella
pneumonia
gene
control
transcript
factor
rama
object
rama
aracxyl
famili
transcript
activ
express
associ
multidrug
resist
phenotyp
multidrug
resist
klebsiella
salmonella
isol
rama
gene
associ
increas
express
acrab
efflux
pump
salmonella
shown
delet
rama
locu
prevent
emerg
multidrug
resist
mutant
therefor
order
understand
role
key
regul
emerg
develop
antibiot
resist
transcriptom
analys
regulon
undertaken
k
pneumonia
method
rna
extract
combin
isogen
mutant
clinic
isol
use
qiagen
ribopur
kit
rna
integr
assess
use
nanodrop
agil
nanochip
system
rna
transcrib
doubl
strand
cdna
prior
label
cdna
hybridis
nimblegen
express
array
platform
design
k
pneumonia
mgh
genom
result
approxim
gene
found
affect
rama
express
twenti
involv
metabol
physiolog
transcript
drug
efflux
protect
respons
cell
envelop
confirm
rtpcr
rama
protein
appear
affect
drug
efflux
operon
previous
shown
associ
multidrug
resist
affect
similar
protein
mara
compar
transcriptom
analys
differ
k
pneumonia
clinic
isol
overexpress
rama
show
variat
exist
level
express
drug
efflux
gene
note
gene
shown
directli
regul
rama
marboxlik
sequenc
within
promot
sequenc
conclus
studi
transcriptom
regulatori
protein
rama
determin
pathogen
k
pneumonia
drug
efflux
protein
previous
associ
rama
overexpress
found
directli
affect
rama
regulon
overlap
mara
sox
regulon
e
coli
salmonella
directli
associ
regul
express
subset
gene
via
marbox
sequenc
interestingli
variat
level
express
regulon
gene
found
differ
rama
overexpress
strain
c
crowder
h
li
h
matthew
meng
sefer
r
sampath
c
stratton
ecker
yw
tang
carlsbad
nashvil
us
object
potenti
fatal
outcom
tickborn
human
infect
ehrlichiosi
emphas
need
rapid
diagnosi
develop
valid
ibi
assay
ibi
bioscienc
inc
carlsbad
ca
detect
identifi
wide
rang
tickborn
pathogen
clinic
sampl
method
multilocu
assay
use
employ
broadrang
pcr
primer
pair
target
known
bacteri
tickborn
pathogen
famili
electrospray
ionis
mass
spectrometri
pcr
amplicon
use
determin
base
composit
base
composit
signatur
subsequ
use
identifi
organ
found
sampl
assay
develop
use
field
collect
tick
wide
rang
clinic
sampl
type
shown
sensit
stochast
limit
pcr
result
whole
blood
cerebrospin
fluid
plasma
sampl
origin
submit
ehrlichia
speci
detect
colorimetr
microtit
plate
pcr
pcreia
collect
consecut
januari
august
vanderbilt
univers
hospit
among
total
specimen
pcreia
detect
ehrlichia
speci
posit
rate
ibi
system
detect
ehrlichia
pcreiaposit
sampl
pcreianeg
specimen
give
sensit
specif
respect
ibi
system
characteris
ehrlichiadu
posit
specimen
speci
level
e
cheffeensi
e
ewingii
agreement
identifi
pcreia
use
addit
speciesspecif
probe
addit
demonstr
detect
borrelia
burgdorferi
blood
skin
patient
lyme
diseas
conclus
demonstr
broadrang
detect
tickborn
pathogen
singl
assay
use
skin
whole
blood
plasma
skin
csf
addit
ehrlichia
ibi
system
detect
rickettsia
rickettsii
posit
specimen
confirm
serolog
clinic
find
ibi
system
complet
within
five
hour
specimen
process
result
report
provid
rapid
accur
detect
identif
broad
rang
pathogen
caus
tickborn
human
infect
r
l
blyn
r
ranken
c
massir
hall
eshoo
r
lovari
h
matthew
toleno
r
housley
hofstadl
ecker
carlsbad
us
object
investig
use
novel
platformbas
approach
rapid
characteris
hai
organ
pathogen
caus
healthcareassoci
infect
hai
pose
ongo
increas
challeng
hospit
clinic
treatment
prevent
crosstransmiss
problemat
pathogen
describ
util
pcr
electrospray
ioniz
mass
spectrometri
pcresim
detect
platform
innov
rapid
approach
detect
complet
characteris
import
hai
pathogen
method
develop
pcresim
base
method
rapidli
identifi
characteris
mrsa
vre
c
difficil
strain
p
aeruginosa
baumannii
target
organ
analyz
use
independ
assay
run
platform
provid
speci
strain
id
virul
factor
antibiot
resist
genotyp
appropri
valid
studi
perform
use
retrospect
wellcharacteris
clinic
isol
organ
follow
prospect
studi
one
organ
mrsa
includ
screen
clinic
specimen
nare
swab
patient
admit
medic
unit
high
preval
mrsa
clinic
infect
result
five
hai
organ
pcresim
speci
identif
compar
gold
standard
test
result
clinic
microbiolog
laboratori
show
concord
aureu
p
aeruginosa
baumannii
molecular
genotyp
pcresim
compar
puls
field
gel
electrophoresi
pfge
cluster
show
concord
characteris
virul
andor
drug
resist
perform
mrsa
vre
c
difficil
show
correct
detect
compar
exist
test
method
analysi
clinic
specimen
mrsa
show
swab
contain
mrsa
either
singli
dual
infect
con
mssa
contain
meca
coagulas
neg
staphylococcu
mrcon
comparison
gold
standard
analysi
show
sensit
mrsa
detect
specif
ppv
npv
pcresim
technolog
high
throughput
assay
system
use
infect
control
epidemiolog
studi
capabl
simultan
identif
hai
organ
detect
presenc
key
phenotyp
marker
genotyp
strain
characteris
j
ossel
j
keijden
g
simon
maastricht
nl
object
molecular
diagnost
play
increasingli
import
role
detect
infecti
agent
cerebrospin
fluid
howev
grow
list
target
rel
small
sampl
volum
challeng
demand
improv
molecular
diagnost
approach
meningofind
multifind
assay
allow
simultan
detect
virus
intern
control
reaction
analysi
multifind
assay
base
sizefraction
identifi
multifind
probe
due
specif
length
present
altern
approach
allow
realtim
detect
eight
meningofind
probe
singl
tube
realtim
detect
enabl
faster
analysi
less
handl
lower
risk
contamin
method
meningofind
assay
multifind
assay
detect
herp
simplex
viru
human
parechoviru
hpev
cytomegaloviru
cmv
epsteinbarr
viru
ebv
enteroviru
ev
varicellazost
viru
vzv
plu
intern
control
singl
reaction
meningofind
probe
distinguish
base
upon
specif
length
probe
sizefraction
use
gel
capillari
electrophoresi
develop
altern
detect
method
use
fluoresc
label
probe
allow
specif
identif
multifind
probe
realtim
pcr
machin
result
larg
number
qcmd
sampl
n
sever
enteroviru
type
n
characteris
clinic
sampl
n
analyz
use
meningofind
meningofind
reaction
analyz
capillari
electrophoresi
fluoresc
label
probe
realtim
pcr
machin
result
meningofind
show
good
correl
expect
result
furthermor
result
meningofind
analys
show
high
degre
correl
realtim
detect
meningofind
probe
decreas
analysi
time
post
pcr
handl
dramat
develop
new
assay
realtim
detect
meningofind
probe
realtim
analysi
show
good
correl
convent
capillari
electrophoresi
analysi
addit
realtim
detect
reduc
contamin
risk
patient
result
becam
avail
quickli
combin
multifind
technolog
combin
realtim
detect
show
great
potenti
fast
easi
multiparamet
screen
clinic
sampl
infecti
pathogen
inhous
naat
appli
nucleic
acid
extract
obtain
inhous
methodolog
centr
result
sensit
detect
respiratori
virus
commerci
mx
naat
inhous
mw
naat
mono
inhous
naat
viral
load
low
time
falseneg
result
obtain
fals
posit
result
obtain
method
use
result
specif
rang
atyp
bacteria
multiplex
naat
fail
detect
low
l
pneumophila
posit
sampl
low
pneumonia
posit
sampl
result
sensit
compar
inhous
mono
naat
commerci
mx
naat
also
fail
detect
strong
posit
sampl
fals
posit
result
obtain
atyp
bacteria
revisit
phage
therapi
problemat
pathogen
past
feed
futur
dherel
modern
phagotherapi
increas
antibiot
resist
problem
boost
interest
altern
treatment
infect
promin
exampl
socal
phagotherapi
make
use
bacteri
virus
bacteriophag
drug
bacteri
agent
bacteriophag
isol
natur
characteris
test
bacteri
strain
target
theori
approach
sever
advantag
instanc
bacteriophag
infect
rule
bacteri
prey
specif
therefor
harm
commens
bacteria
patient
addit
bacteri
strain
becom
resist
certain
bacteriophag
strain
evolut
provid
new
activ
bacteriophag
strain
practic
phagotherapi
use
long
time
alreadi
one
two
discover
bacteriophag
dherel
ardent
advoc
method
fact
first
use
bacteriophag
infect
bacteri
diarrhoea
shigella
spp
phagotherapi
use
quit
extent
europ
us
part
world
penicillin
enter
market
part
former
soviet
union
eastern
bloc
method
utilis
today
sever
compani
univers
research
develop
bacteriophag
therapeut
purpos
histor
document
relat
phagotherapi
oral
histori
reveal
fascin
past
bacteriophag
employ
wide
varieti
bacteri
diseas
time
virtual
antiinfect
exampl
india
million
cholera
patient
treat
bacteriophag
anticholera
phage
also
pour
drink
well
prophylact
bacteri
virus
also
utilis
german
soviet
armi
second
world
war
histori
phagotherapi
make
excit
stori
howev
analysi
old
literatur
help
identifi
import
factor
success
failur
especi
relev
field
hold
promis
limit
fund
dispos
past
year
therefor
make
rather
slow
progress
addit
examin
strategi
use
phagotherapi
soviet
union
poland
also
contribut
better
applic
method
today
discoveri
bacteriophag
particularli
abil
replic
lyse
pathogen
bacteria
may
among
import
mileston
histori
biomed
scienc
preantibiot
era
earli
centuri
phage
therapi
becom
power
weapon
infecti
diseas
bacteri
aetiolog
unfortun
phage
treatment
research
larg
forgotten
western
world
antibiot
becam
wide
avail
nowaday
rapid
propag
multidrug
resist
bacteri
strain
lead
renew
interest
phage
therapi
contrast
declin
west
phage
therapi
remain
standard
part
healthcar
system
eastern
europ
ussr
second
half
centuri
phage
prepar
use
diagnost
therapeut
prophylact
purpos
combat
variou
bacteri
infect
eliava
institut
bacteriophag
microbiolog
virolog
tbilisi
georgia
perhap
famou
institut
world
focus
studi
bacteriophag
particularli
isol
select
phage
activ
variou
bacteri
pathogen
phage
isol
bacteri
strain
receiv
former
ussr
socialist
east
european
countri
consequ
huge
collect
phage
pathogen
bacteri
strain
construct
institut
thousand
peopl
treat
individu
phage
phage
mixtur
soviet
era
prepar
develop
tbilisi
studi
extens
preclin
clinic
trial
howev
littl
inform
ever
publish
even
detail
avail
trial
report
meet
intern
approv
regul
standard
bacteriophag
number
advantag
comparison
antibiot
phage
therapi
altern
approach
treatment
infect
becom
evid
promis
remedi
today
mani
peopl
variou
part
world
express
willing
take
phage
treatment
differ
infect
includ
caus
antibioticresist
bacteri
pathogen
eliava
institut
elabor
new
phagebas
product
technolog
scheme
product
strong
collabor
medic
commun
design
clinic
trial
accord
intern
standard
absolut
critic
support
broader
implement
phage
therapi
australian
male
age
year
die
intracerebr
haemorrhag
ten
day
return
trip
rural
yugoslavia
kidney
liver
donat
three
femal
recipi
age
year
kidney
year
kidney
year
liver
four
five
week
organ
donat
three
recipi
die
febril
ill
alter
mental
statu
subsequ
test
postmortem
tissu
recipi
identifi
novel
arenaviru
relat
lymphocyct
choriomening
viru
lcmv
viral
detect
process
involv
use
highthroughput
sequenc
techniqu
identifi
novel
microbi
rna
sequenc
confirmatori
test
perform
use
techniqu
revers
transcriptasepolymeras
chain
reaction
immunohistochem
analysi
arenaviru
antigen
immunofluoresc
test
igg
igm
antibodi
clinic
featur
four
patient
well
similar
problem
transplantrel
ill
classic
lcmv
discuss
well
detail
laboratori
identif
new
viru
implic
organ
transplant
protocol
futur
success
manag
invas
fungal
infect
depend
time
correct
treatment
last
decad
number
new
test
becom
avail
improv
diagnost
option
contrast
scenario
bacteri
infect
acquir
resist
fungi
rare
thu
speci
identif
valuabl
tool
guid
choic
treatment
therefor
microscopi
cultur
still
corner
stone
diagnosi
cultur
identif
time
consum
app
day
respect
sensit
speed
microscopi
improv
use
fluoresc
brighten
calcofluor
white
blankophor
recent
develop
pna
probe
specif
number
candida
spp
speci
identif
becom
possibl
directli
posit
blood
cultur
subcultur
agar
media
chromogen
agar
allow
presumpt
identif
sever
candida
spp
facilit
recognit
yeast
isol
sampl
contain
sever
yeast
yeast
bacteria
combin
use
plate
shown
lead
better
identif
mix
cultur
recent
nordic
eqa
scheme
includ
laboratori
rapid
speci
identif
import
candida
spp
possibl
routin
laboratori
use
easi
commerci
avail
kit
thu
speci
identif
c
albican
c
dubliniensi
c
krusei
obtain
within
minut
use
latex
agglutin
kit
bichrodubl
kruseicolor
fumouz
diagnost
c
glabrata
rapidli
identifi
due
high
amount
preform
intracellular
trehalas
enzym
glabrata
rtt
fumouz
diagnost
final
pna
probe
fluoresc
microscopi
also
use
day
identif
rang
clinic
relev
candida
spp
advandx
suscept
test
possibl
use
etest
result
compar
obtain
refer
methodolog
head
head
comparison
howev
recent
data
eqa
distribut
suggest
detect
isol
acquir
resist
caus
mani
laboratori
difficulti
illustr
critic
number
isol
test
per
technician
per
week
qualiti
control
strain
includ
regular
basi
conclus
number
new
diagnost
test
becom
avail
last
decad
diagnost
laboratori
encourag
take
advantag
new
option
eccmid
oral
present
sinc
introduct
newer
antifung
differ
vitro
spectra
aetiolog
invas
fungal
infect
ifi
becom
major
diagnost
issu
prerequisit
guid
antifung
therapi
molecular
method
pcr
sequenc
diagnosi
ifi
evalu
specimen
blood
bronchoalveolar
lavag
fluid
year
less
studi
biopsi
characterist
inher
molecular
method
eg
sensit
specif
short
turnaround
time
make
promis
adjunct
convent
diagnost
test
eg
cultur
histopatholog
organ
biopsi
studi
use
tissu
anim
model
mould
infect
suggest
pcr
might
sensit
cultur
allow
better
speci
identif
histopatholog
howev
studi
use
assay
detect
small
rang
agent
even
singl
organ
may
increas
sensit
assay
reduc
likelihood
contamin
limit
use
clinic
set
given
broad
rang
potenti
fungal
pathogen
studi
use
fresh
clinic
sampl
suggest
detect
identif
wide
rang
fungi
possibl
use
broad
rang
assay
combin
sequenc
combin
specif
pcr
assay
studi
need
optimis
dna
extract
defin
best
molecular
target
best
method
amplicon
detect
prevent
contamin
due
ubiquit
fungi
unspecif
amplif
major
problem
especi
use
broad
rang
assay
contrast
fish
probe
may
potenti
specif
pcr
due
visualis
fungal
element
tissu
contrast
pcr
appear
work
well
formalin
fix
specimen
speci
identif
might
challeng
pcr
sequenc
direct
comparison
fish
pcr
need
characteris
pro
con
method
determin
aetiolog
ifi
molecular
tissu
diagnosi
potenti
evolv
use
method
describ
aetiolog
ifi
even
cultur
neg
sampl
result
might
obtain
fast
enough
guid
antifung
therapi
patient
ifi
progress
empir
antifung
therapi
patient
risk
associ
invas
tissu
sampl
might
outweigh
potenti
benefit
guid
antifung
therapi
two
group
carbapenemas
serin
carbapenemas
metallobetalactamas
mbl
encod
gene
carri
plasmid
serin
carbapenemas
distinctli
either
class
oxa
class
latter
mainli
associ
acinetobact
spp
domin
mbl
subgroup
vim
imp
gene
reportedli
carri
plasmid
chromosom
recent
evid
shown
major
even
initi
report
inde
plasmid
mediat
probabl
account
rapid
dissemin
gene
recent
shown
carri
incn
incw
plasmid
brazilian
mbl
gene
exclus
chromosom
encod
mbl
chromosom
encod
wherea
encod
plasmid
approx
kb
recent
describ
gene
also
carri
plasmid
kb
hitherto
two
mblposit
plasmid
sequenc
avail
thu
far
carri
former
carri
resist
gene
approx
kb
wherea
latter
small
plasmid
kb
show
similar
incp
plasmid
oxa
carbapenemas
gene
shown
plasmid
chromosom
mediat
thu
far
cluster
plasmid
chromosom
mainli
found
acinetobact
spp
cluster
found
k
pneumonia
acinetobact
spp
respect
plasmid
mediat
shown
carri
kb
kb
plasmid
respect
plasmid
recent
sequenc
shown
carri
two
differ
replicas
class
carbapenemas
gene
blakpc
blage
carri
plasmid
blakpc
found
mainli
k
pneumonia
carri
plasmid
vari
size
kb
mostli
possess
origin
replic
incn
howev
recent
describ
pseudomona
chromosom
mediat
exclus
usa
carri
kb
plasmid
although
chromosom
blage
gene
found
p
aeruginosa
enterobacteriacea
shown
plasmid
mediat
although
littl
els
known
lectur
provid
synopsi
discuss
evolut
resist
due
plasmid
briefli
predict
may
face
respect
carbapenemas
resist
nosocomi
infect
caus
multidrugresist
pathogen
especi
gramneg
bacilli
becom
seriou
clinic
concern
everi
healthcar
set
worldwid
well
carpapenemhydrolys
metalloblactamas
ctxmtype
blactamas
qunoloneresist
genet
determin
qnr
aac
ibcr
qepa
plasmidmedi
novel
molecular
mechan
rmta
rmtb
rmtc
rmtd
arma
npma
respons
panresist
aminoglycosid
recent
identifi
pseudomona
aeruginosa
acinetobact
spp
serratia
marcescen
esherichia
coli
klebsiella
pneumonia
proteu
mirabili
etc
sinc
enzym
inde
methyl
activ
asit
bacteri
rrna
found
aminoglycosideproduc
actinomycet
plasmidmedi
rrna
methylas
specul
origin
nonpathogen
environment
microb
produc
aminoglycosid
similar
compound
quit
natur
sever
new
enzym
would
identifi
hereaft
clinic
livestock
farm
environ
rmtb
arma
wide
spread
asia
europ
america
australia
via
variou
pathogen
gramneg
bacilli
pay
special
attent
spread
hazard
microb
talk
would
like
give
outlin
newli
identifi
molecular
mechan
confer
panresist
aminoglycosid
pathogen
microb
isol
human
veterinari
environ
acquir
resist
quinolon
mainli
result
chromosom
mutat
respons
modif
dna
gyras
topoisomeras
iv
decreas
drug
accumul
bacteria
due
decreas
permeabl
andor
overexpress
efflux
system
plasmidmedi
quinolon
resist
pmqr
first
report
usa
two
mechan
identifi
date
first
pmqr
determin
qnr
protein
belong
famili
pentapeptid
repeat
protein
five
determin
identifi
qnra
qnrb
qnrc
qnrd
qnr
differ
variant
respect
may
act
bind
directli
dna
gyras
topoisomeras
iv
lead
protect
quinolon
inhibit
confer
resist
nalidix
acid
reduc
suscept
fluoroquinolon
fq
may
facilit
recoveri
mutant
higher
level
resist
overal
preval
qnra
qnrb
qnr
determin
gener
rang
identifi
worldwid
mostli
esblproduc
enterobacteri
isol
origin
qnra
qnr
gene
identifi
shewanella
alga
vibrio
splendidu
respect
second
type
pmqr
determin
aac
ibcr
variant
aminoglycosid
acetyltransferas
aac
ib
confer
resist
kanamycin
tobramycin
amikacin
variant
possess
two
substitut
suffici
acetyl
ciprofloxacin
norfloxacin
mic
increas
overal
preval
aac
ibcr
may
rang
report
mainli
escherichia
coli
klebsiella
pneumonia
third
type
pmqr
determin
qepa
identifi
two
e
coli
clinic
isol
japan
belgium
qepa
gene
encod
put
efflux
pump
belong
major
facilit
superfamili
protein
confer
decreas
suscept
hydrophil
fq
eg
norfloxacin
ciprofloxacin
enrofloxacin
mic
increas
two
epidemiolog
survey
qepa
may
indic
low
preval
natur
reservoir
qepa
remain
unknown
might
actinomycet
speci
discov
three
main
mechan
pmqr
within
last
ten
year
peculiar
may
reflect
emerg
novel
mechan
resist
also
deeper
investig
resist
mechan
clinic
isol
emerg
infect
cope
c
schulz
h
ranisch
p
kutzer
h
nattermann
r
grunow
berlin
frankfurtod
de
object
littl
known
preval
francisella
tularensi
human
anim
germani
interestingli
pathogen
emerg
recent
sever
marmoset
callithrix
jacchu
die
tularaemia
group
hunter
becam
infect
area
western
germani
find
distribut
pathogen
also
eastern
germani
investig
seropreval
tularaemia
fox
vulp
vulp
raccoon
dog
nyctereut
procyonoid
area
brandenburg
around
berlin
method
sera
anim
n
n
respect
year
test
f
tularensi
lp
antibodi
indirect
elisa
suspici
sampl
confirm
western
blot
lp
ladder
recognit
use
protein
g
pod
conjug
furthermor
investig
serum
sampl
competit
elisa
use
peroxidaseconjug
anti
lp
monoclon
antibodi
result
serum
collect
test
fox
raccoon
dog
posit
specif
f
tularensi
antibodi
geograph
distribut
show
hot
spot
area
investig
region
result
indic
higher
seropreval
wildlif
tularaemia
eastern
region
germani
assum
sinc
report
human
case
last
decad
seem
underestim
real
preval
pathogen
unknown
high
number
tularaemia
antibodi
posit
fox
raccoon
dog
indic
zoonos
present
wildlif
eastern
germani
howev
impact
transmiss
zoonot
pathogen
wildlif
domest
anim
human
yet
well
studi
conclus
obtain
data
contribut
creat
uptod
strategi
effici
control
two
rickettsi
zoonos
object
helicobact
pylori
establish
primari
caus
gastriti
peptic
ulcer
human
minor
patient
upper
gastrointestin
symptom
long
tightli
coil
spiral
bacteria
clearli
distinct
h
pylori
provision
name
h
heilmannii
observ
gastric
biopsi
object
isol
identifi
spiral
organ
resembl
h
heilmannii
gastric
mucosa
finnish
patient
present
sever
dyspept
symptom
method
use
two
differ
select
media
isol
bacteria
gastric
biopsi
sampl
treatment
patient
cours
lansoprazol
tetracyclin
metronidazol
isol
characteris
test
ureas
catalas
activ
light
electron
microscopi
sequenc
partial
rrna
ureab
gene
singl
enzym
aflp
use
analys
genet
divers
among
isol
result
growth
long
spiral
organ
obtain
antrum
corpu
biopsi
three
antrum
biopsi
treatment
patient
partial
rrna
gene
sequenc
show
high
sequenc
similar
gastric
helicobact
speci
partial
ureab
gene
show
high
sequenc
similar
h
bizzozeronii
clearli
distinct
gastric
helicobact
speci
aflp
indic
isol
belong
clone
howev
minor
genet
divers
observ
among
isol
result
b
pseudomallei
primarili
found
close
proxim
stream
grassrich
area
also
correl
environment
disturb
soil
caus
presenc
anim
farm
irrig
predict
map
current
verifi
sampl
predict
b
pseudomallei
hot
coldspot
see
figur
predict
map
rural
darwin
red
area
indic
high
probabl
presenc
b
pseudomallei
studi
contribut
elucid
environment
distribut
b
pseudomallei
endem
tropic
australia
clarif
environment
factor
influenc
occurr
also
rais
concern
b
pseudomallei
spread
due
chang
land
manag
concurr
multiserotyp
dengu
infect
variou
bodi
fluid
w
krajiw
chansinghakul
g
suwanpimolkul
prommalikit
p
suandork
j
pupaibool
k
arunyingmongkol
c
pancharoen
u
thisyakorn
bangkok
th
object
dengu
viru
infect
one
rapidlyspread
emerg
diseas
worldwid
viru
divid
distinct
serotyp
limit
crossprotect
immun
therefor
one
reinfect
differ
serotyp
episod
usual
caus
singl
serotyp
individu
occasion
infect
concurr
multipl
one
group
previous
detect
dengu
viru
urin
oral
specimen
patient
studi
sought
determin
characterist
multiserotyp
infect
analys
beyond
patient
blood
compart
method
adult
patient
suspect
dengu
infect
enrol
plasma
peripher
blood
mononuclear
cell
pbmc
urin
pellet
buccal
brush
saliva
collect
febril
episod
specimen
patient
posit
dengu
serolog
pandenguespecif
rtpcr
includ
serotypespecif
rtpcr
perform
aforement
variou
specimen
patient
result
patient
met
criteria
serotyp
success
patient
common
serotyp
account
half
case
demonstr
multiserotyp
infect
combin
data
specimen
type
individu
serotyp
use
singl
convent
serumplasma
specimen
howev
would
detect
half
case
phenomenon
concurr
multiserotyp
infect
present
examin
specimen
type
includ
urin
pellet
buccal
brush
saliva
frequent
combin
case
two
patient
simultan
infect
serotyp
one
serotyp
demonstr
signific
differ
clinic
sever
singleand
multiserotyp
infect
conclus
denguehyperendem
countri
simultan
circul
four
serotyp
phenomenon
concurr
multiserotyp
infect
common
previous
demonstr
tradit
serotyp
singl
serumplasma
specimen
may
explain
sensit
limit
detect
method
biolog
behaviour
viru
find
implic
potenti
accur
epidemiolog
studi
futur
exploratori
investig
regard
dengu
viru
variou
secret
excret
emerg
concept
evolutionari
histori
hantavirus
hj
kang
sn
bennett
l
sumibcay
arai
ag
hope
ja
cook
jw
song
r
honolulu
albuquerqu
us
tokyo
jp
seoul
kr
object
recent
discoveri
genet
distinct
hantavirus
shrew
famili
soricida
captur
wide
separ
geograph
region
challeng
convent
view
rodent
princip
progenitor
reservoir
host
hantavirus
rais
possibl
soricomorph
notabl
mole
famili
talpida
harbour
hantavirus
method
use
oligonucleotid
primer
base
conserv
genom
region
rodentand
soricidborn
hantavirus
rna
extract
tissu
japanes
shrew
mole
urotrichu
talpoid
american
shrew
mole
neurotrichu
gibbsii
european
common
mole
talpa
europaea
analyz
hantaviru
sequenc
rtpcr
newfound
mand
lsegment
sequenc
align
use
clustal
w
analyz
phylogenet
maximumlikelihood
markov
chain
mont
carlo
treesampl
method
gtrig
model
evolut
result
novel
hantaviru
genom
design
asama
viru
asav
oxbow
viru
oxbv
nova
viru
nvav
detect
tissu
urotrichu
talpoid
neurotrichu
gibbsii
talpa
europaea
respect
sequenc
phylogenet
analys
indic
asav
oxbv
relat
hantavirus
harbour
soricin
shrew
eurasia
north
america
respect
contrast
phylogenet
analys
fulllength
sand
lsegment
sequenc
show
nvav
form
uniqu
clade
clearli
distinct
evolutionarili
distant
hantavirus
despit
high
degre
sequenc
diverg
nucleotid
amino
acid
level
secondari
structur
nucleocapsid
protein
well
lsegment
motif
moleassoci
hantavirus
well
conserv
conclus
crossspeci
transmiss
influenc
cours
hantaviru
evolut
hostswitch
event
alon
satisfactorili
explain
coexist
distribut
genet
distinct
hantavirus
among
speci
two
taxonom
order
small
mammal
span
four
contin
view
within
context
molecular
phylogeni
zoogeographi
close
associ
distinct
hantaviru
clade
specif
subfamili
rodent
shrew
mole
like
result
altern
variabl
period
codiverg
certain
taxonom
level
evolutionari
time
thu
primev
hantaviru
might
arisen
insectborn
viru
ancestr
soricomorph
rather
rodent
serv
origin
mammalian
host
southeastern
franc
kaba
b
davoust
jl
barthet
henri
c
tamalet
jm
rolain
raoult
p
marseil
toulon
fr
object
autochthon
hepat
e
current
consid
emerg
diseas
industrialis
countri
sever
studi
suggest
hepat
e
zoonosi
especi
pig
boar
deer
aim
studi
whether
hepat
e
viru
hev
commonli
present
domest
pig
southern
franc
determin
relationship
hev
sequenc
detect
pig
describ
human
hepat
e
case
method
serum
stool
sampl
collect
three
sixmonthold
pig
differ
region
southern
franc
sixmonthold
pig
slaughterhous
threemonthold
pig
pig
farm
swine
igg
antihev
antibodi
test
perform
use
commerci
elisa
kit
clinic
diagnosi
minor
modif
swine
hev
rna
detect
conduct
realtim
pcr
amplificationsequenc
assay
use
hous
protocol
target
region
hev
genom
result
pig
seroposit
threemonthold
pig
hev
rnaposit
wherea
none
sixmonthold
pig
hev
rnaposit
hev
rna
significantli
frequent
detect
stool
serum
versu
p
phylogenet
analysi
show
swine
hev
sequenc
belong
genotyp
form
two
cluster
within
sequenc
show
high
nucleotid
homolog
cluster
correl
geograph
origin
pig
well
repartit
pen
build
pig
farm
sampl
collect
swine
hev
sequenc
present
studi
genet
close
hev
sequenc
found
human
swine
europ
although
strong
phylogenet
link
could
observ
neither
latter
sequenc
human
hepat
e
case
diagnos
laboratori
conclus
data
indic
threemonthold
farm
pig
southern
franc
might
repres
potenti
sourc
contamin
human
underscor
great
potenti
hev
caus
epizoot
infect
popul
farm
pig
clostridium
difficil
chang
epidemiolog
trend
object
clostridium
difficil
infect
cdi
becom
grow
concern
worldwid
increas
report
incid
increas
associ
financi
burden
aim
therefor
review
trend
cdi
occur
inclus
method
patient
admit
lothian
univers
hospit
divis
luhd
test
c
difficil
toxin
ab
eia
includ
retrospect
analysi
prospect
collect
data
perform
number
occupi
bed
day
provid
nhslothian
statist
depart
recent
publish
cost
associ
cdi
use
estim
potenti
cost
lothian
nh
trust
result
faecal
sampl
test
c
difficil
toxin
inclus
sampl
posit
overal
cdi
identifi
patient
day
inpati
hospit
admiss
incid
identifi
cdi
rose
patient
day
patient
day
incid
also
increas
age
patient
day
year
age
group
patient
day
year
age
group
renal
medicin
intens
care
highest
incid
identifi
cdi
greater
patient
day
follow
infecti
diseas
gastrointestin
medicin
whose
rate
patient
day
respect
medicin
elderli
comparison
incid
patient
day
note
patient
transfer
minimum
two
specialti
period
remain
posit
c
difficil
toxin
estim
cost
studi
period
toxin
test
alon
region
minim
potenti
hospitalis
cost
patient
cdi
region
conclus
incid
patient
identifi
cdi
risen
markedli
surprisingli
incid
also
note
increas
age
medicin
elderli
howev
much
lower
incid
sever
specialti
therefor
risk
assess
cdi
develop
contain
also
target
within
specialti
identifi
cdi
patient
transfer
differ
specialti
signific
financi
burden
cdi
impos
healthcar
institut
judici
applic
infect
control
measur
remain
import
factor
prevent
cdi
spread
isol
strain
pvl
neg
posit
enterotoxin
sea
case
also
seb
sek
seq
fifth
strain
taiwan
clone
wa
also
compris
two
close
relat
sequenc
type
strain
carri
sccmec
element
type
v
vii
well
pvl
usual
seb
sek
seq
common
strain
wa
sixth
strain
differ
taiwan
clone
presenc
sccmec
type
v
element
absenc
pvl
differenti
clonal
complex
variou
differ
strain
indic
rapid
evolut
spread
sccmec
element
diagnost
microarray
technolog
allow
one
distinguish
beyond
mlst
level
henc
accur
trace
outbreak
spread
strain
sampl
taker
daili
contact
poultri
exclud
analysi
b
sampl
taker
report
contact
livestock
elsewher
studi
moment
spatyp
sampl
taker
farm
correspond
c
sampl
taker
test
mrsaneg
follow
test
sampl
taker
test
complet
data
set
sampl
taken
directli
hour
visit
collect
visit
sampl
taker
visit
farm
farm
mrsa
collect
pig
stabledust
farm
visit
time
differ
sampl
taker
one
sampl
taker
posit
mrsa
visit
farm
remov
follow
analysi
fifteen
visit
mrsaposit
farm
result
acquisit
mrsa
sampl
taker
acquir
mrsa
least
visit
posit
farm
posit
sampl
taker
acquir
mrsa
twice
sampl
taker
acquir
mrsa
three
time
separ
visit
acquisit
mrsa
neg
hour
spatyp
mrsa
isol
found
farm
sampl
taker
grossli
compar
neg
farm
none
visit
result
mrsa
acquisit
inform
see
tabl
discuss
acquir
sampl
taker
occup
exposur
studi
howev
case
strain
recov
next
day
therefor
acquisit
short
durat
pose
limit
treat
human
health
person
seem
vulner
acquir
mrsa
work
sampl
size
studi
small
draw
final
conclus
concern
interperson
variat
requir
extens
studi
object
communityassoci
mrsa
increas
problem
associ
food
anim
contact
made
region
led
concern
potenti
role
food
mrsa
transmiss
object
studi
evalu
preval
mrsa
colonis
retail
pork
canada
method
pork
chop
ground
pork
pork
shoulder
purchas
retail
outlet
four
canadian
provinc
conjunct
canadian
integr
program
antimicrobi
resist
surveil
direct
inocul
meat
enrich
broth
rins
meat
broth
perform
pork
chop
shoulder
follow
inocul
onto
chromogen
agar
ground
pork
test
use
direct
method
mrsa
isol
type
pfge
spa
type
real
time
pcr
use
detect
pantonvalentin
leukocidin
gene
result
mrsa
isol
ci
sampl
signific
differ
provinc
p
differ
differ
product
mrsa
isol
pork
chop
ground
pork
pork
shoulder
p
sampl
posit
use
direct
cultur
mrsa
isol
sampl
test
use
rins
method
nine
sampl
posit
direct
cultur
neg
use
rins
method
other
posit
rins
method
posit
method
seven
sampl
ground
pork
posit
direct
cultur
test
use
rins
method
main
clone
present
common
isol
group
relat
spa
type
new
relat
type
classifi
canadian
epidem
pfge
human
epidem
clone
associ
hors
pfgenontyp
spa
surprisingli
common
account
isol
main
group
relat
spa
type
new
type
clone
common
human
canada
also
account
isol
clinic
relev
mrsa
contamin
pork
current
unclear
possibl
contact
contamin
food
could
mode
mrsa
transmiss
commun
although
studi
preval
contamin
amount
mrsa
contamin
sampl
sourc
contamin
implic
human
health
requir
preval
novel
trimethoprim
resist
gene
dfrk
among
german
staphylococc
isol
bftgermvet
monitor
studi
k
schwarz
neustadtmariense
de
object
recent
novel
trimethoprim
resist
gene
dfrk
identifi
tet
l
harbour
plasmid
porcin
mrsa
isol
bftgermvet
monitor
studi
studi
includ
total
independ
coagulaseposit
coagulasevari
staphylococci
collect
germani
isol
infect
urinarygenit
tract
pig
isol
skin
infect
pig
isol
respiratori
tract
infect
dogscat
isol
infect
skinearmouth
dogscat
studi
investig
preval
plasmid
locat
dfrk
gene
among
isol
method
pcr
primer
design
pcr
subsequ
restrict
analysi
pcr
product
establish
detect
dfrk
isol
posit
result
test
plasmid
locat
dfrk
transfer
experi
dfrkcarri
plasmid
analys
trimethoprim
resist
gene
dfrk
detect
anoth
isol
isol
pig
skin
infect
remain
urinarygenit
tract
infect
six
staphylococcu
hyicu
subsp
hyicu
isol
aureu
isol
mrsa
mssa
pseudintermediu
isol
harbour
plasmid
isol
hyicu
mrsa
singl
pseudintermediu
plasmid
locat
dfrk
confirm
protoplast
transform
subsequ
suscept
test
pcr
analysi
transform
case
plasmid
harbour
dfrk
also
carri
tet
l
tetracyclin
resist
gene
result
combin
pcr
assay
primer
tet
l
dfrk
confirm
dfrk
gene
alway
locat
immedi
downstream
tet
l
gene
analysi
dfrkand
tet
l
harbour
plasmid
show
vari
size
kb
similar
size
plasmid
differ
ecorv
hindiii
restrict
pattern
novel
trimethoprim
resist
gene
dfrk
occur
porcin
staphylococc
isol
bftgermvet
studi
isol
locat
structur
divers
plasmid
howev
alway
close
proxim
tet
l
gene
linkag
dfrk
tet
l
gene
allow
mainten
coselect
plasmid
select
pressur
either
tetracyclin
trimethoprim
wide
use
veterinari
medicin
tabl
isol
resist
ciprofloxacin
clindamycin
erythromycin
gentamicin
suscept
vancomycin
one
se
methicillinsuscept
two
isol
quinupristindalfopristin
nonsuscept
strain
clonal
relat
cluster
three
subtyp
cfr
gene
detect
linezolid
nonsuscept
strain
mic
mgl
recov
yo
male
underw
liver
transplant
plasmid
analysi
identifi
six
plasmid
band
rang
ca
cfrcarri
strain
hybridis
signal
observ
plasmid
band
well
chromosom
band
iceui
digest
mutat
rrna
detect
cfr
increas
linezolid
mic
valu
report
highlight
abil
se
acquir
linezolid
resist
potenti
mobil
cfr
combin
clonal
tendenc
dissemin
among
staphylococcu
spp
repres
seriou
threat
sever
potent
grampositiveact
agent
includ
oxazolidinon
activ
surveil
combin
effect
infect
control
molecular
studi
seem
prudent
minimis
spread
resist
mechan
object
get
glimps
potenti
impact
infecti
diseas
music
regard
compos
perform
musician
diseas
live
condit
relev
element
might
affect
end
result
music
enjoy
today
music
art
sens
full
drama
despair
realiti
life
opposit
bliss
ignor
realiti
full
romanc
beauti
delicaci
variou
form
music
research
pay
special
attent
infect
potenti
play
signific
role
birth
particular
piec
perform
entir
research
process
subject
bias
emot
done
wholeheartedli
aim
take
account
person
life
compos
perform
musician
also
histor
context
music
born
music
exampl
serv
audienc
along
essenti
background
data
show
extent
infect
impact
music
regard
aetiolog
infect
bacteri
viral
parasit
agent
well
repres
addit
mani
epoch
histori
play
role
sometim
connect
surpris
even
dramat
listen
tender
ear
music
quit
often
turn
affect
also
infecti
diseas
physician
realis
strength
peopl
driven
demon
divin
altogeth
beauti
forc
music
preval
antibiot
resist
increas
asian
countri
recent
year
problem
like
arisen
due
combin
inadequ
infect
control
practic
particularli
hospit
set
widespread
misus
antibiot
hospit
commun
set
factor
lead
antibiot
misus
includ
inappropri
antibiot
prescript
due
lack
clinic
microbiolog
andor
imag
data
mani
clinic
set
asian
region
lack
separ
prescrib
dispens
medic
practition
practis
mani
countri
asia
well
easi
avail
counter
medic
also
contribut
antibiot
misus
optim
control
antibiot
use
achiev
multiprong
approach
includ
better
educ
public
medic
practition
ration
use
antibiot
review
health
system
structur
well
better
control
counter
sale
antibiot
upgrad
microbiolog
laboratori
radiolog
facil
enhanc
accuraci
clinic
diagnosi
also
urgent
need
develop
countri
keep
pace
complex
manag
patient
new
era
minimis
widespread
practis
inappropri
antibiot
use
examin
csf
microorgan
wbc
differenti
count
concentr
glucos
protein
primari
investig
diagnos
mening
howev
csf
examin
may
alway
conclus
difficult
distinguish
bacteri
viral
mening
therefor
improv
diagnost
sensit
specif
bacteri
mening
develop
rapid
test
bacteri
aetiolog
still
need
present
give
review
strength
weak
sever
analys
method
reveal
microbiolog
agent
ie
csf
microscopi
cultur
antigen
antibodi
detect
molecular
method
detect
dna
rna
use
sever
mediat
host
immun
respons
diagnost
prognost
purpos
bacteri
mening
medic
emerg
requir
multidisciplinari
approach
diagnosi
bacteri
mening
often
consid
diseas
difficult
recogn
recommend
antimicrobi
therapi
chang
result
emerg
antimicrobi
resist
lectur
current
concept
initi
approach
treatment
adult
bacteri
mening
summaris
manag
critic
ill
patient
bacteri
mening
pose
import
dilemma
controversi
area
ie
prehospit
admiss
antibiot
review
relev
literatur
discuss
framework
current
treatment
guidelin
highlight
new
develop
adjunct
dexamethason
therapi
acut
bacteri
mening
abm
especif
caus
infect
streptococcu
pneumonia
still
unaccept
poor
prognosi
mortal
bacteri
infect
mening
caus
one
power
inflammatori
reaction
known
medicin
yet
year
ago
inflammatori
reaction
suggest
contribut
substanti
brain
damag
concept
underli
use
antiinflammatori
agent
adjunct
therapi
abm
adjunct
treatment
abm
corticosteroid
properli
evalu
clinic
trial
trial
recommend
corticosteroid
patient
haemophilu
influenza
type
b
pneumococc
mening
pm
howev
adjunct
corticosteroid
therapi
sever
weak
narrow
treatment
window
borderlin
effect
neurolog
sequela
thu
still
need
addit
altern
adjuv
therapi
abm
experiment
studi
use
anim
model
predominantli
pm
provid
insight
pathogen
mechan
underli
brain
injuri
abm
clear
autodestruct
inflammatori
reaction
initi
interact
bacteri
compon
host
pattern
recognit
receptor
prr
like
tolllik
receptor
tlr
prr
signal
result
activ
transcript
factor
like
nfkb
upregul
product
proinflammatori
cytokin
cytokin
like
also
potent
trigger
nfkb
activ
therefor
exagger
inflammatori
reaction
via
posit
feedback
loop
consequ
great
number
neutrophil
recruit
mening
activ
neutrophil
releas
mani
potenti
cytotox
agent
includ
oxid
matrix
metalloproteinas
caus
collater
damag
brain
tissu
addit
inflammatori
respons
direct
bacteri
cytotoxicti
identifi
contributor
tissu
damag
abm
thu
experiment
studi
point
four
differ
target
adjunct
therapi
name
interfer
induct
inflamm
eg
tlr
blockad
ii
exagger
inflamm
eg
antagon
iiiiv
gener
cytotox
factor
either
host
bacteri
origin
eg
scaveng
oxid
present
give
overview
pathophysiolog
abm
special
emphasi
pm
highlight
promis
target
adjunct
therapi
abm
deduc
experiment
studi
clinician
approach
manag
difficult
infect
acut
postsurg
prosthet
joint
infect
optim
manag
prosthet
joint
infect
pji
remain
undefin
import
issu
us
implant
retain
conserv
strategi
optim
durat
antimicrobi
therapi
role
rifampin
yet
matter
controversi
spite
number
report
literatur
appear
confus
among
limit
literatur
must
emphas
differ
criteria
classifi
pji
differ
criteria
select
conserv
strategi
cs
descript
initi
popul
patient
select
cs
differ
week
chronic
suppress
therapi
low
number
patient
short
followup
absenc
clinic
trial
surpris
rate
cs
success
vari
almost
use
classif
approach
pji
propos
tsukayama
seri
patient
earli
pji
manag
cs
debrid
exchang
polyethylen
implant
retent
cure
week
spanish
group
studi
pji
constitut
within
spanish
network
studi
infecti
patholog
reipi
public
fund
initi
data
consecut
case
earli
pji
attend
hospit
record
onlin
databas
case
manag
cs
could
analys
mean
followup
year
sixtyseven
patient
cure
mean
day
infect
control
relaps
mean
day
implant
remov
patient
implant
remov
suppress
given
suspect
ongo
infect
result
significantli
wors
one
hospit
factor
result
statist
signific
trend
wors
result
mrsa
produc
infect
p
time
symptom
appear
debrid
shorter
success
treat
case
median
day
failur
median
day
p
good
function
result
obtain
patient
success
cs
summari
substanti
proport
earli
pji
manag
cs
strategi
definit
non
suppress
difficult
identifi
patient
higher
risk
failur
although
mrsa
aetiolog
longer
time
debrid
seem
predict
failur
differ
outcom
centr
suggest
surgic
techniqu
could
import
factor
failur
million
cardiac
pace
system
implant
worldwid
estim
rate
infect
implant
perman
endocardi
lead
vari
pacemak
infect
correspond
differ
clinic
situat
includ
localis
infect
devic
pocket
pacemak
lead
system
infect
associ
bacteraemia
leadassoci
endocard
latter
repres
case
pacemak
infect
sever
pacemak
relat
infect
endocard
sustain
mortal
rang
risk
factor
relat
infect
implant
pacemak
correl
fever
h
implant
temporari
pace
implant
earli
reintervent
haematoma
lead
dislodg
contrast
invers
correl
observ
develop
infect
antibiot
prophylaxi
implant
new
system
data
guid
therapi
patient
pacemak
infect
limit
appropri
manag
remain
determin
accord
differ
seri
staphylococci
account
respons
organ
coagulaseneg
staphylococci
cn
report
predomin
pathogen
follow
staphylocococcu
aureu
biofilm
product
respons
bacteri
surviv
emerg
methicillinresist
aureu
cn
complic
manag
pacemak
infect
impli
empir
treatment
suspect
pacemak
infect
coverag
staphylococci
includ
methicillinresist
strain
streptococci
corynebacterium
spp
propionibacterium
acn
gramneg
bacilli
candida
spp
caus
occasion
infect
optim
therapi
combin
complet
devic
extract
percutan
ablat
surgic
remov
extracorpor
circul
prolong
cours
antibiot
particular
case
multiresist
bacteria
leav
devic
intact
associ
increas
mortal
risk
relaps
persist
infect
absenc
prospect
studi
durat
antibiot
treatment
remain
determin
month
shown
associ
increas
incid
relaps
shortest
cours
treatment
week
propos
case
veget
strictli
localis
lead
without
affect
cardiac
valv
antibiot
therapi
work
alon
reserv
highli
select
patient
infect
remain
critic
complic
ventriculoperiton
shunt
placement
incid
factor
age
patient
aetiolog
hydrocephalu
type
shunt
implant
surgeon
experi
determin
associ
increas
risk
infect
children
like
adult
acquir
shunt
infect
possibl
reason
longer
hospit
stay
higher
skin
bacteri
concentr
immatur
immun
system
adher
strain
bacteria
staphylococci
skin
commens
main
caus
organ
nevertheless
recent
year
chang
epidemiolog
microorgan
observ
increas
gramneg
bacteria
appropri
system
antibiot
accord
antimicrobi
suscept
test
surgic
remov
shunt
temporari
extern
cerebrospin
fluid
drainag
shunt
replac
follow
erad
infect
cornerston
treatment
cerebrospin
fluid
shunt
infect
good
complianc
infect
control
practic
inserion
cathet
asept
techniqu
shortterm
periop
antimicrobi
prophylaxi
order
prevent
emerg
drugresist
subpopul
import
step
prevent
shunt
infect
influenza
adult
admit
canadian
hospit
data
two
season
mcgeer
gravel
g
c
weir
c
frenett
j
vayalumk
wong
moor
michaud
b
amihod
toronto
ottawa
edmonton
montreal
saskatoon
sherbrook
ca
object
season
influenza
flu
remain
caus
substanti
morbid
mortal
antivir
treatment
consid
hospitalis
patient
influenza
better
understand
epidemiolog
burden
ill
within
hospit
sector
canada
current
use
antivir
therapi
carri
multihospit
survey
virolog
confirm
flu
hospitalis
adult
method
cnisp
network
larg
teach
hospit
across
canada
collabor
collect
data
infect
hospitalis
patient
two
consecut
year
hospit
within
cnisp
identifi
inpati
year
virolog
confirm
flu
case
patient
chart
review
captur
demograph
clinic
data
determin
whether
flu
commun
ca
hospit
acquir
ha
case
review
day
determin
outcom
death
day
review
determin
whether
flu
main
contribut
caus
result
fifteen
hospit
recruit
cnisp
network
virolog
confirm
case
flu
found
flu
flu
mean
patient
age
year
male
document
patient
vaccin
season
incid
ca
flu
admiss
rang
hospit
admit
diagnos
ca
case
pneumonia
influenza
exacerb
copd
sepsi
fever
otherwis
specifi
cardiac
diagnos
diagnos
case
ha
rang
hospit
patient
day
patient
manag
droplet
contact
isol
practic
mask
use
ca
case
ha
case
receiv
antivir
therapi
p
almost
entir
oseltamivir
case
admit
icu
mortal
attribut
influenza
conclus
consider
seasonseason
hospitalhospit
variat
flu
patient
canadian
hospit
hospitalis
patient
ca
flu
present
wide
spectrum
clinic
diagnos
nearli
quarter
case
ha
ca
case
ha
case
treat
antivir
drug
attribut
day
mortal
v
papastamopoulo
e
panagiotopoulo
j
barabouti
samarko
skout
athen
gr
object
studi
sought
describ
influenza
vaccin
coverag
among
adult
greec
season
method
conduct
randomsampl
telephon
base
household
survey
among
adult
individu
greec
purpos
sampl
adult
repres
basic
demograph
social
geograph
characterist
overal
greek
popul
accord
latest
nation
survey
use
two
target
group
determin
analysi
person
year
age
person
chronic
condit
respiratori
heart
condit
hypertens
diabet
mellitu
condit
result
influenza
vaccin
rate
season
among
adult
popul
greec
overal
adult
popul
men
women
peopl
year
age
person
chronic
ill
person
respiratori
ill
person
heart
condit
person
diabet
mellitu
high
rate
overal
popul
reach
among
person
chronic
condit
report
type
contact
nation
health
system
privat
physician
within
last
three
year
among
recommend
get
vaccin
among
one
recommend
vaccin
person
respiratori
ill
person
diabet
mellitu
person
heart
condit
recommend
get
influenza
vaccin
conclus
avail
data
show
unaccept
low
level
influenza
vaccin
coverag
among
vulner
group
popul
year
age
peopl
live
chronic
ill
influenza
vaccin
prevent
measur
reduc
influenza
morbid
mortal
use
proven
costeffect
among
high
risk
group
also
main
vaccin
recommend
physician
howev
overal
rate
physician
recommend
vaccin
low
dynam
effort
thu
need
design
implement
strategi
polici
demonstr
rigor
effect
enhanc
influenza
vaccin
coverag
rate
conclus
nasopharyng
sampl
flock
swab
well
toler
suitabl
use
outpati
set
implement
realtim
mono
multiplex
naat
result
signific
improv
rate
diagnos
lrti
hrv
account
major
viral
lrti
primari
care
follow
influenza
coronavirus
also
rsv
hmpv
preval
adult
popul
studi
polyomavirus
detect
involv
doubl
infect
method
observ
analysi
prospect
cohort
nonsever
immunosuppress
adult
pp
requir
hospitalis
diagnos
urinari
antigen
andor
diagnos
cultur
overal
pneumococc
strain
avail
serotyp
quellung
pfge
smal
mlst
diagnosi
septic
shock
base
systol
blood
pressur
mmhg
peripher
hypoperfus
clinic
bacteriolog
evid
uncontrol
infect
result
total
patient
pp
septic
shock
present
patient
shock
younger
vs
yr
p
frequent
current
smoker
vs
p
receiv
commonli
corticosteroid
therapi
vs
p
frequent
classifi
highrisk
psi
class
vs
p
complic
also
less
like
receiv
prior
influenza
vaccin
vs
p
frequent
bacteraemia
vs
p
signific
differ
found
rate
penicillin
vs
erythromycinresist
vs
serotyp
commonli
associ
shock
vs
p
wherea
serotyp
rare
associ
complic
vs
p
signific
differ
found
regard
genotyp
vs
vs
vs
vs
patient
shock
requir
frequent
mechan
ventil
vs
p
longer
lo
vs
day
p
earli
vs
p
overal
casefat
rate
vs
p
higher
patient
shock
conclus
pp
present
septic
shock
still
associ
poor
outcom
occur
mainli
current
smoker
patient
receiv
corticosteroid
infect
caus
serotyp
prior
influenza
vaccin
pp
caus
serotyp
associ
lower
risk
shock
high
longterm
mortal
rate
initi
recoveri
sever
communityacquir
pneumonia
background
despit
presenc
antibiot
vaccin
strategi
pneumocci
communityacquir
pneumonia
cap
still
major
caus
mortal
develop
countri
howev
unclear
episod
cap
influenc
longterm
surviv
initi
recoveri
therefor
determin
mortal
year
discharg
patient
hospitalis
episod
sever
cap
nonintens
care
set
method
hospit
netherland
patient
pt
sever
cap
psi
class
iv
v
without
need
treatment
icu
prospect
follow
day
mortal
year
discharg
determin
use
dutch
municip
public
record
databas
use
cox
regress
analysi
examin
predictor
mortal
result
compar
strategi
strategi
result
slightli
higher
cost
chf
vs
fewer
infect
vs
patient
mean
lengthofstay
produc
increment
costeffect
ratio
icer
chf
per
mrsa
infect
avoid
strategi
domin
strategi
costli
less
effect
sensit
analys
suggest
preval
colonis
admiss
stronger
predictor
costeffect
cost
infect
rapid
screen
probabl
crosstransmiss
increment
cost
isol
contact
precaut
increas
rel
low
onadmiss
preval
centr
lower
icer
chf
per
infect
avoid
contrast
increas
cost
infect
cost
rapid
screen
risk
crosstransmiss
margin
affect
icer
conclus
analysi
suggest
compar
risk
factor
identif
preemptiv
isol
univers
rapid
screen
upon
surgic
admiss
strongli
costeffect
centr
howev
local
epidemiolog
play
import
role
particular
set
higher
preval
colonis
admiss
may
find
univers
rapid
screen
costeffect
note
screen
undesir
cost
infect
would
higher
result
admiss
weekli
screen
coupl
patient
isol
found
dramat
reduc
number
mrsa
acquisit
largest
reduct
obtain
pcr
technolog
follow
chromogen
agar
differ
howev
surprisingli
small
screen
technolog
achiev
reduct
mrsa
acquisit
close
compar
nointervent
scenario
nonetheless
chromogen
pcrbase
system
abl
decreas
number
unisol
mrsabedday
approxim
respect
conclus
small
differ
abil
screen
technolog
reduc
mrsa
acquisit
reflect
rel
low
estim
isol
efficaci
observ
highli
skew
distribut
icustay
may
provid
import
insight
reason
recent
disappoint
trial
result
particular
skew
length
stay
distribut
mean
mrsabe
day
account
rel
longstay
patient
rapid
detect
make
least
differ
key
sourc
uncertainti
found
isol
effect
attribut
mortal
due
mrsa
infect
difficult
accur
estim
current
avail
data
model
result
allow
us
quantifi
expect
valu
reduc
key
uncertainti
help
provid
ration
basi
set
futur
research
prioriti
object
shown
substanti
colonis
mrsa
among
nurs
home
resid
staff
recent
conduct
point
preval
studi
nurs
home
reveal
overal
preval
rate
resid
aim
studi
therefor
test
effect
intervent
nurs
home
sought
improv
standard
infect
control
mean
reduc
mrsa
preval
method
cluster
randomis
control
trial
crct
involv
nurs
home
home
repres
unit
analysi
perform
studi
ran
month
data
collect
baselin
month
nasal
swab
taken
baselin
consent
resid
staff
home
prior
randomis
audit
infect
control
procedur
also
undertaken
follow
collect
baselin
data
nurs
home
alloc
intervent
control
arm
intervent
home
staff
train
infect
control
specif
hand
hygien
cathet
care
barrier
approach
use
glove
apron
mask
decontamin
equip
environ
usual
practic
continu
control
home
data
collect
timepoint
feedback
given
intervent
home
term
perform
educ
train
provid
requir
primari
outcom
preval
mrsa
intervent
home
compar
control
site
result
preliminari
analysi
data
reveal
signific
chang
preval
mrsa
intervent
control
home
take
account
cluster
oneyear
intervent
period
risk
ratio
confid
interv
ci
howev
improv
infect
control
audit
score
intervent
home
mean
score
control
home
month
compar
intervent
site
score
significantli
differ
pair
ttest
p
result
suggest
infect
control
educ
train
implement
studi
suffici
affect
mrsa
preval
therefor
detail
educ
train
packag
either
alon
combin
mrsa
decolonis
staff
resid
may
requir
reduc
mrsa
preval
within
uniqu
environ
object
respons
rapid
global
increas
nosocomi
preval
multiresist
microorgan
infect
control
measur
patient
isol
increasingli
use
unknown
measur
influenc
qualiti
life
qol
patient
shortterm
isol
determin
prospect
match
cohort
studi
method
adult
patient
need
isol
singlepati
room
umc
utrecht
elig
includ
hour
start
isol
give
inform
consent
abl
fulfil
studi
requir
index
patient
identifi
two
control
patient
admit
ward
time
yet
subject
isol
measur
anxieti
depress
qol
assess
use
hospit
anxieti
depress
scale
had
visual
analogu
scale
patient
opinion
experi
isol
measur
isol
patient
mean
selfdevelop
isol
evalu
questionnair
result
isol
patient
control
includ
compar
baselin
characterist
age
sex
nation
level
educ
length
hospit
stay
sever
underli
diseas
comorbid
use
cumul
ill
rate
scale
reason
isol
clostridium
difficileassoci
diseas
n
high
risk
mrsa
carriag
n
resist
gramneg
bacteria
n
mean
score
questionnair
present
tabl
isin
univari
analysi
durat
isol
hour
compar
hour
associ
reduc
qualiti
life
va
compar
p
visual
analogu
score
opposit
term
isol
measur
rate
mean
safeti
use
quiet
respect
conclus
shortterm
isol
hour
associ
anxious
depress
posit
feel
safeti
use
quiet
index
patient
n
mean
sd
control
patient
n
mean
sd
object
lack
data
impact
healthcar
associ
infect
hai
experi
individu
patient
inform
essenti
empow
health
organis
understand
prioritis
develop
implement
solut
minimis
risk
patient
studi
explor
compar
narr
patient
experienc
staphylococcu
aureu
blood
stream
infect
patient
conduct
qualit
semistructur
interview
eighteen
adult
previous
inpati
acut
teach
hospit
scotland
nine
patient
laboratori
diagnos
staphylococcu
aureu
blood
stream
infect
nine
blood
stream
infect
patient
interview
minut
interview
ask
patient
thought
around
hai
concern
still
measur
took
safeguard
hai
experi
impact
confid
nh
probe
question
ask
depend
respons
given
initi
question
interview
record
transcrib
analys
themat
result
analysi
transcrib
interview
ongo
preliminari
analysi
show
patient
posit
neg
comment
infect
prevent
control
practic
hospit
specif
concern
includ
poor
commun
poor
cleanli
awar
patient
board
lack
facil
staff
shortag
multitask
patient
experienc
bacteraemia
said
inform
infect
inform
given
clear
inform
treatment
subsequ
result
patient
specif
told
famili
safeguard
infect
littl
written
inform
hai
provid
patient
worri
hai
futur
admiss
concern
patient
fundament
differ
experi
blood
stream
infect
patient
report
experi
show
broad
awar
system
issu
may
increas
risk
infect
consequ
need
involv
patient
design
evalu
system
chang
inform
improv
patient
experi
improv
safeti
reliabl
system
direct
benefit
patient
hospit
one
risk
hai
analysi
surgic
specialti
separ
reveal
signific
reduct
mortal
cardiothorac
surgeri
treat
mupchx
vs
p
figur
surgic
specialti
signific
differ
found
conclus
periop
applic
mupchx
nasal
carrier
aureu
undergo
cardiothorac
surgeri
result
threefold
reduct
mortal
one
year
lot
done
survey
teach
healthcareassoci
infect
uk
irish
medic
school
h
obrien
j
richard
k
walton
g
phillip
dublin
ie
norwich
newcastleupontyn
dunde
uk
object
patient
safeti
prevent
healthcareassoci
infect
hcai
increasingli
import
health
issu
medic
doctor
tradit
poor
compli
prevent
measur
minimis
hcai
hand
hygien
complianc
survey
medic
school
uk
ireland
assess
taught
assess
area
method
questionnair
draft
pilot
subsequ
forward
head
medic
school
well
known
contact
profession
interest
hcai
medic
school
questionnair
survey
topic
cover
curricula
modal
use
assess
knowledg
practic
use
variou
teach
method
materi
eg
lectur
educ
resourc
avail
result
repli
receiv
medic
school
two
suppli
data
undergradu
postgradu
cours
cover
hcai
qualiti
safeti
issu
cover
preval
recognis
risk
factor
transmiss
prevent
measur
medic
school
assess
compet
undertak
asept
techniqu
dispos
sharp
mcq
common
mean
assess
case
scenario
resourc
materi
clinic
skill
station
use
educ
student
medic
school
respect
medic
school
would
will
share
educ
resourc
hcai
medic
school
conclus
medic
school
uk
ireland
includ
hcai
curricula
import
safeti
qualiti
issu
need
emphas
potenti
agre
core
curriculum
hcai
share
teach
resourc
video
elearn
materi
object
norovirus
common
caus
outbreak
gastroenter
uk
nation
health
servic
hospit
lead
ward
closur
cost
much
million
per
annum
use
detail
data
set
noroviru
outbreak
three
hospit
system
south
west
england
estim
rel
import
introduct
noroviru
commun
within
hospit
cost
effect
ward
closur
differ
time
point
outbreak
method
use
regress
model
examin
associ
number
new
outbreak
hospit
commun
level
activ
number
outbreak
current
occur
ward
within
hospit
examin
effect
differ
ward
type
admiss
gener
long
stay
unit
whether
ward
open
close
new
admiss
given
day
undertook
analysi
cost
effect
unit
closur
develop
dynam
transmiss
model
take
account
ward
closur
may
reduc
noroviru
transmiss
within
ward
stochast
simul
model
base
actual
characterist
acut
hospit
noroviru
transmiss
paramet
quantifi
statist
analysi
measur
cost
benefit
close
affect
ward
day
onset
symptom
first
case
result
commun
level
noroviru
infect
signific
effect
occurr
new
outbreak
outbreak
admiss
gener
medic
unit
cost
close
ward
new
admiss
vari
million
million
depend
assum
effect
closur
curtail
transmiss
cost
bed
day
loss
compar
staff
ill
account
around
total
cost
closur
although
total
number
case
tend
fall
rapid
ward
closur
around
compar
closur
actual
cost
control
similar
regardless
closur
perform
develop
model
framework
assess
effect
costeffect
strategi
control
noroviru
outbreak
hospit
set
ward
closur
effect
prevent
case
sinc
closur
expens
intervent
may
alway
costeffect
preval
ribotyp
isol
origin
hospit
locat
healthboard
area
remain
isol
ribotyp
origin
hospit
across
scotland
vitro
isol
resist
clindamycin
mic
rang
mgl
mgl
mgl
furthermor
highli
resist
erythromycin
mgl
mgl
levofloxacin
moxifloxacin
mgl
mgl
isol
resist
cefotaxim
mgl
mgl
suscept
metronidazol
vancomycin
meropenem
piperacillintazobactam
high
frequenc
clindamycin
erythromycin
levofloxacin
moxifloxacin
cefotaxim
resist
also
found
among
isol
ribotyp
conclus
c
difficil
ribotyp
report
infrequ
scotland
report
ribotyp
becam
frequent
cluster
detect
hospit
major
ribotyp
isol
resist
clindamycin
three
european
countri
previous
report
clindamycin
resist
pcr
ribotyp
albeit
higher
mgl
object
analyz
trend
mortal
due
clostridium
difficil
enterocol
describ
affect
group
order
better
understand
current
clostridium
difficil
chang
epidemiolog
method
review
mortal
data
flander
brussel
region
belgium
million
inhabit
select
record
code
enterocol
due
clostridium
difficil
appear
underli
caus
death
within
death
certif
ageand
sexspecif
mortal
rate
calcul
period
direct
standardis
perform
use
european
standard
popul
confid
interv
calcul
stata
excel
use
statist
softwar
object
toxigen
clostridium
difficil
enter
pathogen
typic
hospit
environ
also
communityacquir
case
report
howev
rel
attempt
made
clarifi
role
soil
water
sourc
c
difficil
infect
novemberdecemb
drink
water
distribut
system
town
nokia
finland
massiv
contamin
treat
sewag
effluent
result
larg
gastroenter
outbreak
aim
present
studi
evalu
contamin
water
outbreak
also
potenti
sourc
c
difficil
infect
sampl
contamin
tap
water
treat
sewag
effluent
sampl
collect
soon
possibl
massiv
faecal
contamin
drink
water
distribut
system
occur
c
difficil
isol
heattreat
water
sampl
filtrat
ml
ml
ml
volum
water
place
membran
select
ccey
agar
plate
anaerob
incub
stool
sampl
patient
fallen
ill
epidem
examin
enter
pathogen
includ
c
difficil
potenti
c
difficil
coloni
subcultur
ccfa
agar
plate
toxinposit
isol
identifi
pcr
pcr
ribotyp
perform
accord
protocol
anaerob
refer
unit
cardiff
uk
use
cardiffecdc
cultur
collect
set
refer
strain
gel
electrophoresi
band
pattern
analyz
use
bionumer
softwar
result
altogeth
c
difficil
isol
found
water
sampl
twelv
isol
toxinposit
isol
contamin
tap
water
isol
treat
sewag
effluent
latter
contamin
sourc
among
tap
water
sewag
effluent
isol
distinct
pcr
ribotyp
profil
identifi
respect
human
faecal
c
difficil
isol
detect
divid
distinct
pcr
ribotyp
profil
none
profil
ident
hypervirul
pcr
ribotyp
two
isol
one
tap
water
anoth
patient
indistinguish
pcr
ribotyp
profil
conclus
observ
impli
c
difficil
contamin
tap
water
distribut
system
occur
waterborn
transmiss
toxigen
c
difficil
subsequ
c
difficil
infect
seem
possibl
object
accur
rapid
method
need
type
toxigen
clostridium
difficil
commerci
autom
repetit
pcr
system
reppcr
diversilab
inc
st
loui
usa
utilis
amplif
subsequ
autom
electrophoret
separ
repetit
extragen
palindrom
sequenc
c
difficil
aim
evalu
perform
reppcr
method
genotyp
c
difficil
isol
compar
pcr
ribotyp
addit
correl
reppcr
virul
gene
profil
c
difficil
strain
studi
method
total
toxinposit
c
difficil
isol
studi
includ
consecut
isol
two
laboratori
finland
contain
also
strain
hypervirul
c
difficil
ribotyp
addit
select
c
difficil
strain
bp
delet
tcdc
gene
analyz
dna
extract
reppcr
perform
accord
manufactur
instruct
amplif
product
reppcr
detect
analyz
use
diversilab
system
analysi
perform
webbas
softwar
accompani
system
use
librari
construct
option
diverslab
system
isol
comparison
test
virul
gene
tcda
tcdb
cdta
cdtb
tcdc
analyz
convent
pcr
whole
gene
sequenc
tcdc
perform
isol
delet
bp
pcr
ribotyp
perform
use
protocol
anaerob
refer
unit
cardiff
uk
correl
reppcr
profil
ribotyp
excel
major
ribotyp
group
cluster
reppcr
group
interestingli
subgroup
could
found
reppcr
within
two
preval
ribotyp
autom
reppcr
prove
reproduc
result
separ
dna
isol
pcrrunsmicrofluid
electrophoresi
well
result
perform
differ
individu
laboratori
personnel
compar
reppcr
profil
pcr
ribotyp
correl
also
virul
gene
profil
conclus
autom
reppcr
repres
effect
reproduc
method
genet
characteris
c
difficil
strain
clinic
laboratori
molecular
biolog
facil
construct
c
difficil
librari
allow
compar
related
c
difficil
strain
fingerprint
time
object
clostridium
difficil
infect
cdi
seriou
diarrhoeal
ill
associ
high
morbid
mortal
current
avail
treatment
oral
vancomycin
metronidazol
usual
produc
good
resolut
diarrhoea
associ
incid
recurr
first
new
class
macrocycl
antibiot
bactericid
via
uniqu
inhibit
rna
polymeras
phase
noninferior
clinic
trial
conduct
site
north
america
compar
efficaci
safeti
vancomycin
treat
cdi
method
elig
patient
adult
acut
cdi
symptom
posit
stool
toxin
test
patient
receiv
oral
mg
twice
daili
oral
vancomycin
mg
time
daili
day
primari
end
point
clinic
cure
resolut
symptom
need
cdi
therapi
day
stop
studi
drug
secondari
end
point
cdi
recurr
diarrhoea
posit
stool
toxin
test
within
week
treatment
global
cure
defin
clinic
cure
recurr
result
patient
enrol
evalu
per
protocol
pp
popul
n
mean
age
year
patient
male
equival
rate
clinic
cure
observ
vancomycin
pp
analysi
similar
outcom
observ
modifi
intenttotreat
mitt
analysi
significantli
fewer
patient
treat
vancomycin
experienc
recurr
pp
analysi
p
mitt
analysi
vs
p
significantli
patient
achiev
global
cure
vancomycintr
patient
pp
analysi
p
mitt
analysi
vs
p
well
toler
advers
event
profil
similar
vancomycin
studi
largest
compar
trial
new
antimicrobi
agent
versu
vancomycin
treatment
cdi
clinic
cure
rate
treatment
vancomycin
equival
howev
associ
significantli
lower
recurr
rate
higher
global
cure
rate
vancomycin
oral
nonabsorb
agent
conveni
twice
daili
dose
schedul
low
risk
advers
event
repres
potenti
new
treatment
option
cdi
associ
lower
recurr
rate
current
avail
treatment
result
sequenc
analysi
sa
reveal
locu
absent
type
mismatch
present
primer
anneal
site
loci
b
c
g
lower
anneal
temperatur
increas
magnesium
chlorid
concentr
loci
b
c
g
resolv
low
yield
pcr
product
appli
mlva
type
strain
reveal
strain
encompass
isol
human
n
porcin
n
origin
genet
relat
sum
tandem
repeat
differ
strd
three
clonal
complex
cc
defin
strd
recogn
one
cc
contain
human
n
porcin
n
strain
optimis
mlva
identifi
genet
relat
cluster
cc
among
isol
e
ni
cc
contain
isol
one
hospit
inde
sever
cluster
isol
e
ni
isol
obtain
ni
year
earlier
part
one
larg
cc
optimis
mlva
distinguish
andor
group
type
strain
distinct
set
type
strain
human
anim
origin
genet
relat
cluster
isol
distinct
set
consist
commun
sourc
type
last
observ
suggest
zoonot
transmiss
object
paper
updat
assess
contribut
communityassoci
clostridium
difficil
infect
cdi
report
english
mandatori
surveil
scheme
sinc
make
acut
commun
sector
nation
health
servic
nh
england
method
nh
acut
trust
hospit
group
england
requir
report
c
difficil
toxin
posit
diarrhoeal
specimen
process
laboratori
whether
patient
hospit
commun
time
onset
ill
specimen
taken
via
web
enabl
report
system
posit
specimen
patient
within
day
report
report
case
patient
year
age
omit
analysi
enhanc
surveil
data
includ
inform
date
admiss
patient
locat
prior
test
sex
age
patient
categori
cdi
collect
weben
report
system
sinc
april
risk
factor
inform
complet
voluntari
basi
result
case
cdi
patient
age
year
report
case
taken
nonacut
set
taken
gener
practition
specimen
taken
present
day
admiss
acut
trust
approxim
case
least
one
risk
factor
field
complet
case
report
risk
factor
inform
episod
categori
case
commun
associ
hospit
acquir
inform
report
suggest
commun
associ
case
patient
continu
infect
relaps
episod
cdi
compar
hospit
acquir
case
continu
infect
relaps
episod
cdi
conclus
c
difficil
specimen
report
acut
trust
diagnos
commun
set
publish
studi
suggest
might
expect
acquir
hospit
stay
within
previou
month
ie
commun
onset
hospit
acquir
case
futur
work
requir
investig
whether
differ
epidemiolog
risk
factor
eg
antibiot
exposur
outcom
patient
commun
onset
diseas
clostridium
difficileassoci
diseas
newli
notifi
diseas
ireland
skalli
f
roch
oflanagan
p
mckeown
f
dublin
ie
new
case
clostridium
difficileassoci
diseas
cdad
becam
notifi
ireland
may
main
object
new
notif
process
provid
nation
overview
epidemiolog
burden
cdad
paper
review
first
six
month
preliminari
data
notifi
method
interim
case
definit
new
recurr
cdad
case
propos
european
societi
clinic
microbiolog
infecti
diseas
escmid
studi
group
c
difficil
employ
report
review
weekli
event
cdad
extract
computeris
infecti
diseas
report
cidr
system
januari
censu
popul
figur
use
denomin
data
calcul
incid
rate
result
present
repres
week
data
submit
result
new
cdad
case
notifi
cidr
may
decemb
repres
crude
incid
rate
cir
popul
estim
annual
cir
case
laboratori
confirm
higher
occurr
case
femal
male
femal
ratio
period
case
sex
unknown
case
greater
year
age
categori
preliminari
data
submit
cidr
indic
case
hospit
inpati
case
either
gp
patient
outpati
origin
sampl
unknown
larg
variat
public
health
region
tabl
incid
cdad
ireland
promin
older
age
group
healthcar
set
remark
region
variat
case
report
vari
per
north
east
per
west
season
trend
indistinguish
present
due
late
batch
notif
institut
clostridium
difficileassoci
diarrhoea
immunosuppress
patient
cancer
object
assess
epidemiolog
clinic
featur
outcom
clostridium
difficil
cd
associ
diarrhoea
immunosuppress
patient
cancer
method
review
episod
cd
associ
diarrhoea
document
adult
cancer
haematopoiet
stem
cell
recipi
microbiolog
diagnosi
includ
cd
isol
stool
sampl
direct
detect
cd
toxin
test
cytotoxin
product
isol
strain
document
signific
increas
cd
associ
diarrhoea
admiss
admiss
p
episod
patient
thirtyon
patient
male
mean
age
year
forti
three
patient
haematolog
underli
diseas
solid
tumour
receiv
previou
chemotherapi
stem
cell
transplant
recipi
present
gvhd
neutropen
previou
month
patient
receiv
one
antibiot
cephalosporin
glycopeptid
carbapenem
betalactam
betalactam
inhibitor
quinolon
fever
abdomin
pain
frequent
manifest
diarrhoea
hemorrhag
case
patient
treat
metronidazol
median
day
antibiot
therapi
discontinu
patient
recov
neutropenia
diarrhoea
resolv
discontinu
antibiot
therapi
patient
develop
toxic
megacolon
need
surgeri
three
patient
relaps
overal
mortal
day
patient
incid
cd
associ
diarrhoea
cancer
patient
increas
significantli
recent
year
relat
import
morbid
mortal
better
strategi
improv
prevent
treatment
need
link
research
clinic
laboratori
find
relat
manag
invas
candida
infect
role
research
laboratori
manag
invas
candida
infect
goe
beyond
routin
avail
test
identif
candida
speci
suscept
test
antifung
agent
cuttingedg
molecular
epidemiolog
technolog
use
type
isol
candida
speci
base
dna
sequenc
multilocu
sequenc
type
scheme
design
c
albican
c
dubliniensi
c
glabrata
c
krusei
c
tropicali
multilocu
sequenc
type
use
investig
possibl
hospit
outbreak
infect
find
wide
differ
strain
type
within
unit
indic
outbreak
although
convers
true
c
albican
type
multipl
isol
patient
shown
peopl
tend
harbour
commens
mixtur
close
relat
differ
strain
type
may
provid
select
appropri
type
invas
particular
tissu
respons
antifung
treatment
strain
c
albican
clade
largest
group
relat
strain
type
higher
proport
isol
resist
flucytosin
clade
share
common
resist
mechan
research
mechan
resist
candida
speci
mani
type
antifung
progress
point
investig
look
design
dna
chip
could
use
identif
suscept
test
candida
isol
much
research
effort
goe
detail
studi
hostfungu
crosstalk
experiment
candida
infect
anim
model
infect
greatli
refin
latest
research
show
earli
releas
chemokin
attract
neutrophil
infect
tissu
contribut
immunopatholog
candida
infect
rapid
innat
immun
respons
also
emphas
need
antifung
intervent
earliest
possibl
stage
provid
best
chanc
success
treatment
dissemin
candida
infect
find
support
clinic
data
well
experiment
model
translat
latest
research
advanc
practic
diagnost
test
new
therapeut
approach
candida
infect
alway
take
long
time
typic
year
research
result
find
clinic
applic
howev
level
effort
invest
basic
candida
research
ensur
support
steadi
progress
diagnosi
manag
echinocandin
semisynthet
lipopeptid
increasingli
use
prevent
treatment
invas
fungal
infect
understand
pharmacokinet
pharmacodynam
pkpd
characterist
compound
critic
optim
clinic
use
echinocandin
potent
vitro
activ
candida
spp
although
c
parapsilosi
less
suscept
candida
speci
molecular
mechan
resist
candida
speci
relat
amino
acid
substitut
hot
spot
within
gene
becom
well
characteris
suscept
breakpoint
three
clinic
avail
compound
determin
recent
clinic
laboratori
standard
institut
susceptibleonli
breakpoint
mgl
suggest
pkpd
echinocandin
determin
experiment
model
dissemin
candidiasi
dissemin
pulmonari
invas
aspergillosi
studi
suggest
echinocandin
display
concentrationdepend
antifung
kill
effect
extens
distribut
peripher
tissu
exhibit
prolong
mean
resid
time
site
infect
fungicid
candida
spp
induc
dosedepend
morpholog
chang
aspergillu
spp
result
diminish
propens
angioinvas
aspergillu
spp
recent
evid
also
suggest
echinocandin
import
immunomodulatori
properti
may
contribut
significantli
observ
antifung
effect
pkpd
model
laboratori
animaltohuman
bridg
techniqu
use
identifi
safe
effect
dosag
echinocandin
rel
uncommon
clinic
syndrom
neonat
haematogen
candida
meningoenceph
techniqu
effici
method
identifi
effect
regimen
human
expedit
studi
clinic
trial
pkpd
model
techniqu
use
address
outstand
clinic
queri
relat
compound
includ
optim
dosag
decisionsupport
analysi
set
vitro
antifung
suscept
breakpoint
clinic
relev
inher
acquir
reduc
antifung
suscept
invas
candidiasi
antifung
treatment
patient
manag
patient
invas
candidiasi
repres
complex
issu
owe
heterogen
patient
infect
occur
establish
risk
factor
invas
candidiasi
includ
total
parenter
nutrit
multipl
organ
failur
candida
colonis
common
mani
type
patient
treat
within
critic
care
set
furthermor
sever
underli
condit
patient
necessit
swift
antifung
treatment
ensur
optim
outcom
addit
factor
consider
treat
candida
infect
chang
epidemiolog
candida
speci
potenti
fluconazoleresist
speci
c
glabrata
c
krusei
becom
common
particularli
patient
prior
fluconazol
exposur
rang
antifung
agent
avail
vitro
activ
candida
speci
howev
agent
suitabl
option
clinic
manag
invas
candidiasi
overal
complex
infect
underli
condit
exampl
posit
polyen
particularli
amphotericin
b
deoxychol
becom
less
tenabl
risk
renal
complic
increasingli
regard
unaccept
patient
like
risk
multipl
organ
failur
furthermor
increas
preval
fluconazoleresist
speci
recent
guidelin
longer
recommend
use
azol
firstlin
treatment
invas
candidiasi
except
special
case
focus
instead
echinocandin
agent
wealth
clinic
data
avail
echinocandin
micafungin
exampl
assess
invas
candidiasi
clinic
trial
includ
wide
varieti
underli
condit
pattern
infect
includ
neutropen
patient
deep
infect
periton
furthermor
micafungin
extens
evalu
echinocandin
paediatr
patient
test
children
age
year
prematur
infant
neonat
optim
manag
patient
invas
candidiasi
depend
strategi
take
account
complex
natur
diseas
judici
select
antifung
treatment
accompani
consider
nondrugrel
factor
improv
surviv
care
assess
intraven
cathet
potenti
involv
candida
infect
patient
invas
candidiasi
often
underli
condit
sever
ill
rang
neutropenia
cancer
chemotherapi
multiorgan
failur
intens
care
unit
patient
background
sever
underli
ill
difficult
appreci
success
otherwis
treatment
strategi
candida
infect
last
decad
major
advanc
made
antifung
therapi
introduct
echinocandin
extendedspectrum
azol
lipid
formul
amphotericin
b
robust
clinic
studi
success
use
candidaemia
publish
howev
import
translat
studi
practic
strategi
care
individu
patient
present
individu
case
use
provid
insight
success
failur
antifung
class
manag
invas
candidiasi
specif
interest
focus
use
fluconazol
versu
echinocandin
micafunginbas
case
support
insight
evidencebas
literatur
combin
practic
experi
bedsid
factor
consid
spectrum
activ
drug
toxic
drug
interact
drug
resist
pharmacolog
diagnosi
site
infect
use
biomarkerscultur
treatment
strategi
cost
import
realis
larg
clinic
trial
exclud
mani
patient
invas
candidiasi
therefor
use
individu
case
possibl
provid
insight
clinic
use
outstand
antifung
agent
patient
manag
era
rapid
diagnost
result
symposium
organis
cepheid
commun
mrsa
clostridium
difficil
chang
infect
control
hospit
infect
caus
methicillinresist
staphylococcu
aureu
mrsa
vancomycinresist
enterococci
clostridium
difficil
interrel
healthcar
institut
emerg
epidem
mrsa
c
difficil
strain
place
greater
burden
infect
control
system
healthcar
facil
often
must
increas
surveil
chang
disinfect
strategi
halt
transmiss
pathogen
hospit
iron
mrsa
strain
aros
commun
transmit
frequent
healthcar
set
epidem
c
difficil
strain
origin
healthcareassoci
pathogen
caus
consider
morbid
commun
set
success
slow
spread
pathogen
infect
control
must
work
close
laboratori
pharmaci
servic
ensur
organ
detect
rapidli
select
pressur
maintain
organ
institut
reduc
clearli
bundl
intervent
rather
singl
approach
necessari
contain
spread
organ
hospit
continu
influx
patient
communityacquir
mrsa
c
difficil
infect
healthcar
institut
challeng
infect
control
practition
clearli
increas
futur
food
born
pathogen
l
monocytogen
discov
murray
respons
sever
infect
variou
clinic
featur
gastroenter
mening
meningoenceph
materno
foetal
infect
high
mortal
rate
diseas
due
abil
listeria
cross
three
host
barrier
infect
intestin
barrier
placent
barrier
blood
brain
barrier
also
due
listeria
capac
surviv
macrophag
enter
non
phagocyt
cell
epitheli
cell
recoveri
infect
protect
reinfect
due
tcell
respons
explain
listeria
sinc
mani
year
becom
model
immunolog
nearli
three
decad
molecular
biolog
cell
biolog
approach
coupl
genet
postgenom
studi
promot
listeria
among
best
model
infect
biolog
depth
studi
mechan
entri
cell
help
unravel
listeria
cross
intestin
placent
barrier
unsuspect
concept
cell
biolog
discov
postgenom
studi
recent
allow
unveil
listeria
transcript
landscap
switch
saprophyt
virul
talk
give
overview
highlight
recent
result
frame
work
well
establish
data
last
sever
decad
research
medic
mycolog
offer
great
insight
fungal
cell
biolog
epidemiolog
phylogenet
cell
molecul
involv
pathogenesi
fungal
diseas
legitim
question
ask
extent
extens
advanc
comprehens
biolog
fungal
pathogen
contribut
improv
diagnosi
treatment
extent
patient
benefit
translat
basic
research
tool
clinic
manag
equal
valid
question
extent
biolog
scienc
benefit
studi
fungi
opportunist
pathogen
speaker
examin
question
perspect
long
experi
field
curmudgeonli
attitud
develop
age
object
incid
invas
meningococc
diseas
imd
report
czech
republ
sinc
respons
emerg
new
hypervirul
clonal
complex
nationwid
enhanc
surveil
invas
meningococc
diseas
implement
nation
refer
laboratori
meningococc
infect
nrl
case
definit
consist
ecdc
guidelin
cultur
pcr
use
confirm
case
notif
compulsori
perform
local
epidemiologist
strain
neisseria
meningitidi
isol
imd
case
refer
field
laboratori
nrl
characteris
serogroup
pora
feta
sequenc
http
neisseriaorgnmtyp
multilocu
sequenc
type
mlst
http
pubmlstorgneisseria
nrl
epidemiolog
databas
match
strain
avoid
duplic
report
final
enhanc
surveil
databas
result
despit
stabl
trend
imd
incid
sinc
case
fatal
rate
high
diseas
caus
mainli
serogroup
b
meningococci
follow
serogroup
c
frequent
clonal
complex
typic
serogroup
b
typic
serogroup
c
highest
agespecif
morbid
rate
observ
lowest
age
group
ie
month
year
respect
associ
high
preval
serogroup
b
case
fatal
rate
highest
infant
year
age
incid
imd
caus
serogroup
c
current
low
indic
mass
vaccin
menc
conjug
vaccin
menb
vaccin
need
infant
serosubtyp
coverag
current
develop
porinbas
vaccin
low
czech
meningococc
isol
maximum
nineval
meningococc
pora
vaccin
method
vaccin
programm
incorpor
dedic
vaccin
clinic
multidisciplinari
team
includ
nurs
data
manag
pharmacist
specif
appoint
unit
addit
intervent
improv
vaccin
uptak
outcom
includ
use
sm
text
announc
avail
influenza
annual
improv
adher
complet
hepat
b
vaccin
educ
programm
chang
guidelin
eg
varicella
vaccin
creation
vaccin
passport
review
vaccin
clinic
activ
cohort
hiv
posit
patient
sinc
introduct
dedic
vaccin
servic
result
larg
increas
uptak
vaccin
sinc
introduct
servic
varicella
vaccin
uptak
increas
due
target
vaccin
programm
see
graphic
legend
read
left
right
conclus
strategi
implement
increas
uptak
recommend
vaccin
hiv
popul
includ
appoint
dedic
health
profession
team
use
support
educ
staff
patient
develop
vaccin
passport
develop
vaccin
passport
help
patient
educ
awar
serv
record
vaccin
administr
physician
site
latter
year
post
guidelin
chang
target
varicella
non
immun
popul
next
intervent
plan
assess
late
entrant
healthcar
system
determin
need
catch
vaccin
includ
mmr
result
column
purifi
recombin
protein
found
good
antigen
group
anim
use
immunis
antibodi
recombin
test
opsonophagocytosi
found
enhanc
phagocytosi
gb
strain
belong
differ
serotyp
averag
time
rel
control
affect
ga
strain
less
pronounc
time
still
statist
signific
antibodi
also
capabl
interfer
adher
gb
strain
carri
rel
strain
without
protein
adher
strain
toward
differ
cell
line
dramat
higher
prove
function
protein
adhesin
passiv
protect
test
carri
mice
challeng
virul
gb
ga
strain
introduc
intranasali
elimin
lung
anim
time
faster
case
usag
anti
serum
rel
control
experi
activ
protect
immunis
anim
found
significantli
better
protect
gb
ga
infect
tabl
similar
result
obtain
analysi
factor
associ
mortal
conclus
data
suggest
outcom
communityonset
nosocomi
bloodstream
infect
due
aureu
may
improv
expert
consult
servic
factor
critic
better
outcom
modifi
time
id
specialist
consult
remain
determin
may
explor
process
care
qualiti
indic
object
worldwid
present
tuberculosi
epidem
characteris
alarm
emerg
drug
resist
given
limit
therapeut
option
mdr
especi
xdr
tuberculosi
need
defin
resist
level
mechan
present
clinic
isol
categoris
drug
resist
basi
critic
concentr
test
facilit
rapid
therapeut
decis
method
determin
quantit
resist
level
drug
resist
isol
mycobacterium
tuberculosi
sampl
switzerland
past
year
resistanceconf
genet
alter
identifi
probe
assay
pcrmediat
gene
sequenc
result
rifampicin
resist
isol
unanim
show
highlevel
resist
phenotyp
mgl
associ
mutat
rpob
contrast
signific
fraction
clinic
tb
isol
categoris
isoniazid
resist
basi
critic
concentr
test
show
lowlevel
resist
phenotyp
mostli
mutat
inha
heterogen
phenotyp
resist
level
associ
mutat
katg
one
third
streptomycin
resist
clinic
isol
lowlevel
resist
phenotyp
mgl
ethambutol
resist
occur
mostli
mdr
strain
link
alter
embb
resist
never
exceed
mgl
data
indic
first
line
agent
may
consid
therapeut
treatment
option
despit
vitro
resist
critic
concentr
diagnost
mycobacteriolog
would
benefit
standardis
measur
quantit
drug
suscept
test
particular
drug
signific
variat
phenotyp
resist
level
found
clinic
isol
eg
isoniazid
ethambutol
streptomycin
introduct
recent
advanc
diagnost
varicella
zoster
viru
vzv
infect
chang
percept
viru
cn
pathogen
realtim
pcr
method
amplifi
nt
segment
vzv
gb
region
gave
log
improv
sensit
convent
pcr
employ
routin
diagnosi
vzv
dna
sampl
cerebrospin
fluid
csf
addit
new
elisa
method
detect
antibodi
csf
glycoprotein
e
develop
use
mammalian
cell
express
system
optim
glycosyl
antigen
method
utilis
studi
vzvinduc
cn
infect
retrospect
studi
almost
patient
reactiv
vzv
infect
show
skin
lesion
follow
diagnos
made
acut
asept
mening
aam
n
enceph
n
meningoenceph
n
cranial
nerv
affect
n
encephalopathi
n
cerebrovascular
diseas
n
patient
vzv
dna
level
determin
significantli
higher
viral
load
found
aam
enceph
compar
patient
cranial
nerv
affect
includ
ramsay
hunt
syndrom
n
followup
n
neurolog
complic
month
sixtytwo
percent
ctmri
scan
brain
perform
patholog
find
vzv
enceph
show
broad
diseas
spectrum
compar
herp
simplex
enceph
hse
present
detect
intrathec
synthesi
vzv
ge
antibodi
posit
vzv
enceph
patient
well
hse
patient
argu
previou
suggest
role
vzv
copathogen
least
case
latter
diseas
vzv
vascul
common
find
case
expect
literatur
case
report
mr
find
show
middl
posterior
cerebr
arteri
target
surprisingli
despit
substanti
vzv
dna
load
csf
patient
investig
serum
sampl
pcr
neg
thu
vzv
might
suggest
neuron
transport
arteri
wall
rather
haematogen
spread
conclus
vzv
seriou
underestim
caus
cn
infect
substanti
number
patient
present
seriou
neurolog
symptom
sequela
patholog
find
ctmri
brain
abund
especi
patient
enceph
vascul
pkpd
controversi
clinician
pkpd
azol
triazol
revolutionis
treatment
invas
allerg
fungal
diseas
fluconazol
itraconazol
voriconazol
posaconazol
avail
clinic
use
isavuconazol
ravuconazol
develop
triazol
broad
spectrum
antifung
activ
pharmacokinet
pharmacodynam
pkpd
triazol
extens
investig
murin
model
dissemin
candidiasi
pd
paramet
optim
link
drug
exposur
observ
antifung
effect
ratio
area
concentrationtim
curv
auc
mic
auc
mic
increas
inform
magnitud
auc
mic
requir
optim
antifung
effect
pkpd
principl
use
defin
vitro
suscept
breakpoint
triazol
fungistat
candida
spp
mode
action
aspergillu
spp
less
well
defin
although
clearli
exhibit
dosedepend
decrement
fungal
burden
laboratori
anim
model
invas
pulmonari
aspergillosi
triazol
accumul
tissu
import
understand
antifung
effect
human
triazol
characteris
complic
pharmacokinet
properti
itraconazol
voriconazol
exhibit
nonlinear
pharmacokinet
triazol
exhibit
clinic
relev
exposurerespons
relationship
recent
work
laboratori
suggest
itraconazol
exhibit
clinic
relev
concentrationtox
relationship
higher
concentr
voriconazol
associ
progress
higher
probabl
hepatotox
photopsia
central
nervou
system
toxic
signific
pharmacokinet
variabl
clinic
relev
drug
exposurerespons
relationship
therapeut
drug
monitor
tdm
frequent
use
strong
argument
made
routin
monitor
itraconazol
voriconazol
may
also
ground
consid
monitor
posaconazol
level
tdm
consid
patient
receiv
triazol
refractori
diseas
furthermor
tdm
consid
complianc
drug
interact
variabl
pharmacokinet
result
uncertainti
result
drug
exposur
understand
pkpd
relationship
triazol
instrument
optimis
clinic
efficaci
innat
immun
inflammasom
danger
sens
complex
trigger
innat
immun
nodlik
receptor
nlr
famili
intracellular
sensor
microbi
motif
danger
signal
emerg
crucial
compon
innat
immun
respons
inflamm
sever
nlr
nalp
ipaf
form
multiprotein
complex
term
inflammasom
process
proinflammatori
cytokin
includ
amongst
variou
inflammasom
inflammasom
particularli
qualifi
sens
plethora
divers
molecul
rang
bacteri
muramyldipeptid
monosodium
urat
crystal
import
role
inflammasom
emphas
identif
mutat
gene
associ
suscept
inflammatori
disord
issu
relat
inflammasom
present
year
sinc
charl
janeway
hypothes
exist
clonal
deriv
pattern
recognit
receptor
point
import
initi
respons
bacteri
viral
infect
janeway
hypothesi
valid
discoveri
three
group
prr
first
tolllik
receptor
detect
microbi
lipid
nonself
nucleic
acid
cell
surfac
intracellular
compart
addit
cytoplasm
sensor
bacteria
nod
viral
nucleic
acid
rig
also
characteris
well
critic
respons
infect
prr
also
underli
larg
burden
autoimmun
inflammatori
diseas
human
popul
thu
import
target
therapi
talk
describ
molecular
mechan
conserv
pathogen
associ
moecul
recogn
tlr
particular
refer
lipo
polysaccharid
singl
strand
viral
rna
also
present
new
result
show
receptor
activ
coupl
downstream
signal
transduct
particular
role
play
oligomer
signal
platform
assembl
form
adaptor
signal
molecul
involv
pathway
discuss
potenti
structur
analysi
use
ration
design
new
drug
session
propos
critic
review
salient
recent
publish
paper
field
special
focu
control
multi
drugresist
organ
prevent
infect
intens
care
unit
surgeri
etc
highlight
need
validityscop
assess
emphas
also
import
prioritis
inform
publish
abund
literatur
avail
abl
summaris
understand
potenti
chang
clinic
practic
identifi
unresolv
issu
area
possibl
futur
clinic
research
tourism
europ
face
world
also
major
sourc
revenu
employ
product
year
million
arriv
record
contin
approxim
million
latin
america
return
travel
even
numer
often
associ
diseas
transmiss
europ
within
countri
european
contin
import
case
environment
zoonot
ill
cholera
dengu
malaria
viral
haemorrhag
fever
west
nile
viru
infect
rare
establish
fact
diseas
import
latin
america
potenti
autochthon
transmiss
chikungunya
malaria
yellow
fever
high
infect
viral
haemorrhag
fever
describ
detail
possibl
european
outbreak
latin
american
countri
discuss
cutan
leishmaniasi
cl
worldwid
diseas
endem
countri
shown
increas
incid
last
two
decad
far
pentaval
antimoni
compound
consid
treatment
choic
rate
cure
close
howev
high
efficaci
drug
counteract
advers
event
recent
vitro
vivo
studi
shown
play
key
role
erad
leishmania
parasit
object
determin
whether
donor
patch
develop
electrospin
techniqu
effect
meglumin
antimoni
treatment
cl
caus
less
advers
event
method
doubleblind
randomis
placebocontrol
clinic
trial
conduct
patient
diagnos
cl
santand
colombia
southamerica
patient
randomli
assign
two
group
day
group
receiv
simultan
meglumin
antimoni
placebo
nitric
oxid
patch
group
receiv
activ
nitric
oxid
patch
placebo
meglumin
antimoni
biochem
determin
aspart
aminotransferas
alanin
aminotransferas
creatinin
pancreat
amilas
measur
begin
end
treatment
follow
realis
day
begin
treatment
result
studi
includ
women
men
averag
age
group
year
group
year
clinic
demograph
data
similar
two
group
follow
period
complet
clinic
heal
group
versu
group
p
treatment
patch
gener
lower
frequenc
nonseri
advers
event
fever
anorexia
myalgia
arthralgia
headach
reduc
variat
biochemistri
determin
asat
treatment
patch
result
lower
percentag
complet
clinic
respons
compar
meglumin
antimoni
despit
inferior
effect
safeti
lower
frequenc
advers
event
facil
administr
topic
low
cost
patch
justifi
evalu
poblat
studi
especi
popul
colombian
one
seriou
advers
event
due
glucantim
increas
dramat
object
trichinellosi
zoonot
diseas
never
report
taiwan
rare
link
consumpt
reptil
investig
first
document
outbreak
trichinellosi
taiwan
consist
patient
becam
acut
ill
eat
restaur
may
conduct
retrospect
cohort
studi
interview
patient
person
ate
togeth
case
defin
ill
attende
fever
myalgia
week
festiv
seroposit
trichinella
antigen
use
enzymelink
immunoassay
immunohistochem
stain
environment
studi
softshel
turtl
farm
perform
result
attende
person
met
case
definit
attack
rate
common
present
symptom
myalgia
fever
periorbit
swell
patient
sought
medic
care
five
hospitalis
patient
underw
blood
test
moder
eosinophilia
patient
serum
sampl
strongli
reactiv
trichinella
excretorysecretori
antigen
food
item
significantli
associ
ill
raw
softshel
turtl
meat
rel
risk
undefin
p
trace
back
farm
histolog
examin
softshel
turtl
neg
trichinella
speci
like
caus
outbreak
consumpt
raw
softshel
turtl
serv
festiv
investig
indic
taiwan
free
trichinellosi
prevent
control
program
trichinellosi
establish
public
awar
risk
acquir
trichinellosi
consumpt
raw
softshel
turtl
object
develop
evalu
modifi
rapid
giemsa
stain
procedur
detect
malaria
parasit
blood
smear
disadvantag
rapid
commerci
avail
stain
method
requir
highli
experienc
technician
interpret
result
interpret
difficult
reason
mani
laboratori
use
giemsa
stain
shorter
giemsa
stain
time
report
previous
howev
knowledg
effect
minut
stain
differ
giemsa
dilut
evalu
stock
solut
giemsa
stain
merck
darmstadt
germani
use
differ
dilut
incub
differ
length
time
min
min
stain
effect
compar
standard
giemsa
stain
min
sensit
determin
examin
smear
p
falciparum
fresh
edta
blood
level
parasitaemia
follow
two
patient
admit
hospit
p
falciparum
parasitaemia
see
tabl
patient
b
examin
blood
smear
taken
differ
time
point
initi
therapi
sampl
use
evalu
differ
giemsa
dilut
stain
time
smear
read
three
independ
observ
clinic
microbiologist
laboratori
technician
specialis
parasitolog
resid
clinic
microbiolog
tabl
result
three
stain
method
blood
two
patient
ghana
high
parasitaemia
admiss
followup
shown
smear
equal
easi
read
yield
parasit
count
within
intern
accept
rang
variat
see
unit
kingdom
nation
extern
qualiti
assess
servic
conclus
stain
blood
smear
detect
plasmodium
falciparum
parasit
dilut
giemsa
stain
five
minut
provid
easi
read
slide
result
compar
obtain
standard
giemsa
stain
advantag
rapid
method
shorter
turnaround
time
disadvantag
larger
amount
stain
use
object
diarrhoeal
diseas
common
develop
develop
countri
major
caus
morbid
mortal
worldwid
need
differenti
diagnos
protozoan
parasit
versu
gastrointestin
gi
aetiolog
well
recogn
common
gi
protozoan
parasit
infect
human
worldwid
consid
entamoeba
histolytica
giardia
lamblia
blastocysti
homini
dientamoeba
fragili
cryptosporidium
spp
laboratori
detect
parasit
reli
microscop
analysi
stool
sampl
water
concentr
well
enzym
immunoassay
eia
test
utilis
microscop
examin
usual
result
underdetect
gi
parasit
usag
eia
often
costeffect
method
savyon
diagnost
current
engag
develop
approach
aim
address
unmet
need
current
limit
field
approach
includ
major
aspect
abil
detect
panel
organ
one
test
kit
possibl
perform
diagnosi
two
step
first
simultan
detect
organ
without
distinguish
differ
speci
screen
larg
number
specimen
second
distinct
detect
specif
aetiolog
positivelyfound
specimen
abil
appli
eia
diagnosi
formalinpreserv
specimen
mention
parasit
result
polyclon
antibodi
produc
inhous
base
nativ
antigen
extract
recombin
antigen
synthet
peptid
result
inventori
antibodi
enabl
find
optim
combin
provid
desir
perform
paramet
separ
detect
parasit
fresh
frozen
formalin
preserv
faec
specimen
analyt
limit
detect
perform
characteris
clinic
specimen
compar
microscopi
refer
eia
avail
result
show
uniqu
detect
e
histolytica
formalinpreserv
specimen
compar
detect
fresh
specimen
furthermor
demonstr
simultan
detect
parasit
without
compromis
perform
characterist
fresh
preserv
specimen
present
work
paradigm
innov
approach
expect
advanc
diagnosi
protozoan
parasit
gi
patient
thu
enabl
appropri
costeffect
diagnosi
treatment
object
system
administr
certain
facult
anaerob
bacteria
mice
bear
solid
tumour
lead
accumul
tumour
compar
normal
target
organ
like
spleen
liver
retard
tumour
growth
salmonella
enterica
serovar
typhimurium
typhimurium
well
escherichia
coli
nissl
ecn
bacteria
preliminari
experi
show
bacteria
exhibit
abil
form
biofilm
vitro
might
also
tumour
present
studi
systemat
investig
method
biofilm
format
bacteria
detect
lowsalt
biofilm
plate
addit
salmonellaor
e
coliinfect
balbc
mice
left
untreat
treat
deplet
neutrophil
granulocyt
remov
two
day
post
infect
fix
prepar
electron
microscop
analysi
express
differ
gene
probabl
involv
biofilm
format
test
via
realtim
pcr
result
examin
colonis
tumour
typhimurium
well
ecn
almost
exclus
found
extracellular
although
abl
invad
cell
vitro
interestingli
like
vitro
three
bacteria
form
biofilm
variou
extend
resid
tumour
follow
detail
typhimurium
biofilm
form
neutrophil
remov
antibodi
addit
arda
central
switch
biofilm
format
salmonellla
delet
biofilm
could
found
importantli
bacteria
could
found
intracellularli
like
neutrophil
granulocyt
conclus
format
biofilm
facult
anaerob
bacteria
resid
solid
tumour
novel
surpris
find
neutrophil
remov
biofilm
form
uptak
neutrophil
allow
abil
bacteria
form
biofilm
block
henc
appear
bacteria
use
biofilm
format
defenc
system
immun
system
host
object
rama
aracxyl
famili
transcript
activ
found
klebsiella
pneumonia
salmonella
spp
enterobact
spp
overexpress
associ
mdr
phenotyp
recent
tetrlik
gene
lie
upstream
rama
known
ramr
identifi
repressor
rama
k
pneumonia
diazotroph
endophyt
strain
report
exhibit
notabl
resist
antibiot
despit
mdr
phenotyp
shown
exhibit
attenu
pathogen
mous
model
comparison
clinic
k
pneumonia
strain
aim
studi
determin
level
rama
express
establish
role
mdr
phenotyp
determin
effect
ramr
complement
rama
express
antibiot
suscept
method
genom
sequenc
analysi
perform
k
pneumonia
strain
demonstr
bp
delet
within
ramr
gene
clone
complement
full
size
wild
type
ramr
perform
herebi
known
rtpcr
use
assess
level
gene
express
subsequ
quantifi
use
biorad
quantiti
one
softwar
mic
test
perform
chloramphenicol
cm
norfloxacin
tetracyclin
tet
accord
bsac
guidelin
biofilm
format
measur
use
modifi
protocol
otool
kolter
result
contain
mutat
ramr
gene
bp
delet
shown
overexpress
rama
put
outer
membran
protein
roma
complement
ramr
gene
result
repress
rama
roma
transcript
fold
interestingli
ramr
complement
strain
demonstr
increas
biofilm
format
increas
hour
period
lb
medium
static
growth
mic
test
antibiot
reduc
compar
ramr
mutat
conclus
result
demonstr
ramr
act
repressor
rama
put
outer
membran
protein
roma
therebi
increas
suscept
antibiot
howev
restor
function
ramr
also
increas
biofilm
format
significantli
suggest
ramr
play
role
regul
biofilm
format
gene
possibl
bacteri
virul
rifampicin
show
highest
activ
biofilm
matrix
bacteria
sa
pa
biofilm
result
also
indic
biofilm
viabl
mass
suscept
treatment
biofilm
matrix
mainli
respons
biofilm
persist
research
specif
focu
compound
destroy
matrix
use
adjunct
antibiot
therapi
object
staphylococcu
epidermidi
common
caus
foreignbodi
infect
fbi
abil
form
biofilm
biofilm
resist
antibiot
activ
passiv
immunis
biofilmassoci
bacteri
antigen
may
altern
studi
effect
immunis
lpxtg
protein
sesc
epidermidi
biofilm
vitro
vivo
previous
report
sesc
present
epidermidi
strain
test
sesc
mainli
express
earli
late
fbi
higher
level
sessil
cell
plankton
cell
method
use
rabbit
polyclon
antisescigg
mgml
studi
biofilm
inhibit
vitro
vivo
rat
model
mg
igg
per
rat
old
biofilm
also
vaccin
rat
twice
sesc
accord
standard
protocol
serum
sampl
taken
day
week
immunis
test
elisa
show
increas
antisesc
antibodi
level
epidermidi
strain
biofilm
form
strain
describ
vitro
experi
epidermidi
mix
antisescigg
incub
hour
subsequ
cell
ad
well
h
biofilm
wash
stain
crystal
violet
measur
vivo
experi
cathet
fragment
preincub
epidermidi
implant
subcutan
rat
explant
averag
number
cfu
determin
hr
result
data
show
rabbit
antisescigg
inhibit
vitro
biofilm
format
epidermidi
strain
respect
n
vivo
rat
model
rabbit
antisescigg
reduc
bacteria
old
biofilm
n
activ
immunis
recombin
sesc
led
reduct
cfu
compar
control
rat
dayold
biofilm
n
day
reduct
biofilmassoci
bacteria
immunis
rat
n
fig
conclus
sesc
repres
promis
target
prevent
epidermidi
biofilm
format
higher
effect
passiv
immunis
compar
activ
immunis
probabl
due
subcutan
inject
antisescigg
place
cathet
insert
object
staphylococcu
epidermidi
emerg
pathogen
associ
infect
implant
medic
devic
imped
longterm
use
characterist
epidermidi
allow
persist
infect
abil
bacteria
adher
surfac
multilay
cell
cluster
follow
product
mucoid
substanc
commonli
known
slime
encod
ica
operon
adher
bacteria
slime
collect
known
biofilm
coupl
effect
specif
chemic
termin
surfac
group
flow
condit
slime
product
biofilm
format
epidermidi
investig
correl
express
two
gene
ica
operon
method
refer
control
strain
slimeposit
slimeneg
two
clinic
strain
isol
differ
hospitalis
patient
one
icapositiveslimeposit
one
icapositiveslimeneg
test
bacteria
grown
bhi
medium
suspend
physiolog
salin
concentr
cellsml
hydroxyl
oh
termin
hydrophil
methyl
termin
hydrophob
glass
surfac
use
substrat
parallel
plate
flow
chamber
bacteri
adhes
examin
two
flow
rate
mlmin
mlmin
two
four
hour
total
rna
plankton
p
adher
bacteria
detach
trypsin
isol
trizol
method
revers
transcript
follow
rel
realtim
pcr
rrtpcr
toward
bp
part
rrna
gene
allow
detect
express
level
icaa
icad
adher
bacteria
investig
scan
electron
confoc
laser
microscop
result
higher
express
level
icaa
icad
gene
onto
glass
especi
methyltermin
glass
surfac
calcul
rrtpcr
higher
flow
rate
two
hour
refer
clinic
slimeposit
strain
result
correl
well
adher
bacteri
cell
count
imag
taken
microscop
icaposit
slimeneg
clinic
strain
show
lower
express
level
ica
gene
less
adher
abil
pia
product
glass
surfac
observ
microscop
higher
flow
rate
enhanc
express
level
ica
gene
peak
two
hour
hydrophob
biomateri
surfac
seem
play
crucial
role
initi
adher
increas
ica
gene
express
pia
synthesi
consent
men
women
dfi
predefin
clinic
sign
symptom
caus
mrsa
potenti
elig
includ
associ
bacteraemia
patient
initi
osteomyel
exclud
patient
could
receiv
l
mg
bid
either
iv
po
primari
end
point
cure
improv
rate
ci
microbiolog
erad
day
begin
l
secondari
end
point
ci
day
begin
treatment
hospit
discharg
day
need
amput
durat
therapi
mortal
rate
advers
event
collect
result
patient
enrol
relat
men
women
age
patient
year
averag
period
diagnosi
diabet
year
associ
bacteraemia
present
patient
includ
primari
end
point
ci
day
begin
l
achiev
patient
obtain
patient
secondari
end
point
ci
day
hospit
discharg
day
day
begin
treatment
respect
patient
need
minor
amput
primari
secondari
end
point
subgroup
bacteraem
episod
statist
differ
previous
describ
mean
durat
therapi
day
global
mortal
one
episod
polineuropathi
report
neither
thrombocytopenia
lactic
acidosi
found
conclus
l
achiev
excel
ci
even
first
evalu
visit
document
dfi
caus
mrsa
l
also
show
high
rate
although
patient
receiv
prolong
period
treatment
l
safe
drug
object
azithromycin
microspher
formul
azm
develop
enabl
higher
dosag
g
administ
singl
oral
dose
without
decreas
safeti
profil
studi
compar
azm
moxifloxacin
mox
aim
confirm
efficaci
safeti
azm
acut
exacerb
chronic
bronchiti
aecb
method
prospect
multicentr
randomis
doubleblind
doubl
dummi
studi
compar
azm
g
singl
dose
mox
mg
daili
day
enrol
aecb
patient
year
old
anthonisen
type
exacerb
least
exacerb
aecb
past
month
subject
histori
smoke
least
packyear
document
forc
expiratori
volum
second
less
predict
follow
month
result
total
patient
treat
treatment
group
distribut
age
mean
similar
treatment
group
pathogen
isol
patient
patient
azm
patient
mox
clinic
success
sign
symptom
relat
acut
infect
return
subject
normal
baselin
level
clinic
improv
addit
antibiot
deem
necessari
rate
per
protocol
popul
test
cure
toc
day
azm
mox
group
ci
bacteri
erad
rate
bacteriolog
pre
protocol
popul
toc
azm
group
mox
group
ci
although
studi
popul
histori
least
exacerb
past
month
less
half
subject
experienc
recurr
followup
statist
signific
treatment
differ
time
taken
first
occurr
aecb
treatment
well
toler
incid
treatment
relat
advers
event
low
report
subject
receiv
azm
subject
receiv
mox
ae
mild
moder
sever
common
ae
gastrointestin
disord
report
subject
receiv
azm
subject
receiv
mox
conclus
singl
oral
dose
azm
effect
cours
mox
treatment
aecb
well
toler
object
optim
durat
gentamicin
contain
regimen
therapi
human
brucellosi
clearli
determin
method
randomis
clinic
studi
conduct
compar
efficaci
gentamicin
mgday
day
plu
doxycyclin
mg
twice
daili
eight
week
gd
group
versu
streptomycin
im
week
plu
dose
doxycyclin
day
sd
group
case
follow
one
year
cessat
therapi
efficaci
regimen
failur
therapi
relaps
compar
result
seventynin
patient
mean
age
year
case
mean
age
year
treat
regimen
gd
sd
respect
clinic
manifest
two
treat
group
similar
failur
therapi
seen
one
patient
gd
group
case
sd
group
object
studi
efficaci
telavancin
tlv
investig
bactericid
lipoglycopeptid
treatment
complic
skin
soft
tissu
infect
cssti
caus
presum
confirm
gramposit
organ
method
atla
atla
methodolog
ident
doubleblind
randomis
multin
phase
studi
adult
men
women
present
cssti
includ
major
abscess
randomis
tlv
mgkg
intraven
iv
h
vancomycin
van
g
iv
h
day
testofcur
toc
visit
conduct
day
end
studi
treatment
alltreat
popul
includ
patient
confirm
diagnosi
cssti
receiv
dose
studi
medic
analysi
examin
baselin
characterist
cure
rate
toc
patient
major
abscess
combin
atla
popul
result
pool
popul
atla
patient
present
major
abscess
patient
requir
hospitalis
baselin
lesion
surfac
area
exceed
cm
case
patient
present
lesion
exceed
cm
tabl
elev
white
blood
cell
count
found
case
tabl
nearli
patient
requir
surgic
drainag
approxim
perform
prior
first
dose
studi
medic
patient
requir
surgic
procedur
day
start
studi
medic
clinic
cure
rate
toc
present
tabl
overal
advers
event
popul
similar
treatment
group
regard
type
sever
conclus
telavancin
administ
daili
noninferior
vancomycin
treatment
major
abscess
object
b
fragili
relat
speci
member
normal
bowel
flora
wide
isol
anaerob
bacteria
differ
infect
follow
develop
spread
resist
among
strain
difficult
antibiot
suscept
test
clinic
relev
anaerob
differ
routin
laboratori
europ
less
less
frequent
carri
due
fact
clinician
treat
mani
presum
anaerob
infect
empir
follow
chang
antibiot
resist
bacteroid
strain
three
europewid
studi
organis
past
twenti
year
evalu
result
studi
may
show
chang
resist
differ
antianaerob
drug
clinic
isol
normal
flora
member
bacteroid
strain
belong
differ
speci
collect
differ
countri
throughout
europ
studi
agar
dilut
method
use
antibiot
suscept
determin
actual
breakpoint
accept
nccl
clsi
eucast
use
molecular
genet
investig
carri
detect
resist
mechan
sinc
first
studi
chromosom
mediat
betalactamas
product
tetracyclin
resist
preval
among
bacteroid
strain
europ
clindamycin
resist
bacteroid
mediat
macrolidelincomycinstreptogramin
ml
mechan
frequenc
differ
differ
countri
europ
resist
betalactambetalactamas
inhibitor
combin
studi
use
amoxicillinclavulan
acid
andor
piperacillintazobactam
increas
resist
observ
combin
throughout
year
true
cefoxitin
third
studi
sever
heteroresist
isol
found
occurr
spread
resist
imipenem
metronidazol
among
bacteroid
strain
merit
special
clinic
import
presenc
cfia
gene
much
preval
express
imipenem
resist
howev
spread
cfia
gene
among
speci
b
fragili
still
rare
molecular
genet
method
look
resist
gene
among
strain
elev
mic
antibiot
prove
resist
breakpoint
reconsid
resist
moxifloxacin
show
great
differ
differ
countri
lowest
resist
rate
observ
case
tigecyclin
mani
factor
may
affect
respons
treatment
site
infect
surgic
procedur
sever
ill
patient
statu
presenc
pathogen
mix
infect
pkpd
paramet
antibacteri
drug
thu
correl
treatment
failur
antibiot
resist
among
anaerob
remain
difficult
assess
main
discrep
came
intraabdomin
infect
worrisom
disjunct
surgeon
microbiologist
opinion
emerg
patient
primari
therapi
fail
resist
strain
compar
patient
therapi
succeed
contrast
mani
failur
may
due
lack
isol
anaerob
clinic
sampl
anaerob
bacteraemia
salonen
et
al
demonstr
mortal
increas
dramat
initi
effect
treatment
ineffect
treatment
start
face
new
mechan
resist
global
increas
resist
mani
antibiot
among
anaerob
may
lead
nowaday
differ
answer
clindamycin
vs
penicillin
studi
treatment
lung
infect
point
failur
due
blactamas
product
among
gramneg
anaerob
found
mani
report
failur
clindamycin
treatment
osteomyel
septic
arthriti
brain
abscess
presenc
clindamycinresist
anaerob
bacteroid
fragili
group
prevotella
probabl
resist
occur
clindamycin
mic
high
similarli
lack
coverag
undetect
resist
anaerob
allow
select
anaerob
strain
resist
treatment
chosen
associ
aerob
imipenemresist
eghertella
lenta
metronidazoleresist
strain
prevotella
bacteroid
fragili
later
failur
may
give
opportun
set
new
metronidazol
breakpoint
resist
mic
mgl
main
problem
relat
difficulti
detect
heterogen
resist
strain
need
prolong
incub
period
agar
medium
kind
situat
probabl
suitabl
correl
bacteri
antibiot
resist
failur
antibiot
treatment
methicillinresist
aureu
isol
caus
communityacquir
infect
camrsa
children
major
problem
sever
area
around
world
camrsa
associ
skin
soft
tissu
infect
invas
infect
recurr
soft
tissu
infect
infect
within
famili
caus
camrsa
isol
common
camrsa
aureu
isol
contain
gene
code
pvl
associ
seriou
staphylococc
pneumonia
well
osteomyel
complic
subperiost
abscess
venou
thrombos
addit
vancomycin
camrsa
gener
suscept
clindamycin
trimethoprimsulfamethoxazol
treatment
superfici
skin
soft
tissu
infect
involv
surgic
drainag
abscess
follow
oral
agent
tmpsmx
clindamycin
minocyclin
doxycyclin
consider
children
year
old
empir
vancomycin
typic
administ
seriou
invas
infect
osteomyel
septic
arthriti
seriou
head
neck
infect
suspect
staphylococc
pneumonia
clindamycin
efficaci
treat
invas
camrsa
infect
caus
suscept
organ
linezolid
daptomycin
anoth
option
select
circumst
mri
optim
imag
modal
assess
children
camrsa
osteomyel
aggress
surgic
drainag
subperiost
abscess
site
pyomyos
recommend
venou
thombosi
increasingli
recogn
complic
camrsa
osteomyel
anticoagul
thrombu
resolv
recommend
optim
approach
prevent
recurr
camrsa
infect
unclear
strategi
includ
emphas
person
hygien
plusminu
antimicrobi
soap
mupirocin
nose
bleach
bath
frequent
suggest
understand
pathogenesi
group
streptococc
diseas
bedsidetobench
approach
invas
group
streptococc
ga
infect
present
rang
guis
notori
necrotis
fasciiti
streptococc
toxic
shock
syndrom
human
pathogen
ga
pathogenesi
research
ideal
shape
clinic
question
aris
either
epidemiolog
casebas
investig
human
diseas
mid
larg
epidemiolog
studi
point
central
role
specif
cellstimul
superantigen
aetiolog
streptococc
toxic
shock
spark
seri
clinic
laboratori
investig
demonstr
product
superantigen
infect
inde
capabl
trigger
massiv
cell
activ
patient
unlik
alon
account
featur
observ
toxic
shock
genom
clinic
laboratorybas
investig
identifi
novel
highli
potent
superantigen
appear
directli
contribut
sepsi
pathogenesi
togeth
may
constitut
target
adjunct
treatment
invas
diseas
epidemiolog
clinic
laboratori
studi
highlight
role
blunt
trauma
aetiolog
least
quarter
case
ga
necrotis
fasciiti
one
strike
find
examin
tissu
patient
suffer
necrotis
fasciiti
failur
neutrophil
migrat
focu
infect
investig
patient
invas
ga
infect
led
discoveri
ga
produc
enzym
cleav
inactiv
human
chemokin
studi
patient
bacteraemia
highlight
like
role
causal
enzym
spycep
diseas
pathogenesi
bacteri
surfac
enzym
also
shown
promis
potenti
vaccin
antigen
notwithstand
potenti
role
individu
virul
factor
diseas
causat
clinic
studi
demonstr
ga
bacteria
may
persist
site
infect
despit
high
concentr
bactericid
antibiot
born
experiment
studi
reason
behind
persist
unclear
may
includ
internalis
ga
immun
cell
format
biofilm
antibiot
penetr
necrot
tissu
persist
viabl
bacteria
case
wide
recogn
deserv
focus
consider
research
laboratori
genomewid
analysi
microbi
pathogen
molecular
pathogenesi
process
becom
area
consider
activ
last
year
studi
made
possibl
sever
advanc
includ
complet
human
genom
sequenc
public
genom
sequenc
mani
human
pathogen
develop
microarray
technolog
highthroughput
proteom
matur
bioinformat
despit
advanc
rel
littl
effort
expend
bacteri
pathogenesi
arena
develop
use
integr
research
platform
system
biolog
approach
enhanc
understand
diseas
process
exploit
integr
genomewid
research
platform
gain
new
knowledg
human
bacteri
pathogen
group
streptococcu
caus
diseas
result
studi
provid
mani
new
avenu
basic
pathogenesi
research
translat
research
focus
develop
efficaci
human
vaccin
novel
therapeut
new
data
stem
use
system
biolog
approach
provid
new
data
group
streptococcu
pathogenesi
present
streptococc
toxic
shock
syndrom
necrotis
fasciiti
caus
group
streptococcu
rapidli
progress
invas
diseas
associ
signific
morbid
mortal
rang
despit
prompt
antibiot
therapi
surgic
debrid
pyogen
known
primarili
caus
diseas
activ
modul
host
immun
respons
exotoxin
superantigen
activ
demonstr
crucial
trigger
excess
inflammatori
respons
consequ
system
toxic
organ
dysfunct
tissu
necrosi
shock
anoth
import
virul
determin
mprotein
classic
known
antiphagocyt
properti
late
shown
trigger
proinflammatori
respons
well
induct
vascular
leakag
shock
like
repres
import
mechan
contribut
rapid
develop
shock
system
toxic
patient
sever
invas
group
streptococc
infect
understand
infect
hyperinflammatori
diseas
highlight
potenti
immunotherapi
improv
outcom
one
strategi
includ
administr
intraven
polyspecif
immunoglobulin
ivig
adjunct
therapi
mechanist
action
ivig
set
believ
includ
opsonis
bacteria
neutralis
superantigen
suppress
proinflammatori
respons
grow
evid
support
use
ivig
patient
streptococc
toxic
shock
syndrom
studi
includ
one
observ
cohort
studi
base
canadian
patient
identifi
activ
surveil
invas
group
streptococc
infect
one
european
multicentr
placebocontrol
trial
howev
question
remain
whether
ivig
efficaci
also
sever
streptococc
deep
tissu
infect
observ
studi
seven
patient
sever
streptococc
deep
tissu
infect
suggest
use
highdos
ivig
patient
sever
ga
soft
tissu
infect
may
allow
initi
nonop
minim
invas
approach
limit
need
perform
immedi
wide
debrid
amput
unstabl
patient
fact
seven
patient
sever
group
streptococc
infect
surviv
approach
definit
warrant
studi
conduct
use
ivig
sever
infect
hepat
preval
outcom
pregnanc
chronic
hepat
c
viru
infect
sariola
k
melen
p
koskela
p
finn
al
riikonen
hm
surcel
helsinki
oulu
fi
object
western
countri
incid
hepat
c
viru
hcv
infect
steadili
increas
especi
among
young
adult
thu
like
increas
preval
hcv
infect
also
found
pregnant
women
method
assess
frequenc
hcv
infect
metropolitan
area
helsinki
select
antihcv
antibodi
test
carri
pregnant
women
year
addit
hcv
preval
analys
serum
specimen
collect
pregnant
mater
year
result
altogeth
mother
identifi
among
mother
frequenc
antihcv
posit
rose
earli
mother
knew
seroposit
wherea
end
followup
period
almost
mother
knew
hcv
infect
alreadi
pregnanc
intraven
drug
abus
major
risk
factor
case
contract
diseas
mother
chronic
hcv
infect
well
control
popul
mean
serum
alanin
aminotransferas
alt
valu
decreas
toward
end
pregnanc
howev
antihcv
ab
posit
mother
develop
intrahepat
cholestasi
odd
ratio
characteris
itch
elev
serum
bile
acid
level
correspondig
valu
control
pregnanc
antihcv
ab
posit
mother
younger
deliv
earlier
gave
birth
babi
smaller
birth
weight
compar
control
deliveri
comprehens
view
problem
hcv
infect
pregnanc
randomli
select
serum
specimen
finnish
matern
cohort
test
serum
specimen
test
select
cohort
nationwid
preval
steadili
role
metropolitan
area
helsinki
preval
higher
respect
conclus
studi
indic
increas
problem
hcv
infect
pregnant
women
finland
although
women
cope
well
diseas
pregnanc
subpopul
mother
develop
cholestasi
liver
statu
thu
followedup
care
test
mother
serum
antihcv
antibodi
recommend
object
viral
genom
hepat
c
viru
constitut
singlestrand
positivesens
rna
encod
altogeth
viral
protein
order
studi
humor
immun
respons
differ
hcv
protein
patient
suffer
chronic
hcv
infect
produc
three
structur
c
six
nonstructur
protein
insect
cell
use
baculoviru
express
system
recombin
hcv
protein
purifi
use
western
blot
analysi
determin
antibodi
respons
individu
hcv
protein
hcv
rna
antibodi
posit
human
sera
obtain
patient
suffer
genotyp
infect
result
sera
also
analys
innolia
score
test
hcv
antibodi
core
result
similar
western
blot
method
base
western
blot
analys
found
major
viral
antigen
core
protein
recogn
patient
sera
respect
major
genotyp
specif
differ
antibodi
respons
individu
hcv
protein
common
featur
within
studi
sera
except
two
sera
recogn
core
protein
high
titer
wherea
none
sera
recogn
protein
three
sera
genotyp
recognis
data
show
signific
variat
specif
humor
immun
chronic
hcv
patient
antihcv
antibodi
pattern
also
remain
stabl
within
one
individu
alt
ast
level
test
subject
presenc
hbvdna
determin
quantit
plasma
sampl
hd
patient
antihbc
alon
hbsag
neg
antihb
neg
antihbc
posit
realtim
pcr
use
artu
hbv
rg
pcr
kit
rotorgen
realtim
thermal
cycler
result
patient
enrol
studi
subject
ci
antihbc
alon
hbvdna
detect
hd
patient
ci
antihbc
alon
plasma
hbvdna
load
less
iuml
patient
studi
show
detect
antihbc
alon
could
reflect
unrecogn
occult
hbv
infect
hd
patient
major
infect
associ
low
viral
load
includ
studi
subject
never
expos
antiretrovir
therapi
genotyp
resist
test
perform
time
diagnosi
sequencebas
assay
trugen
genotyp
test
target
proteas
region
codon
rt
region
codon
hivl
genom
result
patient
harbour
viru
least
one
mutat
associ
phenotyp
resist
mutat
associ
resist
nucleosid
reversetranscriptas
inhibitor
nrti
nonnucleosid
reversetranscriptas
inhibitor
nnrti
proteas
inhibitor
pi
resist
nrti
associ
key
mutat
resist
nnrti
associ
mutat
among
mutat
pi
major
resist
mutat
found
three
patient
wherea
high
preval
accessori
pi
resist
mutat
posit
conclus
data
estim
preval
primari
resist
mutat
pattern
among
naiv
hiv
patient
underlin
import
genotyp
resist
test
hiv
patient
start
treatment
especi
nnrti
would
includ
initi
antiretrovir
therapi
object
data
avail
genet
mechan
proteas
inhibitor
pi
resist
nonb
pi
resistanceassoci
mutat
ram
commonli
observ
pinaiv
patient
subtyp
ae
infect
studi
aim
compar
piram
pinaiv
experienc
patient
method
genotyp
resist
test
conduct
among
cohort
infect
patient
virolog
failur
patient
categoris
group
pinaiv
piexperienc
focus
piram
previous
describ
iasusa
result
studi
patient
mean
age
year
male
median
cell
count
rna
virolog
failur
cellscumm
copiesml
respect
patient
infect
subtyp
ae
other
subtyp
b
ab
c
patient
pinaiv
group
patient
piexperienc
group
clinic
characterist
group
similar
p
except
durat
antiretrovir
therapi
shorter
pinaiv
group
vs
month
p
percentag
patient
primari
piram
pinaiv
piexperienc
group
p
common
primari
piram
latter
group
percentag
patient
secondari
piram
correspond
group
respect
p
median
number
secondari
piram
also
similar
group
p
common
secondari
piram
group
also
defin
silent
score
ss
resist
score
rs
number
synonym
mutat
resist
mutat
second
sequenc
comparison
first
one
divid
number
day
two
test
respect
pt
drm
nonbst
signific
increas
nonbst
p
signific
decreas
drm
p
observ
preval
nonb
st
nonb
st
pt
italian
among
bst
drm
predict
reduc
suscept
one
drug
class
case
differ
period
two
drug
class
three
class
nonbst
reduc
suscept
one
drug
class
found
case
two
drug
class
three
drug
class
respect
among
pt
one
two
class
resist
decreas
percentag
proteas
inhibitor
relat
drm
persist
non
nucleosid
rt
inhibitor
involv
drm
mainli
observ
method
hiv
person
histori
acut
episod
opc
oral
fungal
burden
evalu
biweekli
buccal
mucosa
tissu
collect
bimonthli
period
one
year
tissu
evalu
presenc
cell
ecadherin
immunohistochemistri
flow
cytometri
object
defin
secular
trend
epidemiolog
candidaemia
queensland
australia
popul
million
period
method
episod
candidaemia
within
queensland
public
hospit
identifi
laboratori
inform
system
data
speci
identif
antifung
suscept
demograph
hospit
ward
diagnosi
denomin
data
hospit
admiss
accru
patientday
ptday
fluconazol
usag
collect
result
period
uniqu
episod
case
ascertain
identifi
healthcar
facil
tertiari
paediatr
secondari
smaller
hospit
median
patient
age
year
overal
incidencedens
ptday
highest
paediatr
ptday
tertiari
hospit
ptday
year
incidencedens
increas
tertiari
hospit
secondari
hospit
p
trend
paediatr
smaller
hospit
incidencedens
icu
ptday
higher
nonicu
ward
significantli
increas
studi
period
rel
proport
episod
occur
adult
gener
medicalsurg
ie
nononcologynonicu
ward
significantli
increas
p
account
episod
end
period
wherea
occur
paediatr
adult
oncolog
ward
decreas
p
p
respect
overal
c
albican
account
c
parapsilosi
c
glabrata
although
incidencedens
speci
increas
studi
period
rel
proport
caus
c
albican
decreas
p
c
parapsilosi
increas
p
despit
significantli
increas
fluconazol
usag
ptday
p
rel
proport
caus
c
glabratac
krusei
chang
p
overal
incid
candidaemia
increas
almost
queensland
public
hospit
last
year
rel
proport
episod
occur
among
gener
medicalsurg
patient
caus
c
parapsilosi
increas
candidaemia
increas
problem
epidemiolog
continu
evolv
increasingli
affect
patient
outsid
tradit
risk
group
conclus
surveil
studi
pharmacoeconom
model
prove
immens
benefici
set
inhous
process
improv
tat
reduc
cost
outsourc
subsequ
use
expens
antifung
reduct
mortal
note
statist
signific
c
albican
commonest
isol
fluconazol
resist
minim
associ
mortal
lower
report
europ
mani
pt
receiv
system
prophylaxi
itraconazol
fluconazol
use
pt
respect
differ
emerg
empir
vs
preemptiv
therapi
none
drug
result
significantli
influenc
outcom
pt
initi
empiricalpreempt
drug
remain
unchang
ia
diagnosi
clinician
shift
combin
treatment
conclus
studi
allow
analyz
multipl
factor
potenti
influenc
outcom
confirm
aml
phase
neutropenia
influenc
ia
outcom
present
data
confirm
percept
last
year
applic
correct
time
diagnost
workup
avail
efficaci
less
toxic
drug
ie
voriconazol
liposom
amphotericin
b
caspofungin
modifi
cours
ia
howev
none
new
drug
emerg
efficaci
seri
even
combin
treatment
confer
advantag
surviv
analysi
first
line
therapi
monotherapi
voriconazol
caspofungin
lipid
formul
amb
use
antifung
drug
combin
mortal
rate
day
first
line
therapi
includ
voriconazol
compar
p
conclus
comprehens
collect
case
base
systemat
report
descript
case
use
dedic
network
hospit
select
region
stringent
definit
criteria
appli
train
clinician
microbiologist
use
describ
ia
assess
burden
secular
trend
identifi
potenti
chang
diagnost
therapeut
procedur
network
expand
region
near
futur
data
help
assess
impact
new
manag
strategi
prophylaxi
posaconazol
impact
modif
new
diagnost
criteria
recent
propos
clin
infect
di
identifi
new
popul
risk
ia
nosocomi
aspergillosi
repres
seriou
threat
sever
immunocompromis
patient
outbreak
attribut
airborn
sourc
role
hospitalindepend
fungal
spread
sourc
eg
privat
home
busi
suit
known
investig
relationship
fungal
exposur
prior
hospitalis
ensu
onset
invas
mould
infect
imi
patient
risk
patient
admit
depart
haematolog
oncolog
depart
transplant
surgeri
innsbruck
medic
univers
receiv
structur
questionnair
regard
fungal
exposur
prior
hospitalis
question
inquir
heavi
fungal
exposur
five
day
prior
hospitalis
patient
enrol
studi
smoker
suffer
airborn
allergi
live
old
build
ruralist
expos
outdoor
indoor
fungu
sourc
poor
hous
condit
fungu
exposur
associ
onset
communityacquir
imi
patient
acut
myelogen
leukaemia
p
aml
patient
risk
imi
smoke
cigarett
p
live
countri
site
p
two
fungu
exposur
p
suffer
allergi
dust
pollen
andor
mould
p
similar
trend
lung
transplant
recipi
receiv
extens
immunosuppress
agent
treat
allograft
reject
overal
imi
communityacquir
case
hospitalindepend
fungal
sourc
highlight
riskfactor
imi
sever
immunocompromis
patient
rate
communityacquir
imi
increas
analysi
individu
patient
risk
factor
fungal
infect
type
fungu
suscept
indic
prevent
strategi
like
success
icumh
aspergillu
spp
detect
signific
amount
clinic
sampl
underli
condit
patient
heart
transplant
n
major
heart
surgeri
n
n
eight
patient
develop
provenprob
ia
lung
infect
mediastin
dissemin
ia
prostat
involv
mortal
patient
ia
icumh
divid
area
one
equip
hepa
filter
case
ia
occur
protect
area
measur
fungal
conidia
level
air
area
sampl
analyz
monthli
total
strain
fumigatu
clinic
strain
patient
environment
strain
genotyp
use
microsatellit
de
valk
et
al
jcm
mean
airborn
conidia
level
month
outbreak
respect
case
ia
occur
period
howev
case
ia
link
peak
abnorm
high
airborn
conidia
level
fumigatu
involv
case
ia
patient
infect
nonfumigatu
aspergillu
genotyp
patient
mediastin
pulmonari
ia
colonis
demonstr
similar
genotyp
air
clinic
sampl
patient
locat
protect
area
uniqu
genotyp
patient
two
differ
cluster
genotyp
one
cluster
similar
patient
also
found
patient
air
genotyp
present
patient
also
detect
air
period
conclus
epidemiolog
molecular
type
suggest
causal
relationship
aspergillu
caus
ia
present
air
find
also
support
need
hepa
filtrat
icumh
j
guinea
contract
fi
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
calcul
refer
proven
probabl
case
ia
reason
perform
bronchoscopi
patient
also
record
protocol
receiv
approv
local
ethic
committe
result
sampl
studi
classifi
proven
probabl
possibl
case
aspergillosi
twelv
sampl
repres
colonis
bal
sampl
obtain
routin
surveil
pulmonari
aspergillosi
main
clinic
present
ia
use
roc
analysi
best
cutoff
galactomannan
test
bal
defin
sensit
specif
ppv
npv
median
bal
gm
index
group
patient
provenprob
aspergillosi
neg
case
respect
p
overal
mortal
n
odd
death
patient
diagnos
ia
comparison
patient
infect
ci
conclus
gm
test
bal
ad
diagnosi
ia
lung
transplant
recipi
order
avoid
falseposit
result
higher
test
cutoff
appli
bal
sampl
comparison
sera
increas
cutoff
result
high
npv
associ
sensit
object
determin
perform
characterist
galactomannan
gm
assay
bronchoalveolar
lavag
bal
haematologyoncolog
patient
evalu
prognost
valu
gm
assay
particular
popul
method
platelia
gm
eia
assay
biorad
perform
bal
specimen
obtain
haematologyoncolog
patient
institut
march
april
addit
routin
laboratori
stain
cultur
result
report
physician
conduct
chart
review
classifi
case
proven
probabl
possibl
without
invas
pulmonari
aspergillosi
ipa
accord
revis
definit
invas
fungal
diseas
eortcmsg
consensu
group
perform
characterist
proven
probabl
case
consid
ipa
possibl
case
consid
without
ipa
result
bal
gm
consid
criterium
classifi
case
order
avoid
incorpor
bia
patient
posit
gm
index
specimen
first
one
consid
analysi
mortal
calcul
day
follow
first
bal
procur
data
analyz
stata
result
bal
sampl
patient
includ
haematopoiet
stem
cell
transplant
hsct
recipi
found
proven
probabl
possibl
case
ipa
total
ipa
case
gm
bal
posit
specimen
sensit
specif
gm
assay
bal
respect
posit
predict
neg
predict
valu
respect
falseposit
result
found
patient
without
ipa
possibl
ipa
index
valu
significantli
associ
mortal
risk
patient
posit
gm
die
within
day
bal
compar
neg
gm
ci
p
associ
even
stronger
restrict
hsc
recipi
ci
p
clinic
util
gm
assay
bal
mainli
lie
neg
predict
valu
identifi
patient
low
risk
ipa
test
also
carri
prognost
valu
predict
patient
higher
risk
mortal
see
tabl
signific
differ
found
among
pneumocysti
colonis
copd
statu
evalu
well
signific
differ
respect
age
sex
lymphocyt
leucocyt
blood
count
found
background
infliximab
monoclon
antibodi
target
tumour
necrosi
factor
alpha
tnfa
indic
treatment
rheumatoid
arthriti
ra
autoimmun
diseas
howev
use
associ
opportunist
infect
includ
pneumocysti
jirovecii
pneumonia
pcp
moreov
p
jirovecii
observ
colonis
human
sever
disord
object
obtain
inform
p
jirovecii
colonis
among
patient
rheumatolog
diseas
treat
infliximab
inform
could
use
assess
new
strategi
prevent
pcp
patient
risk
method
consecut
patient
treat
infliximab
rheumat
disord
includ
studi
oropharyng
wash
ow
sampl
collect
p
jirovecii
detect
clinic
demograph
data
collect
sex
age
rheumatolog
diagnosi
durat
infliximab
use
concomit
use
drug
rheumatolog
treatment
use
antitnfa
agent
use
antipc
drug
last
six
month
smoke
diagnosi
chronic
pulmonari
respiratori
diseas
p
jirovecii
colonis
identifi
ow
sampl
pcr
mtlsurrna
gene
primer
adapt
method
previous
describ
realtim
pcr
set
use
lightcycl
roch
germani
individu
presenc
p
jirovecii
detect
two
independ
assay
absenc
respiratori
symptom
radiolog
find
suggest
pcp
consid
colonis
result
clinic
demograph
data
patient
treat
infliximab
present
tabl
object
research
human
bocaviru
recent
found
respiratori
pathogen
done
molecular
biolog
polymeras
chain
reaction
pcr
result
ambigu
viru
often
found
coinfect
virus
also
clinic
healthi
subject
propos
bocaviru
antigen
detect
could
better
indic
aetiolog
qualit
nucleic
acid
detect
develop
rapid
antigen
detect
test
viru
onestep
test
bocaviru
antigen
base
separationfre
twophoton
excit
fluorometri
arcdia
tpx
assay
techniqu
assay
protocol
simpl
swab
sampl
dissolv
sampl
buffer
solut
dispens
ml
onto
microtitr
plate
contain
reagent
dri
form
incub
autom
quantit
measur
immunoassay
appli
microspher
solidphas
carrier
purifi
bocavirusspecif
polyclon
antibodi
viru
antigen
concentr
onto
solidphas
probe
realtim
fluoresc
label
antibodi
reagent
strong
posit
sampl
report
minut
low
posit
neg
sampl
report
hour
perform
method
studi
recombin
human
bocaviruslik
particl
purifi
respiratori
pathogen
group
streptococci
streptococcu
pneumonia
influenza
b
respiratori
syncyti
metapneumo
adeno
parainfluenza
virus
result
analyt
detect
sensit
method
lowest
limit
detect
ngml
dynam
concentr
rang
three
order
magnitud
intraassay
imprecis
crossreact
respiratori
pathogen
found
new
method
enabl
rapid
detect
bocaviru
antigen
new
test
easi
perform
comparison
standard
elisa
analyt
sensit
method
expect
allow
analysi
clinic
sampl
sensit
antigen
detect
test
could
significantli
increas
use
monoclon
antibodi
fold
futur
object
includ
increas
detect
sensit
analysi
clinic
sampl
order
studi
correl
antigen
detect
clinic
aetiolog
lifeyear
patient
surviv
analys
perform
use
treeag
softwar
result
overal
mortal
rate
empir
vancomycin
v
semisyntheticpenicillin
ssp
respect
appos
receiv
rapid
mrsa
pcr
test
mortal
rate
similar
eu
us
subset
furthermor
number
need
test
order
save
one
life
empir
v
ssp
respect
use
sensit
analysi
preval
mrsa
vari
yield
absolut
mortal
differ
favour
pcr
test
group
respect
compar
empir
v
compar
empir
ssp
eu
ce
empir
v
ssp
treat
patient
respect
compar
rapid
pcr
test
us
ce
empir
v
compar
rapid
pcr
test
use
sensit
analysi
preval
mrsa
vari
yield
favour
ce
eu
us
rapid
pcr
test
regardless
empir
treatment
regimen
conclus
rapid
mrsa
pcr
test
use
xpert
mrsasa
blood
cultur
pcr
assay
appear
improv
mortal
rate
cost
effect
eu
us
across
wide
rang
mrsa
preval
rate
background
rapid
detect
gastrointestin
carriag
glycopeptideresist
enterococci
gre
screen
cultur
crucial
effici
control
spread
assess
media
chromogen
chromid
chromagar
chromagar
microbiolog
select
vre
select
oxoid
eccv
bd
abil
detect
gre
use
wellcharacteris
isol
stool
sampl
hospitalis
patient
high
risk
gre
colonis
method
twentyf
isol
consist
gre
faecalisfaecium
carri
variou
van
gene
nonvr
concentr
cfuml
cfuml
respect
stool
sampl
randomis
spiral
plate
media
score
blind
investig
characterist
coloni
hr
incub
standard
confirmatori
test
done
put
gre
coloni
characterist
colour
coloni
e
faecalisfaecium
select
chromogen
media
respect
detect
van
gene
ddl
soda
base
speciat
done
pcrsequenc
mean
sensit
sen
specif
spec
confid
interv
ci
estim
medium
logist
regress
model
use
penalis
likelihood
approach
base
reader
respons
stool
sampl
isol
addit
confirm
test
result
stool
sampl
aggreg
gre
detect
penalis
level
correct
speciescoloni
colour
correl
result
chromagar
show
highest
sen
base
reader
respons
aggreg
penalis
level
stool
sampl
isol
tabl
use
confirm
test
result
aggreg
level
sen
eccv
highest
two
chromogen
media
show
decreas
sen
least
comparison
valu
obtain
base
reader
respons
sen
chromogen
media
even
lower
base
confirm
test
result
penalis
level
eccv
chromid
show
highest
spec
reader
respons
stool
sampl
confirm
test
result
aggreg
level
chromid
also
penalis
level
narrow
ci
indic
high
precis
paramet
estim
isol
spec
highest
chromagar
level
conclus
chromagar
show
best
overal
perform
consid
sen
spec
estim
eccv
perform
well
select
medium
gre
detect
stool
sampl
object
metallobetalactamas
mbl
express
pseudomona
abl
confer
resist
betalactam
except
aztreonam
howev
enterobacteriacea
possess
mbl
exhibit
moder
cephalosporin
low
carbapenem
mic
thu
often
underestim
herein
describ
data
new
etest
prototyp
specif
design
detect
problemat
resist
mechan
method
mblposit
vim
imp
deriv
enterobacteriacea
clinic
isol
countri
randomli
select
enterobacteriacea
neg
control
includ
atcc
type
strain
test
differ
etest
mbl
prototyp
betalactam
substrat
use
imipenem
ip
meropenem
mp
ceftazidim
tz
cefotaxim
ct
without
inhibitor
dipicolin
acid
dpa
edta
etest
standard
procedur
gram
neg
aerob
use
reduct
betalactam
mic
equal
greater
dilut
edta
dpa
interpret
posit
mbl
presenc
esbl
test
use
etest
ctctl
tztzl
cefepim
pm
pml
strip
ampc
product
detect
use
etest
cefoxitin
fx
fxi
cefotetan
cn
cni
strip
select
specimen
neg
gb
grew
turquoiseblu
coloni
major
requir
work
rule
gb
grew
hour
two
strain
gb
miss
grew
white
coloni
select
even
h
exhibit
characterist
turquoiseblu
colour
conclus
ssb
enrich
follow
select
subcultur
extrem
sensit
superior
cnassb
detect
gb
genit
specimen
howev
nongb
organ
produc
turquoiseblu
coloni
select
work
must
perform
rule
presenc
gb
object
screen
chlamydia
trachomati
ct
specif
antibodi
valuabl
investig
recurr
caus
miscarriag
pelvic
inflammatori
diseas
tubal
damag
follow
repeat
episod
pelvic
inflammatori
diseas
immunofluoresc
consid
gold
standard
detect
ct
antibodi
present
studi
aim
compar
perform
commerci
test
detect
serum
igg
antibodi
specif
ct
two
ct
igg
pelisa
use
major
outer
membran
protein
momp
mompmedac
ctiggpelisa
medac
wedel
germani
mompruwag
ct
pelisa
ruwag
bettlach
switzerland
one
ct
igg
pelisa
medac
wedel
germani
new
autom
epifluoresc
immunoassay
inodiag
must
chlamydia
inodiag
sign
franc
method
total
patient
n
without
n
miscarriag
test
serolog
test
describ
sensit
specif
calcul
use
gold
standard
second
standard
defin
true
posit
neg
sampl
sera
respect
posit
neg
other
test
also
use
see
tabl
object
particip
diagnost
microbiolog
intern
extern
qualiti
control
qc
process
good
laboratori
practic
essenti
compon
qualiti
manag
system
compulsori
european
countri
current
qc
scheme
diagnost
oral
microbiolog
aim
studi
collat
inform
current
qc
need
process
undertaken
diagnost
oral
microbiolog
laboratori
method
onlin
questionnair
devis
ascertain
interest
particip
oral
microbiolog
qc
scheme
sent
oral
microbiolog
diagnost
laboratori
laboratori
identifi
particip
attend
european
oral
microbiolog
workshop
helsinki
follow
pilot
round
qc
sampl
distribut
interest
laboratori
result
identifi
individu
work
diagnost
oral
microbiolog
laboratori
receiv
posit
respons
laboratori
repres
european
countri
particip
either
intern
extern
qc
laboratori
process
averag
total
sampl
annual
particip
favour
europeanwid
oral
microbiolog
qc
scheme
prefer
frequenc
receiv
extern
qc
specimen
month
prefer
specimen
type
periodont
pocket
oral
pu
specimen
follow
oral
mucos
swab
cari
activ
test
particip
laboratori
will
share
harmonis
specimen
process
interpret
standard
oper
procedur
pilot
round
specimen
periodont
pocket
sampl
six
laboratori
report
find
specifi
time
predomin
pathogen
aggregatibact
actinomycetemcomitan
porphyromona
gingivali
identifi
laboratori
addit
convent
cultur
one
laboratori
use
pcr
laboratori
perform
antibacteri
sensit
test
primarili
disc
diffus
conclus
first
attempt
standardis
europeanwid
approach
diagnost
oral
microbiolog
find
feasibl
studi
indic
qc
scheme
oral
microbiolog
interest
rais
number
pointer
subsequ
round
specimen
work
improv
qualiti
standardis
methodolog
interpret
diagnost
oral
microbiolog
european
level
ongo
object
sinc
sever
sepsi
acut
organ
dysfunct
fatal
within
hour
customari
start
empir
broadspectrum
antimicrobi
therapi
patient
hospitalis
suspicion
system
inflammatori
respons
syndrom
howev
increas
use
broadspectrum
antimicrobi
year
contribut
emerg
drug
resist
strain
bacteria
especi
drug
resist
among
gramposit
bacteria
lead
caus
sepsi
seriou
problem
object
preliminari
studi
develop
method
distinguish
gram
bacteri
infect
method
prospect
studi
leukocyt
neutrophil
count
crp
esr
quantit
flow
cytometr
analysi
neutrophil
complement
receptor
obtain
hospitalis
febril
patient
bacteri
viral
infect
patient
data
compar
healthi
control
result
notic
infect
n
averag
amount
neutrophil
significantli
higher
gram
infect
n
contrari
serum
crp
level
significantli
higher
gram
infect
measur
paramet
differ
significantli
gram
infect
deriv
ratio
divid
serum
crp
valu
amount
neutrophil
thirteen
patient
gram
sepsi
ratio
cutoff
valu
figur
patient
diagnos
streptococcu
pneumonia
staphylococcu
aureu
enterococcu
faecali
streptococcu
intermediu
streptococcu
orali
correspond
percentag
patient
local
gram
infect
infect
clinic
pneumonia
clinic
infect
viral
infect
respect
conclus
detect
gram
sepsi
possibl
combin
neutrophil
data
serum
crp
level
ratio
viral
infect
central
nervou
system
display
sensit
specif
detect
gram
sepsi
propos
ratio
test
could
part
assist
physician
decid
appropri
antibiot
treatment
patient
sever
bacteri
infect
bacteri
biofilm
structur
consortium
bacteria
cell
surround
selfproduc
polym
matrix
biofilm
may
monospeci
polyspeci
biofilm
biofilm
grow
bacteria
give
rise
chronic
infect
persist
spite
therapi
spite
host
immuneand
inflammatori
respons
biofilm
infect
characteris
persist
patholog
immun
respons
contrast
colonis
bacteri
biofilm
use
biofilm
specif
b
convent
plankton
resist
mechan
p
expos
antibiot
follow
resist
mechan
describ
bacteri
biofilm
stationari
phase
physiolog
b
low
oxygen
tension
b
slow
growth
b
especi
insid
biofilm
wherea
surfac
biofilm
similar
plankton
growth
penetr
barrier
b
bind
polym
matrix
b
mutat
hypermut
b
p
chromosom
betalactamas
upregul
b
p
antibiot
toleranceadapt
resist
b
efflux
pump
b
p
algin
product
b
high
cell
densiti
quorum
sens
b
p
pbp
so
respons
b
knowledg
resist
mechan
howev
use
design
new
therapeutica
approach
especi
regard
quorum
sens
inhibitor
consid
two
factor
contribut
treatment
failur
absenc
inherit
resist
densiti
popul
treat
physiolog
state
bacteria
also
explor
factor
might
contribut
evolut
inherit
resist
cours
treatment
conclud
computerand
chemostatassist
consider
potenti
clinic
implic
densiti
physiolog
effect
make
suggest
treatment
protocol
deal
use
vitro
cultur
staphylococcu
aureu
clinic
isol
antibiot
six
differ
class
determin
function
relationship
inoculum
densiti
efficaci
antibiot
measur
rate
extent
kill
andor
minimum
inhibitori
concentr
mic
efficaci
antibiot
declin
increas
densiti
bacteria
albeit
differ
extent
daptomycin
vancomycin
much
densiti
effect
attribut
bacteriaassoci
declin
effect
concentr
antibiot
medium
gentamicin
vancomycin
ciprofloxacin
oxacillin
bioassay
fail
reveal
signific
reduct
effect
concentr
medium
effect
physiolog
state
aureu
efficaci
antibiot
examin
bacteria
cultur
stationari
phase
differ
time
chemostat
run
differ
gener
time
experi
current
way
time
symposium
full
true
stori
howev
clear
efficaci
antibiot
declin
time
stationari
phase
age
even
slowli
divid
cultur
chemostat
suscept
antibioticmedi
kill
earli
stationari
phase
batch
cultur
efficaci
kill
nongrow
bacteria
vari
among
bactericid
antibiot
examin
ascertain
potenti
clinic
implic
densiti
physiolog
effect
use
comput
vitro
simul
antibiot
treatment
result
simul
provid
compel
support
proposit
antibiot
treatment
regim
includ
design
prevent
ascent
resist
take
account
anticip
densiti
physiolog
state
target
popul
suscept
bacteria
increas
number
neurotroph
viral
infect
play
import
role
world
last
decad
list
includ
west
nile
viru
nipah
hendra
viru
paramyxovirus
well
chikungunya
viru
suddenli
emerg
furthermor
relat
jc
viru
progress
multifoc
leukoencephalopathi
pml
patient
multipl
sclerosi
treat
new
immunosuppress
drug
trigger
attent
develop
implement
molecular
base
amplif
method
assist
us
detect
virus
effici
technolog
use
routin
larg
number
laboratori
enabl
detect
commonli
known
neurotroph
virus
like
hsv
vzv
neurotroph
picornavirus
like
enteroviru
parechoviru
pitfal
molecular
method
gener
solv
implement
regular
qualiti
control
test
scheme
like
organis
qcmd
qualiti
control
molecular
diagnost
introduct
intern
control
whole
diagnost
process
final
abil
quantifi
amount
nucleic
acid
present
csf
inform
pathogenesi
viral
infect
well
signific
tool
monitor
antivir
effect
treatment
option
virus
becom
avail
rare
diseas
europ
restrict
endem
foci
howev
current
data
suggest
incid
ae
significantli
increas
diseas
spread
north
west
east
ae
becom
emerg
diseas
baltic
countri
thu
human
infect
e
multiloculari
arriv
centr
europ
ae
lifethreaten
diseas
characteris
tumourlik
lesion
liver
larva
infiltr
surround
tissu
metastas
distant
organ
attempt
classifi
larg
varieti
anatom
find
ae
pnmclassif
system
develop
serv
benchmark
standardis
evalu
diagnost
therapeut
measur
modern
imag
techniqu
ultrasound
ct
mri
petct
contribut
much
better
descript
lesion
also
judgment
upon
activ
metacestod
differenti
diagnosi
ae
vari
haemangiomalik
lesion
liver
cancer
diagnost
skill
limit
reason
frequent
misdiagnosi
geograph
area
ae
rather
unknown
continu
treatment
benzimidazol
backbon
lifelong
manag
ae
howev
radic
resect
procedur
choic
alway
strive
ae
still
rare
diseas
europ
occur
often
diagnos
late
patient
misdiagnos
month
year
receiv
correct
treatment
late
stage
diseas
progress
radic
cure
liver
lesion
anymor
possibl
recent
report
provid
hint
acceler
larval
growth
echinococcu
spp
immunodefici
host
care
monitor
patient
receiv
immunemodifi
drug
warrant
modern
clinic
manag
longterm
parasitostat
treatment
benzimidazol
highli
effect
thu
higher
alert
tumour
centr
would
increas
prognosi
hepat
diseas
resembl
liver
cancer
percutan
treatment
liver
hydatid
cyst
consid
contraind
due
two
main
potenti
risk
anaphylact
shock
abdomin
dissemin
diseas
sinc
first
case
percutan
treat
publish
sever
seri
success
percutan
treatment
liver
abdomin
organ
peritoneum
thorax
soft
tissu
orbit
caviti
hydatid
cyst
appear
literatur
percutan
treatment
hydatid
liver
diseas
effect
safe
procedur
uniqu
advantag
eg
shorter
hospit
stay
low
complic
rate
today
percutan
approach
import
role
treatment
hydatid
cyst
liver
also
organ
tissu
therefor
must
first
treatment
option
whenev
indic
europ
dirofilaria
immiti
dirofilaria
repen
respons
autochthon
filarias
dog
adult
immiti
kill
dog
heart
locat
repen
often
found
subcutan
nodul
dog
cat
microfilaria
present
blood
anim
dirofilariasi
due
transmiss
microfilaria
mosquito
bite
aed
culex
anophel
mansonia
psorophora
taeniorhynchu
usual
non
pathogen
human
parasit
particularli
present
around
mediterranean
basin
immiti
rare
human
europ
sometim
found
pulmonari
nodul
heart
locat
describ
repen
frequent
emerg
human
usual
one
larva
develop
produc
immatur
adult
worm
insid
subcutan
nodul
ultrasound
examin
may
suggest
parasit
origin
lesion
extract
parasitolog
diagnosi
worm
often
fortuit
diagnosi
made
histolog
examin
rare
adult
worm
may
matur
produc
system
diffus
microfilaria
dirofilariasi
due
repen
present
problem
diagnosi
treatment
ocular
subconjunctiv
locat
worm
subcutan
nodul
enclos
immatur
adult
commonest
clinic
form
except
pulmonari
locat
describ
subcutan
locat
describ
skull
cheek
breast
inguin
area
buttock
arm
leg
case
testicular
locat
pain
symptom
observ
blood
hypereosinophilia
except
observ
human
treat
surgic
excis
without
chemotherapi
major
esbl
isol
clinicallyrelev
gram
neg
bacteria
gnb
mostli
enterobacteriacea
p
aeruginosa
baumannii
tem
shvor
ctxmtype
other
report
sfo
be
bel
tla
ge
bel
per
vebtyp
oxaesbl
laboratori
detect
esblproduc
import
avoid
clinic
failur
due
inappropri
antimicrobi
therapi
prevent
nosocomi
outbreak
select
cultur
media
macconkey
drigalski
agar
supplement
cefotaxim
andor
ceftazidim
propos
detect
gnb
resist
expandedspectrum
cephalosporin
esc
media
use
chromogen
base
substrat
select
antibiot
develop
recent
detect
presumpt
identif
esblproduc
enterobacteriacea
directli
clinic
specimen
detect
esbl
base
suscept
test
easi
due
varieti
blactamas
variabl
express
blactam
resist
commerci
avail
esbl
detect
method
yield
accur
esbl
identif
sinc
esblproduc
may
appear
suscept
esc
therefor
organ
show
reduc
suscept
esc
investig
use
esbl
confirmatori
test
test
abl
discrimin
esblproduc
mechan
confer
esc
resist
phenotyp
test
doubledisk
synergi
test
esbl
etest
combin
disk
method
base
clavulan
inhibit
esc
suscept
test
often
need
slight
chang
either
reduc
distanc
disk
esc
clavulan
use
cefepim
hydrolys
ampc
use
cloxacillincontain
plate
inhibit
ampc
doubl
inhibit
edta
clavulan
mask
metalloenzym
enzymat
test
also
propos
identif
esblproduc
sever
pcrbase
techniqu
endpoint
real
time
develop
clinic
sampl
coloni
sever
esbl
gene
detect
use
pcr
coupl
either
pyrosequenc
invers
hybridis
dhplc
fluoresc
probe
techniqu
even
though
specif
requir
technic
knowledg
special
equip
costli
detect
known
gene
regardless
express
detect
esblproduc
remain
challeng
microbiolog
laboratori
one
shall
awar
esbl
screen
media
avail
resist
antimicrobi
agent
becom
common
mani
bacteri
speci
particularli
caus
human
infect
rapid
detect
resist
organ
directli
clinic
sampl
realtim
pcr
coupl
molecular
beacon
potenti
resist
bacteria
yeast
blood
cultur
bottl
peptid
nucleic
acidfluoresc
situ
hybridis
pnafish
alreadi
posit
impact
antimicrobi
therapi
direct
detect
mycobacterium
tuberculosi
sputum
approxim
hour
concomit
detect
mutat
rpob
indic
rifampin
resist
surrog
multidrug
resist
near
futur
like
improv
outcom
tuberculosi
patient
mani
develop
develop
countri
sever
molecular
technolog
includ
microarray
bacteri
tag
encod
flx
amplicon
pyrosequenc
btefap
ultra
deep
sequenc
yet
transit
clinic
laboratori
like
provid
even
greater
inform
antimicrobi
resist
singl
speci
whole
commun
microorgan
complex
wound
like
diabet
foot
ulcer
contain
multipl
resist
genotyp
amen
analysi
btefap
implement
technolog
clinic
laboratori
expens
potenti
dramat
improv
therapeut
outcom
especi
lifethreaten
diseas
unpreced
object
determin
appropri
antimicrobi
therapi
amt
dutch
hospit
method
data
obtain
preval
survey
perform
within
dutch
surveil
network
nosocomi
infect
prezi
amt
administr
day
survey
regist
antivir
antifung
drug
tuberculostat
cement
contain
amt
prophylaxi
administr
operationtheatr
exclud
appropri
amt
assess
accord
standardis
algorithm
base
local
antimicrobi
prescript
guidelin
per
patient
classif
appropri
use
inappropri
use
insuffici
inform
made
figur
rel
risk
ia
use
amt
largest
hospit
hospit
c
result
total
patient
includ
rang
per
centr
rpc
receiv
amt
latter
group
amt
consid
appropri
rpc
inappropri
rpc
judg
insuffici
inform
rpc
consider
variat
inappropri
use
among
particip
centr
figur
univari
analysi
older
age
use
quinolon
urolog
ward
presenc
suprapub
cathet
associ
significantli
inappropri
use
admiss
icu
presenc
intravascular
cathet
associ
significantli
appropri
use
multivari
analys
presenc
suprapub
cathet
urolog
ward
use
quinolon
determin
inappropri
use
studi
show
larg
differ
overal
use
appropri
use
amt
hospit
base
result
possibl
defin
target
intervent
improv
prudent
use
amt
high
fraction
patient
insuffici
inform
sever
centr
may
influenc
analys
address
futur
studi
metzgercek
r
mechtler
f
buyl
lechner
h
mittermay
f
allerberg
w
kern
object
euproject
antibiot
strategi
intern
ab
qi
team
develop
process
qi
audit
perform
key
treatment
prophylact
practic
intern
network
pilot
hospit
test
tool
feasibl
reliabl
sensit
improv
method
qi
includ
surgic
prophylaxi
indic
drug
choic
time
durat
administr
manag
communityacquir
pneumonia
cap
blood
cultur
legionella
antigen
test
drug
choic
empir
treatment
manag
aureu
bacteraemia
echocardiographi
iv
cathet
remov
durat
therapi
ivpo
switch
bioavail
antibiot
minimum
consecut
case
per
centr
qi
retrospect
review
clinic
laboratori
administr
record
assess
data
avail
interobserv
reliabl
data
collect
workload
perform
score
result
total
patient
evalu
acut
care
hospit
countri
rang
case
centr
per
indic
seven
centr
alreadi
implement
antibiot
qualiti
improv
audit
programm
avail
data
case
rang
cathet
remov
aureu
bacteraemia
diagnost
test
cap
indic
found
reliabl
kappa
good
excel
agreement
workload
per
case
rang
median
time
cap
min
ivpo
switch
intent
treat
qi
score
show
high
level
adher
surgic
prophylaxi
qi
bundl
median
valu
hip
prosthesi
colorect
surgeri
cap
manag
diagnost
test
appear
suboptim
complianc
idsa
guidelin
aureu
bacteraemia
manag
indic
result
rang
use
bio
avail
antibiot
median
iv
administr
avoid
mark
differ
score
centr
qi
conclus
ab
qi
reliabl
broadli
applic
tool
audit
antibiot
treatment
prophylact
practic
interhospit
variat
adher
recommend
practic
indic
substanti
potenti
improv
differ
local
prioriti
qi
recommend
assess
effect
qualiti
care
intervent
either
local
multicentr
level
dj
e
charani
smith
b
cooper
balakrishnan
sp
stone
london
uk
introduct
reduct
clostridium
difficil
infect
cdi
often
follow
use
third
gener
cephalosporin
nation
prioriti
three
year
period
antibiot
polici
review
chang
elderli
medicin
depart
accord
local
sensit
common
pathogen
level
cdi
lamin
pockets
card
describ
antibiot
polici
given
doctor
depart
induct
instruct
depart
without
microbiologist
approv
prospect
control
interrupt
time
seri
examin
whether
intervent
increas
complianc
antibiot
polici
decreas
cdi
incid
method
depart
narrowspectrum
cephalosporin
antibiot
polici
chang
august
replac
trimethoprim
cephradin
gener
cephalopsporin
empir
treatment
urinari
tract
infect
reflect
local
escheriscia
coli
sensit
octob
cephalosporin
quinolon
remov
polici
cdi
level
increas
notion
day
antibiot
usag
calcul
prospect
pharmaci
gener
data
aspirin
calcium
bisphosphon
lax
prescript
use
nonantibiot
control
analys
segment
regress
robust
varianc
estim
cdi
rate
prospect
collect
separ
analys
poisson
regress
model
result
immedi
respons
chang
antibiot
guidelin
observ
figur
august
highli
signific
increas
cephalosporin
cephradin
alon
p
signific
fall
trimethoprim
p
signific
increas
trend
cdi
tool
exist
assess
readi
public
hospit
receiv
technolog
therefor
guid
resourc
alloc
facilit
implement
aim
assess
readi
victorian
public
hospit
introduc
electron
antimicrobi
stewardship
method
literatur
readi
chang
organis
cultur
inform
technolog
accept
review
group
interview
project
team
site
initi
meet
one
one
interview
project
offic
subsequ
meet
observ
appropri
use
determin
potenti
barrier
enabl
inform
record
use
readi
assess
tool
analys
identifi
number
key
domain
triangul
data
questionnair
distribut
project
offic
ask
assess
site
readi
implement
system
result
novel
readi
assess
tool
develop
cover
domain
technic
readi
skill
readi
process
readi
administr
support
readi
resourc
readi
hospit
organis
characterist
assess
sever
hospit
highlight
varieti
issu
differ
site
allow
earli
effort
address
form
readi
assess
use
identifi
systemat
problem
might
facilit
hinder
uptak
electron
antimicrobi
stewardship
inform
adopt
potenti
resourc
requir
buis
k
thurski
k
robertson
black
j
street
richard
brown
g
electron
antibiot
stewardshipreduc
consumpt
broadspectrum
antibiot
use
computeris
antimicrobi
approv
system
hospit
set
j
antimicrob
chemoth
wv
steibbauert
pritzkow
g
peyerlhoffmann
h
von
baum
u
frank
dettenkof
c
schneider
k
de
h
bertz
freiburg
ulm
de
object
fluoroquinolon
prophylaxi
fqpx
may
reduc
morbid
mortal
cancer
patient
pt
neutropenia
develop
fluoroquinolon
resist
fqr
escherichia
coli
target
organ
limit
use
evalu
chang
incid
densiti
gramneg
bloodstream
infect
gnb
vitro
fqr
rate
introduct
fqpx
levofloxacin
standard
care
pt
high
risk
neutropenia
univers
hospit
method
collect
individu
data
pt
admit
baselin
first
month
follow
intervent
assess
clinic
outcom
individu
pt
data
compar
aggreg
data
period
aggreg
data
analysi
unitwid
antibiot
consumpt
gnb
number
vitro
fqr
bloodstream
isol
continu
total
eight
period
haematologyoncolog
servic
gener
intern
medicin
new
polici
introduc
second
half
year
unitwid
baselin
fqr
e
coli
coagulaseneg
staphylococc
con
bloodstream
isol
haematologyoncolog
unit
gener
intern
medicin
respect
individu
pt
data
analysi
reveal
pt
given
fqpx
much
higher
incid
gnb
given
fqpx
monthli
use
iv
oral
quin
calcul
base
data
pharmaci
depart
statist
analys
perform
use
segment
linear
regress
analysi
bayesian
model
averag
use
account
model
uncertainti
result
intervent
use
quin
iv
total
stabl
best
fit
model
indic
first
intervent
associ
stepwis
reduct
iv
use
prescrib
daili
dose
pdd
ci
p
also
indic
smaller
reduct
iv
use
associ
intervent
intervent
effect
robust
model
uncertainti
overal
use
quin
also
significantli
reduc
figur
larg
stepwis
reduct
pdd
ci
associ
intervent
studi
show
hospitalwid
use
quin
significantli
improv
decreas
activ
polici
consist
multipl
intervent
j
broomhal
c
mccowan
gonzalezmcquir
k
akhra
merchant
p
davey
dunde
high
wycomb
uk
raritan
us
aim
object
describ
antibiot
treatment
outcom
stratifi
sever
repres
sampl
adult
patient
age
older
treat
hospit
skin
soft
tissu
infect
inadequ
also
judg
patient
receiv
unnecessarili
broad
spectrum
therapi
conclus
ssti
common
associ
signific
mortal
howev
choic
empir
therapi
evid
base
signific
treatment
high
risk
patient
ab
mostli
prescrib
gp
deliv
public
n
hospit
pharmaci
n
surveil
ab
use
nh
organis
ms
countri
nh
specif
pharmaceut
formulari
avail
prescript
profil
prescrib
avail
countri
qualiti
improv
initi
nh
regular
train
prescrib
promot
microbiolog
sampl
collect
antimicrobi
resist
profil
pharmacist
advic
ab
prescript
scarc
guidelin
ab
treatment
frequent
infect
avail
mani
countri
focuss
ambulatori
care
consid
specif
nh
situat
countri
presenc
infect
control
practition
compulsori
partnership
hospit
infect
control
team
legal
impos
ms
conclus
import
structur
function
regulatori
nh
differ
exist
eu
countri
specif
tool
improv
infect
prevent
ab
therapi
nh
take
account
differ
european
nh
network
creat
framework
esac
nh
subproject
organis
point
preval
survey
ab
use
c
escherichia
coli
southwestern
finland
j
meurman
h
marttila
hakanen
lindgren
k
rantakokkojalava
turku
fi
object
extendedspectrum
betalactamas
esbl
especi
enzym
ctxm
group
spread
rapidli
europ
enterobacteriacea
reduc
suscept
third
gener
cephalosporin
posit
esbl
confirmatori
test
also
increas
southwest
finland
purpos
work
studi
resist
genet
esblposit
enterobacteriacea
method
studi
compris
total
clinic
enterobacteriacea
strain
isol
inpati
outpati
specimen
enterobacteriacea
strain
esbl
confirmatori
test
posit
januari
decemb
includ
studi
escherichia
coli
klebsiella
pneumonia
one
isol
per
patient
strain
urin
isol
resist
determin
done
use
disk
diffus
method
clsi
vitek
esbl
confirm
doubl
disk
method
use
cefotaxim
ceftatzidim
without
clavulan
thu
far
strain
collect
end
june
analys
presenc
import
esbl
gene
tem
shv
ctxm
use
pcr
pyrosequenc
describ
haanpera
et
al
aac
result
esblposit
strain
found
harbour
ctxm
type
esbl
gene
sinc
number
esblproduc
enterobacteriacea
strain
increas
significantli
tenfold
compar
year
figur
high
major
strain
analys
thu
far
ctxmtype
esbl
gene
belong
group
accord
pyrosequenc
result
group
next
common
ctxm
gene
belong
group
two
strain
ctxm
group
enzym
found
conclus
enterobacteriacea
strain
produc
esbl
increas
rapidli
southwest
finland
especi
true
e
coli
strain
isol
urin
toward
end
studi
period
esbl
enzym
almost
exclus
ctxm
group
common
research
need
characteris
genet
element
carri
esbl
gene
esbl
strain
proport
ctxm
gene
franc
n
spain
n
portug
n
uk
n
kuwait
n
canada
n
china
n
includ
hong
kong
n
studi
clonal
establish
pfge
phylogenet
group
ec
kp
determin
report
suscept
test
clsi
transfer
locat
nucleas
investig
plasmid
analysi
includ
determin
inc
group
pcrreplicon
type
hybridis
sequenc
comparison
rflp
pattern
associ
establish
pcr
sequenc
identifi
pfge
type
among
isol
ec
kp
cf
distribut
among
phylogroup
follow
ec
n
n
n
n
ii
kp
kpi
n
kpii
n
resist
tetracyclin
nalidix
streptomycin
sulfonamid
ciprofloxacin
trimetroprim
common
spread
horizont
hospit
characteris
plasmid
respons
major
k
pneumonia
strain
identifi
survey
method
plasmid
repres
k
pneumonia
strain
enzym
extract
alkalin
lysi
compar
apai
psti
ecori
restrict
analysi
transfer
e
coli
electropor
transform
select
cefotaximecontain
agar
screen
pcr
betalactamas
gene
aminoglycosid
resist
gene
aac
ib
plasmidmedi
quinolon
resist
gene
qnrab
result
twelv
isol
characteris
repres
major
strain
ad
f
found
mostaffect
hospit
restrict
analysi
divid
plasmid
sever
group
repres
strain
n
essenti
plasmid
group
two
repres
strain
group
one
strain
f
isol
plasmid
group
similar
plasmid
strain
indic
possibl
horizont
transfer
plasmid
group
retriev
repres
strain
b
c
indic
probabl
transfer
plasmid
three
strain
differ
substanti
plasmid
nevertheless
plasmid
blactxm
gene
link
upstream
element
known
involv
mobilis
encod
multiresist
one
group
one
ungroup
plasmid
carri
aac
ib
aac
iia
detect
except
group
plasmid
blatem
found
group
one
group
two
ungroup
plasmid
blashv
qnrab
gene
detect
consider
divers
plasmid
encod
enzym
major
slovenian
k
pneumonia
strain
suggest
limit
transfer
even
multipl
strain
present
hospit
evid
plasmid
transfer
strain
b
c
possibl
strain
f
although
plasmid
strictli
ident
analysi
resist
gene
encod
plasmid
reveal
divers
group
coincid
larg
base
restrict
profil
ingold
g
borthagaray
ak
merkier
h
bello
cm
montevideo
uy
bueno
air
ar
cl
object
examin
genet
context
class
integron
harbour
fifteen
nosocomi
k
pneumonia
isol
south
america
order
enhanc
understand
antibiot
resist
spread
among
region
method
dna
extract
use
axypreptm
bacteri
genom
dna
miniprep
kit
analysi
cassett
array
carri
use
primer
target
adjac
conserv
region
examin
surround
perform
use
two
pcr
primer
pair
amplifi
initi
iri
termin
irt
invert
repeat
boundari
respect
primer
pair
use
whenev
neg
result
obtain
pcr
product
purifi
sequenc
data
analyz
ncbi
blast
tool
sequenc
obtain
primer
reveal
presenc
three
differ
transposon
backbon
iri
end
modul
modul
present
isol
modul
present
isol
amplicon
obtain
use
primer
amplifi
insert
two
uruguayan
isol
boundari
iri
end
test
target
backbon
one
gener
product
consist
mer
region
uruguayan
isol
carri
singl
cassett
one
contain
array
four
argentinian
isol
carri
combin
chilean
isol
array
process
conclus
among
extendedspectrum
betalactamas
cefotaximas
constitut
rapidli
grow
cluster
enzym
dissemin
geograph
high
frequenc
isol
produc
k
pneumonia
associ
class
integron
region
despit
common
presenc
link
k
pneumonia
isol
studi
provid
new
relev
inform
sequenc
context
iri
report
cassett
array
divers
divers
element
class
integron
embed
differ
integrontransposon
carri
gene
seem
circul
differ
region
pattern
could
emerg
studi
highlight
abil
differ
genet
element
act
cooper
spread
rearrang
antibiot
resist
l
fortini
p
poeta
moreno
c
torr
es
rome
vila
real
pt
madrid
es
object
ctxm
enzym
frequent
detect
europ
particular
strain
recov
human
farm
anim
spain
itali
greec
portug
suggest
exist
commun
reservoir
enzym
aim
studi
compar
escherichia
coli
strain
plasmid
harbour
gene
isol
human
anim
method
four
e
coli
eight
epidemiolog
unrel
produc
sick
healthi
anim
pig
dog
cow
chicken
human
urin
blood
faecal
sampl
analys
xbaipfg
plasmid
transfer
pcrbase
replicon
type
plasmid
restrict
analysi
southern
blot
hybridis
isol
spain
dog
isol
portug
genet
context
blactxm
gene
previous
investig
strain
result
three
strain
one
healthi
chicken
two
hospitalis
patient
show
pfge
pattern
chromosom
localis
gene
suspect
strain
five
remain
produc
show
gene
plasmid
belong
incn
strain
untyp
group
strain
two
incn
plasmid
show
ident
pvuiirestrict
pattern
one
identifi
strain
healthi
chicken
one
hospitalis
human
patient
two
strain
isol
respect
show
differ
pfge
pattern
produc
three
anim
strain
one
healthi
human
show
clonal
pfge
gene
alway
locat
plasmid
three
belong
incn
one
group
two
incn
plasmid
carri
gene
show
highli
relat
restrict
pattern
one
healthi
dog
one
healthi
human
conclus
studi
demonstr
presenc
clonal
e
coli
produc
anim
human
sourc
also
detect
epidem
incn
plasmid
dissemin
among
unrel
isol
human
anim
clearli
suggest
potenti
anim
reservoir
gene
characteris
novel
integronloc
metallobetalactamas
gene
pseudomona
stutzeri
clinic
isol
netherland
l
j
rodriguezmartinez
n
al
naiemi
debetsossenkopp
p
nordmann
kbicetr
fr
amsterdam
nl
object
characteris
mechan
involv
uncommon
resist
carbapenem
observ
pseudomona
stutzeri
isol
recov
patient
hospitalis
netherland
chronic
tibia
osteomyel
strain
resist
ticarcillin
piperacillintazobactam
imipenem
meropenem
intermedi
suscept
ceftazidim
cefepim
suscept
aztreonam
method
screen
metallobetalactamas
mbl
product
perform
use
etest
method
strip
combin
imipenem
edta
shotgun
clone
perform
xbaidigest
dna
p
stutzeri
pbkcmv
clone
vector
select
perform
amoxicillin
kanamycincontain
plate
result
e
coli
recombin
strain
obtain
display
resist
penicillin
ceftazidim
reduc
suscept
cefepim
imipenem
meropenem
full
suscept
aztreonam
sequenc
analysi
identifi
novel
ambler
class
b
betalactamas
dutch
imipenemas
pi
weakli
relat
mbl
share
amino
acid
ident
close
relat
mbl
ident
imp
vim
subgroup
respect
hydrolyz
effici
imipenem
meropenem
expandedspectrum
cephalosporin
spare
aztreonam
gene
form
gene
cassett
locat
first
posit
class
integron
gene
cassett
truncat
give
rise
fusion
aadb
gene
cassett
encod
aminoglycosid
adenylyltransferas
third
last
gene
cassett
correspond
qach
cassett
encod
resist
disinfect
conclus
novel
mbl
gene
identifi
p
stutzeri
underlin
divers
acquir
mbl
gene
especi
among
nonferment
ii
pseudomona
sp
may
reservoir
gene
iii
possibl
spread
import
resist
determin
northern
part
europ
isol
greec
p
giakkoupi
pappa
polemi
bakosi
athen
gr
object
metallobetalactamas
vim
famili
main
mechan
carbapenem
resist
p
aeruginosa
greec
preliminari
report
attempt
survey
subtyp
vim
betalactamas
current
prevail
p
aeruginosa
clinic
isol
greek
hospit
genet
related
respect
isol
well
genet
environ
blavim
gene
method
fifteen
mbl
produc
epidemiolog
unrel
p
aeruginosa
clinic
isol
collect
septemb
fifteen
differ
hospit
around
greec
mbl
product
initi
identifi
edta
synergi
test
identif
blavim
gene
well
map
blavim
cassett
carri
integron
perform
pcr
sequenc
product
serotyp
isol
determin
slide
agglutin
test
use
p
aeruginosa
antisera
biorad
molecular
type
perform
pulsefield
gel
electrophoresi
speirestrict
genom
dna
result
gene
detect
nine
isol
five
one
isol
cassett
nine
isol
locat
bp
variabl
region
class
integron
preced
gene
cassett
cassett
five
isol
first
cassett
bp
variabl
region
class
integron
follow
gene
cassett
uniqu
cassett
class
integron
produc
belong
serotyp
wherea
four
isol
nontyp
produc
belong
three
serotyp
wherea
one
nontyp
produc
belong
serotyp
nine
produc
p
aeruginosa
isol
reveal
great
degre
variabl
pfge
molecular
type
belong
seven
type
contrari
five
produc
p
aeruginosa
isol
display
higher
genet
similar
fell
one
major
type
homolog
also
includ
produc
isol
correl
result
serotyp
molecular
type
conclus
mbl
product
p
aeruginosa
greec
seem
mainli
due
specif
class
integron
harbour
either
gene
genet
variabl
higher
among
bacteria
carri
betalactamas
fact
indic
wider
intraclonar
spread
respect
integron
jm
rodriguezmartinez
l
p
nordmann
kbicetr
fr
object
extendedspectrum
betalactamas
ampctyp
esac
contribut
reduc
suscept
imipenem
recent
report
enterobacteriacea
aim
studi
evalu
put
role
natur
ampctyp
betalactamas
p
aeruginosa
similar
resist
profil
method
thirtytwo
nonrepetit
p
aeruginosa
clinic
isol
recov
hospit
includ
select
basi
criteria
intermedi
suscept
resist
ceftazidim
intermedi
suscept
resist
imipenem
mic
determin
agar
dilut
etest
techniqu
level
express
ampc
betalactamas
evalu
measur
specif
activ
pcr
sequenc
clone
allow
characteris
differ
bla
ampc
gene
identifi
esac
purifi
km
kcat
valu
betalactam
determin
spectrophotometri
result
use
cloxacillincontain
ampc
betalactamas
inhibitor
plate
suscept
ceftazidim
restor
isol
suggest
overproduct
ampc
addit
presenc
cloxacillin
reduc
mic
valu
also
observ
ceftazidim
cefepim
imipenem
isol
clone
sequenc
identifi
distinct
ampc
blactamas
variant
among
isol
recombin
plasmid
express
ampc
transform
refer
p
aeruginosa
strain
reduc
suscept
cefepim
imipenem
observ
recombin
p
aeruginosa
strain
express
ampc
betalactamas
arginin
residu
posit
catalyt
effici
kcatkm
ampc
variant
possess
arginin
residu
increas
oxyiminocephalosporin
imipenem
addit
invitro
assay
demonstr
ampc
variant
constitut
favour
background
select
addit
degre
carbapenem
resist
conclus
ampc
p
aeruginosa
possess
extend
activ
torward
carbapenem
may
contribut
carbapenem
resist
background
oxatyp
esbl
deriv
display
low
homolog
percentag
oxatyp
esbl
divid
five
group
accord
differ
homolog
freder
bert
etc
group
includ
deriv
group
includ
group
includ
group
name
group
includ
singl
enzym
call
oxatyp
esbl
report
widespread
world
sinc
first
report
turkey
franc
england
report
china
object
investig
preval
genotyp
distribut
oxatyp
extendedspectrum
betalactamas
esbl
clinic
pseudomona
aeruginosa
strain
isol
xiangya
hospit
central
south
univers
changsha
citi
hunan
provinc
china
method
ninetyseven
nonrepetit
clinic
isol
p
aeruginosa
collect
octob
januari
hospit
screen
oxatyp
esbl
product
polymeras
chain
reaction
pcr
five
pair
prime
specif
blaoxa
gene
respect
amplif
oxatyp
esbl
product
perform
pcr
specif
primer
purifi
amplifi
product
sequenc
confirm
genotyp
oxatyp
esbl
result
sequenc
three
oxatyp
esbl
pcr
product
compar
genbank
databas
complet
ribonucleotid
amino
acid
sequenc
two
novel
oxatyp
esbl
name
regist
genbank
databas
access
number
respect
conclus
occur
infect
caus
p
aeruginosa
produc
oxatyp
esbl
xiangya
hospit
central
south
univers
two
novel
oxatyp
esbl
p
aeruginosa
strain
discov
studi
name
respect
pneumonia
one
common
nosocomi
infect
associ
high
mortal
last
year
gramposit
bacteri
pathogen
risen
preval
caus
hospitalacquir
pneumonia
hap
includ
occur
mechan
ventil
ventilatorassoci
pneumonia
vap
particular
staphylococcu
aureu
major
caus
hap
includ
vap
rise
multidrugresist
infect
sourc
concern
methicillinresist
aureu
mrsa
account
aureu
isol
european
hospit
symposium
take
format
questionandansw
roundtabl
session
expert
answer
question
initi
discuss
surround
emerg
concern
appropri
therapeut
strategi
nosocomi
pneumonia
includ
caus
multidrugresist
gramposit
pathogen
recent
shift
suscept
aureu
establish
therapeut
agent
nosocomi
pneumonia
ad
challeng
select
appropri
empir
therapi
patient
suspect
multidrugresist
infect
mechan
ventil
prompt
initi
therapi
often
pathogen
confirm
critic
vancomycin
goldstandard
treatment
multidrugresist
infect
resist
remark
slow
emerg
howev
clinic
report
europ
mic
creep
emerg
vancomycinintermedi
aureu
visa
hvisa
linezolidresist
mrsa
present
new
clinic
dilemma
elev
vancomycin
mic
link
treatment
failur
increas
mortal
henc
vancomycin
remain
use
therapeut
tool
treatment
decis
present
increas
challeng
especi
group
patient
rapid
erad
infect
appropri
agent
critic
telavancin
novel
lipoglycopeptid
investig
treatment
nosocomi
pneumonia
number
key
featur
suggest
telavancin
potenti
attract
option
nosocomi
pneumonia
telavancin
uniqu
dual
mechan
action
disrupt
bacteri
cell
wall
biosynthesi
cell
membran
integr
agent
rapidli
bactericid
broad
rang
clinic
relev
gramposit
bacteria
includ
mrsa
two
pivot
phase
iii
studi
demonstr
telavancin
efficaci
equival
vancomycin
hap
includ
vap
includ
serious
ill
patient
subgroup
caus
mrsa
hantavirus
envelop
rna
virus
carri
primarili
rodent
insectivor
specif
host
speci
coevolv
host
caus
almost
asymptomat
persist
infect
human
hantavirus
caus
diseas
haemorrhag
fever
renal
syndrom
hfr
eurasia
europ
puumala
puuv
bank
vole
saaremaa
saav
field
mice
caus
mild
hfr
dobrava
dobv
yellowneck
mice
sever
hfr
asia
hfr
caus
mainli
hantaan
seoul
virus
america
virus
caus
hantaviru
cardiopulmonari
syndrom
sin
nombr
and
virus
carri
sigmodontin
rodent
found
eurasia
addit
europ
common
vole
carri
tula
rat
seoul
viru
howev
definit
associ
diseas
europ
although
infect
human
discuss
epidemiolog
molecular
genet
detect
infect
carrier
host
human
includ
rtpcr
serolog
test
function
hantavir
protein
risk
factor
human
catch
hantaviru
infect
includ
smoke
diseas
includ
risk
protect
hla
haplotyp
role
map
epitop
cytotox
tcell
mechan
hantavirusinduc
apoptosi
newli
discov
clinic
featur
includ
hypophys
haemorrhag
puuv
infect
longterm
consequ
pathogenesi
hfr
endotheli
permeabl
thrombocytopenia
tnfalpha
puuv
occur
wide
europ
except
far
north
mediterranean
region
saav
northern
eastern
central
europ
dobv
mainli
balkan
epidemiolog
pattern
differ
western
central
europ
hfr
epidem
follow
mast
year
increas
oak
beech
seed
product
promot
rodent
breed
north
hantaviru
infect
hfr
epidem
occur
year
cycl
driven
preypred
interact
infect
hfr
increas
europ
partli
better
diagnost
partli
perhap
due
environment
chang
sever
european
countri
hantaviru
infect
notifi
countri
eg
belgium
finland
franc
germani
scandinavian
countri
slovenia
epidemiolog
rel
well
studi
larg
area
europ
howev
hantaviru
infect
hfr
studi
systemat
still
heavili
underdiagnos
mrsa
screen
ever
agre
mrsa
univers
screen
success
control
outbreak
epidem
reli
detect
harbour
pathogen
infect
colonis
person
combin
elimin
spread
new
individu
approach
contain
reduct
global
mrsa
pandem
discuss
challeng
infect
person
harbour
mrsa
exhibit
sign
diseas
thu
order
detect
potenti
spreader
organ
surveil
must
done
requir
level
detect
surveil
screen
known
like
vari
preval
colonis
diseas
given
mrsa
preval
factor
seem
crucial
reduc
spread
percentag
potenti
isol
day
captur
oper
process
highli
influenc
sensit
screen
detect
includ
site
test
laboratori
method
use
speed
result
newli
detect
posit
patient
report
laboratori
assum
preemptiv
isol
employ
select
patient
popul
undergo
screen
laboratori
test
major
impact
detect
mrsa
colonis
patient
realtim
pcr
sensit
possibl
hour
report
time
compar
direct
chromogen
agar
cultur
sensit
hour
report
enrich
chromogen
agar
test
sensit
hour
report
j
clin
pathol
reduc
sensit
prolong
report
time
neg
impact
success
mrsa
time
isol
shown
captur
mrsa
isol
day
modest
mrsa
preval
set
patient
day
high
sensit
test
hour
result
report
time
reduc
hospitalwid
mrsa
diseas
ann
int
med
other
demonstr
surveil
icu
similar
mrsa
preval
high
sensit
test
day
result
report
reduc
icu
diseas
preemptiv
isol
initi
crit
care
final
demonstr
univers
admiss
surveil
decolonis
captur
possibl
mrsa
isol
day
dramat
impact
reduc
inhospit
infect
mrsa
futur
research
area
focu
better
defin
patient
benefit
mrsa
screen
role
decolonis
program
clostridium
difficil
infect
cdi
toxinmedi
intestin
diseas
extraintestin
manifest
except
clinic
outcom
rang
asymptomat
colonis
mild
diarrhoea
sever
diseas
characteris
inflammatori
lesion
pseudomembran
colon
toxic
megacolon
bowel
perfor
sepsi
shock
death
main
clinic
symptom
secretori
diarrhoea
inflamm
colon
mucosa
great
part
explain
action
two
larg
protein
toxin
toxin
tcda
toxin
b
tcdb
toxin
cytotox
destroy
intestin
epithelium
decreas
colon
barrier
function
disrupt
actin
cytoskeleton
tight
junction
result
decreas
transepitheli
resist
allow
fluid
accumul
addit
c
difficil
toxin
also
caus
releas
variou
inflammatori
mediat
affect
enter
nerv
sensori
neuron
promot
inflammatori
cell
ad
fluid
secret
inflamm
transmigr
neutrophil
experiment
evid
point
also
possibl
extraintestin
action
c
difficil
toxin
b
zebrafish
embryo
tcdb
caus
damag
edema
cardiac
tissu
hamster
toxin
caus
lung
damag
recent
effici
system
develop
genet
manipul
c
difficil
comparison
knockout
mutant
produc
one
toxin
shown
tcdbpositiveonli
mutant
retain
abil
kill
hamster
wherea
tcdapositiveonli
mutant
virul
hamster
result
concord
epidemiolog
find
natur
occur
ab
strain
still
caus
entir
spectrum
cdi
concord
effect
observ
intragastr
challeng
hamster
purifi
toxin
tcda
tcdb
role
third
toxin
produc
c
difficil
binari
toxin
cdt
develop
human
diseas
well
understood
cdt
shown
enterotox
effect
rabbit
ileal
loop
assay
natur
strain
produc
cdt
neither
tcda
tcdb
colonis
anim
lethal
hamster
compar
genom
analysi
like
reveal
addit
factor
involv
pathogenesi
increas
virul
includ
cell
surfac
layer
protein
sporul
characterist
antibiot
resist
addit
role
host
immun
respons
cdi
start
better
understood
sinc
escal
rate
clostridium
difficil
infect
cdi
epidem
c
difficil
pcr
ribotyp
american
pulsedfield
type
respons
outbreak
sever
infect
north
america
europ
fluoroqinolon
resist
overus
thought
drive
epidem
age
popul
improv
case
ascertain
contribut
dramat
increas
case
factor
may
also
import
increas
prescript
proton
pump
inhibitor
netherland
sinc
increas
preval
human
cdi
ribotyp
strain
usual
found
anim
infect
younger
popul
frequent
commun
acquir
alarm
report
retail
beef
sampl
canada
contain
c
difficil
figur
higher
usa
packag
meat
beef
pork
turkey
arizona
store
contain
c
difficil
anim
isol
c
difficil
produc
binari
toxin
pig
cattl
harbour
pcr
ribotyp
strain
like
ribotyp
also
produc
toxin
b
binari
toxin
eastern
part
netherland
pig
farm
locat
human
isol
ribotyp
human
pig
strain
c
difficil
highli
genet
relat
suggest
overlap
locat
pig
farm
netherland
occurr
human
ribotyp
infect
involv
common
sourc
sourc
like
environ
upsurg
cdi
prompt
diagnost
compani
tri
either
improv
current
test
develop
new
one
laboratori
diagnost
method
divid
group
tradit
faecal
cytotoxin
detect
without
cultur
enzym
immunoassay
eia
molecular
method
faecal
cytotoxin
detect
specif
lack
sensit
cultur
sensit
lack
specif
new
eia
find
nich
medium
size
laboratori
current
inhous
pcr
method
potenti
great
sensit
specif
avail
larger
laboratori
new
commerciallyavail
platform
make
methodolog
access
smaller
laboratori
whatev
method
chosen
necessari
laboratori
fast
turnaroundtim
possibl
particularli
outbreak
situat
saintmauric
fr
advisori
board
immunis
abi
ask
make
recommend
ministri
health
regard
inclus
french
immunis
schedul
soon
licens
first
hpv
vaccin
main
element
consid
establish
benefitrisk
balanc
routin
hpv
vaccin
benefit
side
signific
potenti
prevent
burden
diseas
high
efficaci
vaccin
persist
hpv
infect
naiv
subject
expect
addit
impact
relat
lesion
cancer
fact
vaccin
prevent
precancer
lesion
advantag
screen
reduc
cost
anxieti
relat
detect
manag
avail
data
favour
satisfactori
safeti
profil
benefit
vaccin
women
cover
opportunist
screen
program
risk
side
high
cost
vaccin
unknown
durat
protect
need
continu
screen
even
vaccin
women
fact
major
residu
cervic
cancer
could
prevent
organis
screen
program
risk
decreas
complianc
screen
vaccin
women
low
benefit
vaccin
screen
women
cost
effect
analysi
carri
multi
cohort
markov
model
show
year
period
impact
vaccin
year
old
girl
organis
screen
compar
reduct
cancer
death
close
howev
costeffect
ratio
vaccin
higher
screen
organis
resp
per
life
year
save
discount
rate
basi
econom
analysi
screen
organis
therefor
first
prioriti
howev
intervent
implement
overal
reduct
cervic
cancer
death
estim
costeffect
addit
vaccin
top
organis
screen
appear
accept
per
life
year
save
base
result
abi
issu
march
recommend
includ
hpv
vaccin
immunis
schedul
year
old
girl
togeth
catch
year
old
women
start
sexual
life
one
year
ago
vaccin
cost
reimburs
sinc
juli
clinic
microbiolog
outsourc
way
go
r
evolut
clinic
microbiolog
europ
good
bad
laboratori
medicin
gener
clinic
microbiolog
particular
present
subject
rapid
r
evolut
awar
command
know
go
oppos
cooper
choic
recognis
drive
forc
money
good
bad
plain
necessari
gain
lose
one
evolutionari
process
sever
parallel
process
vari
emphasi
differ
area
least
four
distinct
major
trend
last
year
gradual
format
bigger
bigger
unit
concentr
amalgam
mani
differ
laboratori
servic
one
laboratori
medicin
accredit
explos
profession
profici
background
staff
microbiolog
laboratori
person
withstood
first
two
pleasur
succumb
latter
recent
trend
outsourc
microbiolog
servic
larg
privat
consortium
split
clinic
microbiolog
pure
analyt
highthroughput
moneysav
activ
often
leav
consult
clinic
part
microbiolog
health
care
infect
control
adrift
drive
evolut
costsav
also
inabl
recruit
medic
train
microbiologist
need
broaden
knowledg
base
microbiolog
laboratori
autom
develop
new
techniqu
apparatu
common
mani
laboratori
disciplin
computeris
medicin
polit
trendi
power
struggl
much
much
gain
concentr
amalgam
much
lost
well
mani
consid
heart
soul
clinic
microbiolog
risk
period
year
ration
highthroughput
product
consult
personalis
microbiolog
may
fine
product
neg
hivantibodyantigen
analysi
screen
blooddonor
certainli
bacteriolog
cultur
taken
conjunct
hip
replac
come
understand
advis
intricaci
antimicrobi
resist
develop
case
outsourc
andor
amalgam
mean
blood
cultur
sent
xtown
cmvantibodi
ytown
everyth
els
zvill
happen
clinic
microbiolog
lost
sever
instanc
concentr
amalgam
andor
outsourc
clinic
microbiolog
servic
alon
servic
meant
tie
clinic
microbiolog
infect
control
sever
mani
small
larg
hospit
lost
personalis
servic
necessari
control
outbreak
multiresist
bacteria
health
care
relat
infect
good
servic
requir
strong
knowledg
enthusiast
champion
servic
encompass
mani
branch
laboratori
medicin
expect
champion
everi
one
equal
strength
fervour
outsourc
big
compani
clinic
microbiolog
medic
microbiolog
broke
laboratori
medicin
uem
strive
toward
strong
medic
microbiolog
servic
europ
mani
facet
much
strength
weak
great
opportun
mani
threat
escmid
certainli
intend
help
shape
microbiolog
europ
optim
organis
microbiolog
laboratori
european
metropoli
evolutionari
task
driven
evolut
laboratori
task
laboratori
technolog
commun
technolog
regul
financi
issu
past
fiveten
year
medic
societ
queri
rapid
refin
detect
identif
pathogen
antimicrobi
resist
determin
coincid
expans
internetbas
remot
tool
commun
unpreced
revolut
laboratori
technolog
new
financi
constraint
concentr
laboratori
workforc
one
uniqu
laboratori
one
way
address
appar
contradictori
issu
tertiari
medic
school
hospit
system
marseil
metropolitan
area
franc
compris
four
hospit
total
bed
system
four
microbiolog
laboratori
progress
embed
uniqu
act
per
year
laboratori
deal
bacteriolog
virolog
environment
microbiolog
hygien
medic
staff
compris
ingenior
staff
technic
staff
support
staff
person
total
person
organis
allow
reduc
labour
time
routin
microbiolog
develop
prospect
sophist
timeconsum
diagnost
method
develop
advanc
diagnost
method
molecular
method
realtim
pcrbase
test
sequenc
mass
spectrometri
identif
new
gener
serolog
new
sophist
technolog
autom
serolog
mass
spectrometri
cornerston
base
constant
diminut
routin
labour
time
develop
timeconsum
task
fastidi
organ
isol
evolut
parallel
exponenti
increas
ratio
ingenior
laboratori
paradigm
allow
constitut
larg
collect
biolog
specimen
retrospect
analys
specialis
everi
medic
senior
one
particular
field
intern
recogn
expertis
increas
knowledg
output
term
peerreview
paper
patent
grant
implant
pointofcar
emerg
depart
perman
internetbas
connect
central
laboratori
last
least
evolut
system
tuberculosi
epidemiolog
seen
global
perspect
millennium
develop
goal
consid
clear
two
region
world
africa
europ
sever
behind
control
diseas
africa
especi
subsaharan
africa
tb
problem
close
relat
endem
hivaid
situat
europ
especi
eastern
part
part
former
soviet
union
main
obstacl
effect
tb
control
relat
drug
resist
form
tuberculosi
preval
sever
form
resist
mdrand
xdrtb
high
make
control
effort
extrem
complic
expens
unfortun
increas
level
drug
resist
tb
today
also
seen
mani
african
countri
hiv
infect
spread
eastern
europ
last
tenyear
period
new
tool
base
molecular
fingerprint
tuberculosi
strain
increasingli
adapt
studi
tb
transmiss
molecular
method
characteris
clinic
isol
tuberculosi
possibl
studi
spread
individu
strain
bacteria
detail
laboratori
tool
use
rflp
miruvntr
spoligotyp
other
present
use
exemplifi
molecular
epidemiolog
contribut
detect
characteris
major
outbreak
drug
resist
tb
stockholm
area
discuss
molecular
characteris
clinic
isol
differ
part
world
led
increas
recognit
differ
differ
famili
tuberculosi
strain
describ
understand
role
differ
clinic
field
well
tb
epidemiolog
ongo
interest
field
research
increas
understand
tb
transmit
hope
help
effort
control
global
health
threat
local
level
global
perspect
live
era
increas
tuberculosi
drug
resist
import
make
earli
accur
diagnosi
drug
sensit
never
greater
epidemiolog
tuberculosi
defin
extent
latent
diseas
proport
becom
activ
accur
diagnosi
vital
patient
treat
time
manner
reduc
amount
time
infecti
individu
go
untreat
commun
dissemin
diseas
mani
area
world
dot
programm
forefront
tuberculosi
control
howev
diagnost
current
reli
sputum
smear
microscopi
known
miss
case
tuberculosi
provid
data
drug
sensit
second
major
issu
around
tb
lack
worldwid
diagnost
facil
need
simpl
low
cost
easili
implement
diagnost
test
talk
briefli
consid
issu
around
diagnosi
latent
activ
diseas
quit
distinct
focu
diagnosi
activ
infect
particular
use
mod
microscop
observ
drugsuscept
assay
diagnosi
tuberculosi
discuss
potenti
use
resourc
poor
countri
review
well
way
sophist
technolog
mayb
har
improv
report
allow
translat
part
world
import
issu
distinguish
patient
latent
activ
diseas
also
consid
key
issu
principl
diagnosi
futur
review
term
treatment
main
issu
first
even
shortcours
therapi
prolong
minimum
month
lead
issu
complianc
may
result
drug
resist
massiv
rise
multidrug
resist
tuberculosi
approxim
case
worldwid
around
countri
report
extens
drugresist
diseas
mean
need
new
approach
therapi
urgent
second
part
talk
review
differ
approach
use
current
antimycobacteri
drug
emerg
small
number
new
drug
diarylquinolon
entir
novel
approach
control
treat
tuberculosi
great
success
also
mani
threat
field
infecti
diseas
previou
year
antimicrobi
resist
especi
increas
carbapenem
resist
among
aerob
gramneg
rod
xdr
mycobacteri
tuberculosi
strain
alreadi
big
threat
countri
probabl
spread
mani
area
world
futur
need
new
drug
indic
unfortun
new
promis
drug
seem
pipelin
moment
purpos
virul
clostridium
difficil
strain
spread
rapidli
mani
new
countri
eg
finland
kill
mani
time
peopl
compar
mrsa
esbl
strain
howev
possibl
stop
spread
need
new
think
antibiot
use
polici
infect
control
polici
hospit
clostridium
difficil
infect
high
relaps
rate
metronidazol
vancomycin
therapi
experiment
stool
exchang
treatment
promis
therapi
although
control
studi
need
prove
assumpt
interest
research
area
last
year
role
infect
etiopathogenesi
chronic
diseas
like
cancer
atherosclerosi
cardiovascular
diseas
mani
autoimmun
diseas
fight
mani
cancer
like
liver
cancer
cervix
cancer
viru
vaccin
gastric
cancer
antimicrobi
drug
also
high
incid
malign
tumour
seem
decreas
haart
treatment
hiv
patient
role
infect
etiopathogenesi
cardiovascular
diseas
atherosclerosi
complex
obviou
infect
play
role
etiopathogenesi
atherosclerosi
stroke
myocardi
infarct
undirect
routin
antimicrobi
treatment
recommend
patient
seem
subgroup
patient
variou
cardiovascular
diseas
may
benefit
antimicrobi
treatment
recent
studi
seem
suggest
hla
type
protect
make
peopl
suscept
coronari
heart
diseas
hla
type
hlab
seem
risk
factor
coronari
heart
diseas
also
risk
factor
chronic
chlamydia
pneumonia
infect
fear
pandemia
due
influenza
appear
recent
year
world
much
prepar
meet
next
pandemia
howev
hope
come
next
year
c
gisk
u
naseer
tofteland
dh
skutlaberg
onken
r
hjetland
sundsfjord
stockholm
se
kristiansand
bergen
oslo
object
worldwid
dissemin
kpcproduc
multidrugresist
enterobacteriacea
worrisom
first
kpcproduc
klebsiella
pneumonia
norway
isol
late
patient
hospitalis
greec
throughout
follow
year
seven
addit
kpcproduc
k
pneumonia
isol
detect
clinic
sampl
six
new
patient
aim
studi
perform
molecular
characteris
strain
examin
epidemiolog
related
materi
method
antimicrobi
suscept
examin
etest
molecular
characteris
perform
mlst
pfge
sequenc
blakpc
genet
structur
plasmid
analysi
carri
pfge
nucleasedigest
total
dna
southern
blot
hybridis
use
blakpc
probe
relev
epidemiolog
data
collect
retrospect
result
eight
kpcproduc
clinic
isol
k
pneumonia
identifi
seven
patient
two
differ
region
norway
follow
specimen
blood
cultur
n
urin
n
expector
n
perin
swab
n
wound
secret
n
two
blood
cultur
isol
clonal
relat
differ
pfgeprofil
observ
one
patient
detect
kpcproduc
k
pneumonia
isol
norwegian
patient
associ
import
four
case
hospitalis
greec
two
patient
hospitalis
hospit
greec
isol
kpcproduc
isol
fifth
patient
epidemiolog
link
one
import
case
case
nosocomi
transmiss
norway
latter
two
case
risk
factor
identifi
respect
recent
hospitalis
travel
abroad
molecular
analysi
six
isol
shown
genet
relat
pfgepattern
common
sequenc
type
associ
dissemin
hungari
blakpc
gene
localis
kb
plasmid
two
recent
isol
current
undergo
similar
analysi
conclus
first
seven
case
kpcproduc
k
pneumonia
norway
associ
hospitalis
abroad
nosocomi
transmiss
norway
urinari
tract
infect
outpati
without
obviou
risk
factor
clonal
relationship
isol
underlin
exist
biolog
fit
genet
lineag
kpcproduc
k
pneumonia
epidem
potenti
object
two
recent
public
report
isol
kpc
produc
k
pneumonia
infect
two
patient
one
franc
one
sweden
origin
hospitalis
greec
sinc
resist
mechan
identifi
countri
purpos
report
confirm
presenc
blakpc
produc
k
pneumonia
greec
assess
extent
spread
studi
genet
related
respect
bacteri
strain
transfer
blakpc
harbour
plasmid
method
three
month
period
februari
april
hospit
particip
greek
system
surveil
antibiot
resist
wwwmednetgrwhonet
ask
seek
possibl
kpc
produc
among
k
pneumonia
isol
display
reduc
suscept
imipenem
equal
higher
mgl
posit
hodg
test
presenc
carbapenemas
neg
edta
synergi
test
presenc
metalloenzym
presenc
blakpc
gene
strain
confirm
pcr
sequenc
mic
carbapenem
determin
etest
conjug
experi
carri
broth
agar
possibl
absenc
porin
detect
pcr
molecular
type
perform
pulsefield
gel
electrophoresi
xbairestrict
genom
dna
result
nineti
two
k
pneumonia
clinic
isol
one
per
patient
hospit
greec
found
harbour
gene
although
coloni
present
inhibit
zone
made
exact
determin
imipenem
mic
difficult
absenc
porin
alway
associ
mic
imipenem
higher
mgl
isol
exhibit
resist
drug
class
except
colistin
tetracyclin
tigecyclin
pfge
analysi
reveal
isol
hospit
display
similar
classifi
one
pulsotyp
wherea
remain
seven
isol
belong
four
differ
pulsotyp
gene
could
transfer
conjug
strain
belong
main
pulsotyp
howev
transfer
strain
belong
three
four
remain
pulsotyp
conclus
product
betalactamas
seem
new
emerg
resist
mechan
klebsiella
pneumonia
greec
gene
possibl
clonal
spread
impos
urgent
need
implic
infect
control
practic
affect
hospit
galani
souli
e
papadomichelaki
f
panayea
n
mitchel
antoniad
g
poulak
f
kontopid
h
athen
gr
background
carbapenem
resist
among
klebsiella
pneumonia
kp
clinic
isol
greek
hospit
attribut
dissemin
metallobetalactamas
describ
first
outbreak
kpcproduc
kp
greec
first
occur
outsid
usa
israel
set
icu
attikon
univers
hospit
athen
method
kp
isol
imipenem
mic
mgl
neg
edtaimipenem
disk
synergi
test
submit
boron
acid
disk
test
pcr
kpc
gene
specif
primer
sequenc
record
patient
colonis
infect
kpcproduc
kp
retrospect
review
clinic
epidemiolog
data
environment
cultur
kpcproduc
perform
clinic
isol
submit
molecular
type
use
pfge
result
februari
novemb
kp
isol
patient
boron
acid
posit
produc
isol
sinc
august
total
patient
identifi
colonis
infect
kpc
produc
belong
genet
clone
sourc
faec
bronchial
secret
blood
cvc
tip
urin
pu
throat
among
patient
whose
medic
record
avail
median
age
apach
ii
score
length
preced
hospit
stay
day
total
length
stay
day
immunosuppres
identifi
one
crude
mortal
kpcproduc
kp
frequent
icu
acquir
wherea
minor
patient
alreadi
present
icu
admiss
seventi
percent
patient
previous
receiv
carbapenem
median
day
environment
colonis
identifi
ten
kpcproduc
patient
identifi
caus
infect
bacteraemia
ventilatorassoci
pneumonia
surgic
site
infect
exhibit
mgl
imipenem
meropenem
gentamicin
ciprofloxacin
fosfomycin
colistin
tigecyclin
patient
success
treat
colistincontain
combin
mostli
betalactam
attribut
mortal
isol
bacteri
speci
type
pfge
autom
ribotyp
kpcencod
gene
fulli
sequenc
plasmid
prepar
iceu
digest
total
dna
resolv
agaros
gel
blot
hybridis
blakpc
probe
blakpccarri
element
amplifi
variou
primer
pair
digest
eag
sequenc
result
strain
carri
one
e
cloaca
carri
k
oxytoca
marcescen
harbour
usa
great
genet
divers
observ
among
isol
differ
type
one
clone
e
cloaca
detect
new
york
state
small
cluster
strain
detect
among
e
coli
e
cloaca
k
oxytoca
plasmid
present
isol
persist
clone
throughout
year
observ
isol
kpcencod
gene
locat
high
molecular
weight
plasmid
kb
blakpc
locat
chromosom
strain
e
cloaca
e
coli
k
oxytoca
locat
gene
could
determin
strain
small
plasmid
present
sever
strain
harbour
blakpc
carri
blakpc
isol
transposon
element
conserv
structur
detect
strain
conclus
kpcencod
gene
often
locat
among
sever
enterobacteriacea
speci
collect
usa
israel
blakpccarri
element
locat
plasmid
chromosom
studi
highlight
import
dissemin
blakpc
gene
sever
genet
divers
bacteri
speci
blakpc
associ
strain
strain
investig
object
evalu
carbapenem
resist
mechan
raoultella
planticola
bacteraemia
isol
recov
patient
hospitalis
ohio
usa
method
speci
identif
perform
vitek
confirm
rrna
sequenc
suscept
test
use
clsi
broth
microdilut
method
blakpc
amplifi
sequenc
blakpc
genet
element
amplifi
sequenc
plasmid
extract
conjug
experi
carri
isol
screen
esblencod
gene
qnr
qepa
year
old
femal
patient
admit
hospit
locat
akron
diagnosi
cap
sputum
paracentesi
blood
cultur
neg
urin
cultur
grew
e
coli
patient
receiv
cours
moxifloxacin
ceftriaxon
azithromycin
meropenem
patient
discharg
return
three
week
respiratori
problem
tracheal
aspir
grew
multidrug
resist
baumannii
blood
cultur
grew
entericlik
gramneg
bacillu
isol
identifi
r
planticola
vitek
confirm
sequenc
r
planticola
strain
demonstr
resist
blactam
includ
carbapenem
screen
kpcencod
gene
posit
strain
carri
fluoroquinolon
aminoglycosid
mic
valu
elev
gene
locat
conjug
experi
fail
esbl
qnrqepa
gene
detect
conclus
kpc
serinecarbapenemas
detect
sever
gramneg
speci
commonli
isol
clinic
specimen
kpc
gene
embed
transposonlik
structur
usual
harbour
conjug
plasmid
carri
multipl
antimicrobi
resist
mechan
first
report
kpcproduc
r
planticola
environment
organ
relat
klebsiella
spp
similar
organ
could
facilit
transfer
genet
materi
kpcproduc
isol
appear
preval
among
differ
enterobacteriacea
speci
usa
hospit
detect
isol
appar
environment
origin
object
long
known
individu
specif
diseas
present
clinic
manifest
ident
prognos
respons
treatment
becom
clear
variat
human
genom
like
impact
aspect
tankbind
kinas
central
molecul
induct
ao
type
interferon
respons
pathogen
goal
studi
investig
frequenc
singl
nucleotid
polymorph
snp
promot
code
region
dutch
caucasian
popul
search
potenti
associ
snp
bloodstream
infect
method
whole
blood
sampl
sampl
posit
blood
cultur
collect
genom
dna
isol
pcr
sequenc
perform
snp
identif
function
studi
includ
promot
activ
measur
use
luciferas
assay
well
electrophoret
mobil
shift
assay
emsa
studi
bind
transcript
factor
wt
mutant
promot
snp
incid
studi
case
control
studi
result
sampl
dutch
caucasian
healthi
volunt
snp
found
allel
frequenc
higher
wherea
known
snp
frequenc
lower
cohort
two
snp
locat
promot
region
studi
larger
cohort
anonymis
patient
maastricht
univers
medic
center
either
gramposit
gramneg
blood
cultur
found
preval
significantli
increas
patient
posit
blood
cultur
comparison
neg
blood
cultur
healthi
volunt
investig
snp
show
locat
outsid
site
measur
promot
activ
use
luciferas
assay
mutant
promot
exhibit
decreas
activ
observ
confirm
emsa
show
recombin
protein
reduc
bind
affin
mutant
promot
conclus
snp
promot
region
signific
associ
gramposit
infect
result
demonstr
like
due
decreas
express
due
reduc
bind
transcript
factor
mutant
promot
result
support
recent
find
play
also
import
role
host
respons
gramposit
infect
object
lymphocyt
apoptosi
recogn
import
factor
contribut
onset
sepsi
post
infect
progress
septic
shock
anim
data
suggest
prevent
lymphocyt
apoptosi
caspas
inhibit
stabilis
immun
system
improv
bacteri
clearanc
decreas
mortal
experiment
sepsi
present
studi
evalu
potenti
novel
broad
caspas
inhibitor
therapi
sepsi
method
result
initi
characteris
number
enzymat
cellular
assay
clearli
demonstr
compound
broad
caspas
inhibitor
potent
antiapoptot
activ
vitro
vivo
test
murin
model
endotox
shock
clinic
relev
model
periton
endotox
shock
model
male
mice
n
per
group
administ
lp
mgkg
iv
surviv
monitor
h
administ
repeat
iv
bolu
h
postlp
significantli
improv
surviv
dosedepend
fashion
p
rat
periton
model
adult
male
spraguedawley
rat
n
per
group
underw
caecal
ligat
punctur
clp
surviv
monitor
continu
administr
miniosmot
pump
mgkgh
immedi
follow
surgeri
significantli
improv
surviv
p
control
group
compoundtr
group
mode
action
studi
rat
clp
model
confirm
reduc
thymic
atrophi
lymphocyt
apoptosi
p
support
antiapoptot
activ
compound
vivo
addit
reduc
plasma
endotoxin
level
p
strongli
suggest
improv
clearanc
bacteria
bloodstream
importantli
demonstr
fulli
retain
efficaci
dose
hour
insult
p
improv
surviv
versu
control
anim
highlight
potenti
antiapoptot
therapi
sepsi
overal
data
demonstr
inhibit
lymphocyt
apoptosi
improv
clearanc
bacteri
endotoxin
improv
surviv
experiment
sepsi
importantli
improv
surviv
clp
model
dose
post
insult
therefor
repres
signific
progress
develop
therapeut
viabl
broad
caspas
inhibitor
treatment
diseas
v
van
voorden
n
hen
h
goossen
g
molenbergh
e
wiertz
wilrijk
leiden
nl
hasselt
object
tolllik
receptor
function
key
regul
innat
adapt
immun
lactobacilli
modul
immun
system
differ
way
aim
studi
examin
tolllik
receptor
signal
induc
clinic
probiot
lactobacillu
strain
method
total
lactobacillu
strain
l
paracasei
l
rhamnosu
differ
origin
probiot
faecal
clinic
test
combin
tlr
signal
measur
rel
promotor
activ
transfect
human
embryon
kidney
hek
cell
concentr
measur
use
enzymelink
immunosorb
assay
heatkil
listeria
monocytogen
hklm
use
posit
control
assay
wherea
lp
use
posit
control
respect
assay
perform
least
duplic
linear
mix
model
analys
stepwis
model
select
use
identifi
statist
signific
effect
random
effect
use
account
heterogen
across
homogen
within
isol
p
consid
statist
signific
result
cell
releas
upon
stimul
uvinactiv
lactobacilli
enhanc
cotransfect
interestingli
product
shown
variabl
differ
lactobacillu
isol
although
similar
result
seen
isol
product
significantli
higher
log
pgml
compar
log
pgml
p
signific
differ
product
seen
clinic
probiot
isol
howev
l
rhamnosu
isol
induc
significantli
higher
product
compar
l
paracasei
isol
cell
line
log
pgml
respect
p
intraisol
correl
found
signific
p
conclus
studi
show
lactobacilli
activ
combin
result
also
indic
heterodimeris
lead
improv
recognit
lactobacilli
furthermor
take
intraisol
correl
consider
prove
import
final
result
suggest
differ
immunomodul
lactobacilli
may
relat
differenti
signal
tlr
includ
mc
gagliardi
v
sargentini
r
teloni
remoli
g
federico
videtta
g
de
libero
e
coccia
r
rome
basel
ch
object
gain
insight
mechan
use
mycobacterium
tuberculosi
bacillu
calmett
caus
human
monocyt
differenti
neg
dendrit
cell
mymodc
unabl
present
lipid
antigen
specif
cell
method
human
monocyt
infect
mycobacteria
induc
differenti
dc
gmcsf
presenc
absenc
erk
specif
inhibitor
kinas
activ
detect
western
blot
use
antibodi
specif
phosphoryl
non
phosphoryl
isoform
differenti
monocyt
dc
express
evalu
flow
cytometri
real
time
pcr
differ
time
point
infect
function
express
molecul
assess
recognit
lipid
antigen
restrict
cell
clone
result
show
mycobacteria
trigger
phosphoryl
erk
mitogenactiv
protein
kinas
human
monocyt
well
activ
transcript
factor
atf
mycobacteriainfect
monocyt
treat
specif
inhibitor
specif
erk
inhibitor
becom
insensit
mycobacteri
subvers
differenti
posit
mymodc
fulli
capabl
present
lipid
antigen
data
indic
phosphoryl
directli
involv
inhibit
conclus
propos
signal
pathway
exploit
mycobacteria
affect
express
thu
repres
novel
target
possibl
pharmacolog
intervent
treatment
mycobacteri
infect
ribe
r
nau
u
michel
gottingen
de
object
activin
act
multifunct
cytokin
role
immun
system
inflammatori
respons
act
level
elev
cerebrospin
fluid
patient
mening
microgli
cell
major
constitu
innat
immun
within
brain
express
tolllik
receptor
tlr
recognis
exogen
endogen
ligand
upon
stimul
tlr
agonist
primari
mous
microgli
cell
becom
activ
releas
nitric
oxid
cytokin
also
act
suggest
sourc
elev
conclus
pretreat
act
enhanc
releas
microgli
cell
activ
agonist
princip
tlr
involv
recognit
bacteria
find
provid
evid
role
act
innat
immun
respons
suggest
act
act
proinflammatori
modul
infect
inflammatori
process
cn
insert
sequenc
genet
tool
mediat
express
previous
silent
gene
respons
overexpress
certain
gene
case
provid
promot
sequenc
addit
involv
gene
transcript
level
element
also
play
import
role
gene
acquisitionmobilis
usual
made
two
invertedrepeat
sequenc
ir
bracket
gene
encod
transposas
activ
enabl
entiti
replic
target
anoth
sequenc
isrel
mechan
origin
antibiot
resist
gene
acquisit
divers
includ
compositetransposit
rollingcircl
transposit
oneend
transposit
element
may
also
involv
gene
acquisit
mediat
cointegr
process
recombin
event
hypothet
relat
blashv
extendedspectrum
blactamas
esbl
gene
origin
chromosom
klebsiella
pneumonia
blactxm
esbl
gene
known
extrem
widespread
worldwid
encod
plasmid
found
associ
act
oneend
transposit
act
rollingcircl
transposit
case
iss
play
role
mobilis
chromosom
kluyvera
spp
blactxm
progenitor
express
also
gene
encod
acquir
ampc
blactamas
blaacc
bladha
blacmytyp
mostli
found
associ
sometim
antibiot
resist
gene
mobilis
composit
transposon
made
two
copi
given
bracket
mobilis
fragment
acinetobact
baumannii
worldwid
dissemin
carbapenemas
gene
part
composit
transposon
structur
made
two
copi
form
transposon
mobilis
chromosom
fragment
acinetobact
radioresisten
actual
correspond
progenitor
anoth
possibl
form
composit
transposon
structur
bracket
two
differ
share
similar
ir
observ
esbl
gene
pseudomona
aeruginosa
divers
iss
element
origin
mobilisationacquisit
antibiot
resist
gene
therefor
respons
effici
dissemin
mani
resist
island
role
accumul
spread
antimicrobi
resist
gene
histor
multiantibiot
resist
mani
bacteri
speci
larg
attribut
acquisit
resist
r
plasmid
encod
one
resist
determin
howev
last
decad
rplasmid
paradigm
begun
challeng
resist
island
compris
larg
chromosomallyintegr
span
alien
dna
harbour
multipl
antibiot
resist
gene
identifi
major
hospit
pathogen
methicillinresist
staphylococcu
aureu
mrsa
multiresist
acinetobact
baumannii
foodand
waterborn
diarrhoeal
pathogen
shigella
salmonella
vibrio
cholera
addit
compar
genom
analysi
archetyp
haemophilu
influenza
conjug
resist
element
spread
worldwid
reveal
belong
larg
synten
famili
integr
island
member
could
found
least
band
gproteobacteria
except
baumannii
island
element
describ
classic
selfexcis
circularis
integr
element
three
function
mediat
short
islandflank
direct
repeat
cognat
integras
protein
encod
island
fournier
et
al
describ
kb
baumannii
island
harbour
resist
gene
packag
within
highli
mosaic
integronrich
element
almost
certainli
evolv
via
recombin
transposit
integronmedi
cassett
captur
empti
ancestr
prototyp
probabl
repres
new
class
resist
island
exhibit
sever
featur
reminisc
complex
nest
transposon
suggest
distinct
function
natut
howev
despit
widespread
distribut
resist
genom
island
minor
known
code
part
conjug
machineri
necessari
dissemin
other
mobilis
helper
plasmid
bacteriophag
regardless
data
mechan
mobilis
vast
major
similar
nonresist
island
remain
spars
importantli
resist
island
may
consist
mere
packag
resist
gene
contrari
divers
frequent
hybrid
entiti
could
potenti
confer
upon
host
advantag
trait
relat
hostpathogen
interact
virul
surviv
environ
andor
transmiss
truli
justifi
label
selfish
island
explain
evolutionari
success
due
avail
new
techniqu
genom
sequenc
bacteria
becom
fast
inexpens
furthermor
recent
method
use
pairedend
read
locat
sever
kb
apart
genom
eas
assembl
process
even
though
refer
sequenc
avail
reason
close
futur
possibl
obtain
fulli
assembl
sequenc
bacteri
isol
overnight
new
sequenc
techniqu
gener
enorm
amount
genom
data
therebi
need
new
tool
abl
quickli
analyz
genom
point
zone
interest
prompt
analysi
reduc
number
region
gene
genom
island
pathogen
island
subset
genom
island
carri
gene
toxin
resist
gene
particular
mobil
ie
may
transfer
speci
strain
therebi
confer
new
host
resist
infecti
phenotyp
make
phenomenon
particularli
import
studi
nucleotid
composit
genom
fairli
homogen
insid
bacteri
genom
gener
horizont
transfer
region
spot
due
particular
nucleotid
content
tend
retain
composit
origin
host
nt
share
one
new
host
analog
languag
genom
speak
dialect
one
would
easili
spot
paragraph
finnish
english
text
know
finnish
one
spot
genom
pathogen
island
transfer
given
genom
sever
techniqu
reli
variou
composit
aspect
differ
algorithm
method
recent
develop
detect
pathogen
island
bacteri
genom
even
simpl
measur
genom
composit
variat
vs
bia
ta
skew
lead
identif
known
prophag
streptococcu
pyogen
even
trigger
discoveri
put
ancient
genom
island
carri
larg
number
gene
relat
pathogen
strain
speci
conclus
rise
fast
inexpens
genom
sequenc
new
quick
simpl
method
develop
take
advantag
homogen
nucleotid
composit
bacteri
genom
uncov
mobil
genet
element
carri
gene
involv
pathogen
past
year
signific
progress
achiev
manag
chronic
hepat
b
success
develop
six
potent
antivir
medic
lamivudin
adefovir
dipivoxil
pegyl
interferon
alpha
entecavir
telbivudin
tenofovir
howev
clinic
result
antivir
therapi
limit
emerg
antivir
drug
resist
especi
first
gener
nucleosid
analog
lamivudin
adefovir
telbivudin
furthermor
uniqu
mechan
viral
genom
replic
persist
within
infect
cell
respons
viral
persist
even
prolong
therapi
newer
antivir
entecavir
tenofovir
major
reason
lifelong
treatment
envisag
major
patient
may
expos
longterm
risk
develop
resist
use
vitro
phenotyp
assay
crucial
characteris
newli
identifi
resist
mutant
determin
crossresist
profil
result
allow
understand
differ
mechan
viral
resist
lamivudin
adefovir
mechan
primari
failur
adefovir
therapi
uniqu
mechan
entecavir
resist
characteris
emerg
multidrugresist
strain
patient
receiv
sequenti
antivir
therapi
crossresist
profil
main
resist
mutant
determin
allow
provid
recommend
clinician
treatment
adapt
base
molecular
virolog
data
understand
develop
hbv
drug
resist
allow
significantli
improv
manag
antivir
resist
design
better
treatment
strategi
prevent
resist
current
standard
care
reli
treatment
initi
antivir
combin
strong
antivir
potenc
high
barrier
resist
precis
virolog
monitor
requir
measur
antivir
efficaci
diagnos
partial
respons
viral
breathrough
earli
stage
allow
adapt
antivir
treatment
preferr
use
addon
strategi
drug
complementari
crossresist
profil
strategi
shown
effici
control
viral
replic
prevent
liver
diseas
progress
major
patient
treatment
chronic
hepat
b
viru
hbv
infect
aim
suppress
viral
replic
lowest
possibl
level
mani
prospect
clinic
trial
shown
sustain
hbv
dna
respons
correl
serolog
histolog
biochem
respons
despit
recent
progress
hepat
b
antivir
treatment
shown
antivir
drug
resist
inevit
mani
nucleosid
analog
emerg
antiviralresist
strain
hbv
lead
viral
subsequ
biochem
breakthrough
may
lead
diseas
progress
increas
death
data
clinic
impact
antivir
resist
hbv
came
data
deriv
studi
lamivudin
therapi
limit
data
hbv
antivir
drug
like
adefovir
shown
sever
studi
treatment
hbeagneg
chronic
hepat
b
lamivudin
effect
suppress
hbv
replic
result
biochem
remiss
histolog
improv
two
third
patient
howev
relaps
occur
major
hbeagneg
patient
cessat
therapi
sever
studi
support
occurr
sever
hepat
flare
liver
failur
emerg
lamivudin
resist
sever
studi
liver
biopsi
taken
demonstr
histolog
improv
reduc
patient
experienc
lamivudin
resist
clinic
outcom
patient
antivir
resist
relat
age
sever
underli
liver
diseas
sever
hepat
flare
hand
differ
studi
found
longterm
lamuvidin
treatment
associ
reduc
chanc
develop
cirrhosi
hcc
patient
without
advanc
diseas
although
resist
mutant
reduc
benefit
lamivudin
therapi
outcom
patient
still
better
untreat
patient
result
sever
clinic
trial
shown
addit
substitut
newer
antivir
agent
restor
suppress
viral
replic
normalis
liver
function
revers
histolog
progress
patient
antivir
resist
consequ
welltoler
potent
therapi
offer
strong
genet
barrier
develop
resist
desir
sinc
antivir
resist
poor
adher
key
risk
factor
treatment
failur
subsequ
revers
clinic
improv
resist
enter
fevercaus
nontyphoid
salmonella
serovar
agent
tradit
use
treat
infect
past
show
extens
geograph
variat
decreas
suscept
ciprofloxacin
rapidli
increas
world
target
alter
increas
efflux
import
mechan
behind
infect
strain
often
result
extend
hospitalis
even
therapeut
failur
furthermor
like
moder
increas
mic
valu
facilit
develop
strain
higher
level
resist
ie
pattern
describ
variou
locat
screen
method
base
quinolon
sensit
test
may
fail
indentifi
decreas
fluoroquinolon
suscept
typhoid
well
nontyphoid
salmonella
plasmid
mediat
quinolon
resist
gene
detect
increasingli
around
world
although
neither
frequenc
varieti
gene
identifi
approach
seen
member
enterobacteriacea
treatment
gatifloxacin
azithromycin
altern
option
invas
system
infect
caus
strain
decreas
suscept
ciprofloxacin
part
world
resist
extend
spectrum
cephalosporin
reach
incid
may
therapeut
implic
particularli
initi
empir
treatment
invas
infect
concern
resist
due
plasmid
code
ampc
type
beta
lactamas
particularli
often
esbl
usual
ctxm
type
frequent
encount
one
carbapenem
resist
still
rare
albeit
occur
among
salmonella
isol
recent
descript
nontyphoid
salmonella
strain
gene
coloc
integron
sever
resist
determin
conjug
plasmid
particular
concern
campylobact
exhibit
natur
resist
varieti
antimicrobi
drug
choic
use
fluoroqunolon
macrolid
howev
current
incid
ciprofloxacin
resist
made
former
drug
alreadi
obsolet
serious
limit
use
sever
part
world
except
locat
incid
macrolid
resist
still
rel
low
seen
frequent
c
coli
c
jejuni
howev
strain
exhibit
resist
group
drug
emerg
particularli
southeast
asia
neisseria
meningitidi
meningococcu
major
caus
mening
septicaemia
worldwid
neisseria
gonorrhoea
gonococcu
respons
one
widespread
sexual
trasmit
diseas
behaviour
two
speci
toward
antibiot
differ
resist
n
gonorrhoea
widespread
occur
chromosom
plasmid
mediat
varieti
drug
wherea
besid
resist
sulphonamid
n
meningitidi
remain
larg
suscept
antibiot
use
therapi
prophylaxi
howev
gonococcu
resist
antibiot
n
meningitidi
also
evolv
document
ever
higher
frequenc
strain
intermedi
resist
penicillin
mani
countri
transform
appar
provid
speci
mechan
increas
resist
penicillin
replac
part
pena
gene
encod
part
pena
gene
relat
speci
fortuit
produc
form
less
suscept
antibiot
n
meningitidi
still
step
wherea
n
gonorrhoea
acquir
also
mutat
pona
gene
encod
mutat
porin
ib
increas
express
efflux
pump
blactamas
plasmid
emerg
spread
gonococci
fulli
resist
penicillin
sinc
second
half
year
led
recommend
use
fluoroquinolon
primari
therapi
howev
class
antibiot
becam
rapidli
unefficaci
mainli
asia
due
emerg
mutat
gyra
parc
abl
block
activ
quinolon
gyras
topoisomeras
iv
sinc
cdc
longer
recommend
use
treatment
gonococc
diseas
fortun
occurr
quinolon
resist
meningococci
due
mutat
gyra
still
rare
even
case
still
great
concern
epidem
potenti
pathogen
requir
prophylaxi
contact
also
antibiot
frequent
use
aim
rifampicin
meningococci
show
resist
presenc
mutat
case
rpob
gene
code
bsubunit
meningococc
rna
polymeras
molecular
epidemiolog
identif
clonal
cluster
neisseria
speci
distinct
resist
profil
requir
monitor
ongo
trend
may
pose
problem
therapi
prophylaxi
l
c
butler
k
hood
l
cooper
h
goossen
cardiff
uk
antwerp
introduct
grace
european
network
excel
establish
focu
antibiot
use
communityacquir
lower
respiratori
tract
infect
lrti
antimicrobi
resist
across
europ
second
studi
begin
within
grace
larg
qualit
studi
explor
attitud
clinician
patient
antibiot
use
lrti
antibiot
resist
aim
present
focu
clinician
account
factor
contribut
variat
manag
lrti
patient
view
antibiot
necessari
method
semistructur
interview
clinician
patient
conduct
primari
care
network
nine
european
countri
interview
audiorecord
transcrib
necessari
translat
english
analysi
theme
identifi
organis
compar
use
framework
approach
result
analysi
clinician
interview
show
besid
clinic
find
factor
influenc
manag
decis
patient
divid
two
main
area
firstli
within
european
network
group
countri
specif
factor
impos
system
consult
take
place
factor
includ
near
patient
test
usag
selfmed
patient
financ
lack
consist
local
prescrib
guidelin
secondli
group
factor
similar
across
network
relat
person
characterist
certain
group
clinician
includ
clinician
profession
etho
selfbelief
decis
make
attitud
toward
doctorpati
relationship
analysi
patient
interview
show
belief
antibiot
use
tend
draw
clinic
factor
name
sever
specif
symptom
fever
andor
cough
mani
patient
also
impli
period
wait
altern
action
requir
antibiot
use
identifi
whether
immun
system
would
fight
infect
whether
nonantibiot
manag
effect
turn
antibiot
discuss
conclus
greater
understand
factor
contribut
decis
prescrib
discuss
idea
enhanc
appropri
prescrib
analysi
highlight
need
intervent
sensit
factor
relat
system
differ
european
network
oper
target
individu
characterist
specif
group
clinician
build
clinic
belief
alreadi
held
patient
pretreat
lowdos
endotoxin
prolong
surviv
experiment
lethal
endotox
shock
k
kopanaki
tzepi
ej
machera
athen
gr
object
clinic
trial
immunointervent
antiendotoxin
antibodi
patient
sever
sepsi
fail
disclos
surviv
benefit
failur
led
us
assumpt
opposit
approach
low
endotoxin
stimulu
may
result
low
level
immunoaralysi
subsequ
surviv
benefit
approach
test
experiment
set
method
total
male
mice
studi
divid
two
group
group
stimul
ip
inject
sodium
salin
follow
one
day
ip
inject
mgkg
lipopolysaccharid
lp
escherichia
coli
group
b
stimul
ip
inject
mgkg
lp
isol
follow
one
day
ip
inject
mgkg
lp
lp
dilut
sodium
salin
volum
inject
ml
surviv
record
six
hour
time
interv
result
surviv
group
b
consider
prolong
compar
group
logrank
p
shown
figur
thirteen
mice
group
die
compar
seven
mice
group
b
p
group
conclus
administr
low
dose
lp
prolong
surviv
lethal
endotox
shock
approach
open
promis
novel
pathway
immunointervent
sepsi
fragili
isol
mxf
mic
mgml
n
mgml
n
mgml
n
virul
mgp
model
use
determin
efficaci
mxf
mgp
model
pouch
creat
inject
ml
air
ml
croton
oil
oliv
oil
skin
back
day
air
withdrawn
replac
ml
soft
agar
day
bacteri
suspens
inject
pouch
infect
mice
n
micegroup
treat
mxf
mgkg
iv
bid
day
dose
simul
auc
human
mg
oncedaili
mxf
iv
dosag
efficaci
assess
reduct
coloni
form
unit
cfu
pouch
exud
hour
postinfect
compar
untreat
infect
control
result
mgp
model
mxf
mgkg
bid
display
good
efficaci
term
cfu
reduct
use
strain
studi
nonrespond
term
cfu
reduct
conclus
loss
atl
impact
mic
cloxacillin
vancomycin
convers
mutant
atl
strain
less
suscept
bactericid
activ
antibiot
support
implic
atl
toler
epidermidi
cell
wall
activ
antibiot
loss
atl
alter
virul
epidermidi
mous
periton
model
wherea
decreas
virul
previous
publish
experi
use
intraven
cathet
infect
model
therefor
mous
periton
model
suit
compar
antibiot
efficaci
atl
atl
strain
result
show
loss
atl
alter
significantli
activ
cloxacillin
vancomycin
mous
periton
model
studi
show
loss
atl
result
decreas
suscept
bactericid
activ
cell
wall
activ
antibiot
appar
impact
activ
antibiot
mous
periton
model
infant
rat
pneumococc
mening
ceftriaxon
plu
daptomycin
versu
ceftriaxon
attenu
brain
damag
hear
loss
ceftriaxon
plu
rifampicin
versu
ceftriaxon
grandgirard
burri
k
oberson
f
simon
sl
bern
ch
object
lytic
antibiot
therapi
bacteri
mening
bm
increas
releas
proinflammatori
bacteri
compound
turn
induc
inflamm
exacerb
inflammatori
respons
cerebrospin
fluid
csf
contribut
develop
neurolog
sequela
survivor
bm
daptomycin
nonlyt
antibiot
act
gramposit
bacteria
shown
decreas
inflamm
brain
injuri
vs
ceftriaxon
experiment
pneumococc
mening
view
clinic
applic
empir
therapi
paediatr
bacteri
mening
investig
whether
therapi
combin
daptomycin
rifampicin
ceftriaxon
benefici
compar
ceftriaxon
monotherapi
infant
rat
pneumococc
mening
method
eleven
day
old
wistar
rat
infect
intracistern
inject
pneumonia
anim
treat
daptomycin
mgkg
sc
daili
plu
ceftriaxon
mgkg
sc
bid
rifampicin
mgkg
ip
bid
plu
ceftriaxon
ceftriaxon
alon
csf
sampl
h
h
initi
therapi
assess
concentr
chemoand
cytokin
tnfa
subset
anim
sacrif
h
post
infect
h
pi
brain
damag
quantifi
histomorphometri
remain
anim
treat
test
hear
loss
assess
auditori
brainstem
respons
abr
week
infect
result
compar
ceftriaxon
alon
daptomycin
plu
ceftriaxon
significantli
p
lower
csf
concentr
h
h
initi
therapi
led
significantli
p
less
apoptosi
assess
h
pi
significantli
p
improv
hear
capac
rifampicin
plu
ceftriaxon
also
led
lower
csf
inflamm
p
h
apoptosi
hear
loss
significantli
differ
ceftriaxon
group
conclus
compar
ceftriaxon
monotherapi
daptomycin
plu
ceftriaxon
lower
level
proinflammatori
mediat
csf
reduc
hippocamp
apoptosi
hear
loss
infant
rat
pneumococc
mening
l
piroth
pe
charl
biek
ge
p
chavanet
dijon
fr
alameda
us
object
ceftarolin
cpt
novel
parenter
broadspectrum
cephalosporin
exhibit
bactericid
activ
gramposit
organ
includ
methicillinresist
aureu
mrsa
multidrugresist
pneumonia
well
common
gramneg
pathogen
efficaci
simul
human
dose
cpt
ceftriaxon
cro
evalu
rabbit
model
penicillinresist
pneumococc
pneumonia
method
pneumonia
strain
use
induc
pneumonia
rabbit
pssp
pisp
prsp
mic
mgl
cro
cpt
respect
anim
randomis
treatment
control
intraven
iv
cpt
human
equival
dosag
h
iv
cro
dosag
h
intramuscular
im
cpt
mgkg
prspinfect
rabbit
serum
level
measur
microbiolog
assay
pk
data
obtain
evalu
efficaci
base
bacteri
count
lung
spleen
per
gram
tissu
result
animalsgroup
test
iv
cptiv
cro
mean
mghl
cmax
mgl
cmin
mgl
respect
bacteri
count
target
tissu
list
iv
cpt
iv
cro
highli
efficaci
pssp
pisp
iv
im
cpt
superior
iv
cro
prsp
quasi
sterilis
lung
spleen
combin
result
iv
im
studi
indic
mic
cpt
associ
bacteri
count
reduct
respect
rabbit
model
penicillinresist
pneumococc
pneumonia
cpt
administ
iv
dose
im
administr
effect
prsp
iv
cro
r
hoepker
k
merfort
glenscheksieberth
wuppert
de
object
moxifloxacin
mxf
approv
usa
countri
treatment
complic
intraabdomin
infect
ciai
compar
efficaci
mxf
piperacillintazobactam
piptaz
commonli
use
treatment
ciai
three
differ
model
c
clp
model
surviv
day
significantli
higher
mxf
group
piptaz
group
p
conclus
use
humanis
dosag
mxf
greater
antimicrobi
activ
provid
higher
surviv
rate
piptaz
three
differ
model
ciai
nairz
theurl
schroll
theurl
mair
sonnweb
g
fritsch
r
bellmannweil
g
innsbruck
mutat
hfe
predispos
hereditari
haemochromatosi
type
frequent
genet
disord
characteris
progress
parenchym
iron
deposit
eventu
organ
failur
sinc
hfe
mutat
associ
reduc
iron
level
within
mononuclear
phagocyt
hypothes
hfe
defici
may
benefici
infect
intramacrophag
pathogen
use
hfe
mice
model
typhoid
fever
found
anim
lack
one
hfe
allel
protect
system
infect
salmonella
typhimurium
display
prolong
surviv
improv
bacteri
control
increas
resist
refer
enhanc
product
siderophorebind
peptid
lipocalin
reduc
avail
iron
salmonella
engulf
hfe
defici
macrophag
effect
mediat
via
stimul
lipocalin
iron
export
infect
cell
sinc
macrophag
concurr
knock
lipocalin
unabl
effici
control
infect
withhold
iron
intracellular
salmonella
correspondingli
infect
hfe
mice
siderophor
defici
salmonella
abolish
protect
confer
hfe
defect
thu
induc
format
ironcaptur
peptid
lipocalin
hfe
mutat
harbour
genet
determin
immunolog
advantag
toward
infect
intracellular
pathogen
salmonella
koutelidaki
kotsaki
pd
carrer
k
loui
savva
ej
thessaloniki
athen
gr
object
major
clinic
trial
immunointervent
sever
sepsi
fail
disclos
surviv
benefit
like
explan
may
administr
therapi
immunoparalysi
septic
host
superven
attempt
revers
immunoparalysi
inject
mononuclear
cell
attempt
experiment
sepsi
multidrugresist
pseudomona
aeruginosa
mdrpa
method
peripher
blood
mononuclear
cell
pbmc
dilut
rpmi
isol
five
healthi
human
volunt
gradient
centrifug
ficol
kg
one
mdrpa
live
heatkil
isol
one
patient
sever
sepsi
inject
intraperiton
bacteri
challeng
total
male
mice
studi
divid
four
group
group
n
pretreat
rpmi
challeng
one
hour
live
isol
group
b
n
pretreat
pbmcskg
challeng
one
hour
live
isol
group
c
n
pretreat
rpmi
challeng
one
hour
heatkil
isol
group
n
pretreat
pbmcskg
challeng
one
hour
heatkil
isol
surviv
record
mice
group
b
mice
group
c
six
mice
group
b
sacrif
six
hour
challeng
blood
collect
lower
vena
cava
tnfalpha
estim
serum
enzym
immunoassay
bacteri
growth
liver
lung
time
assess
result
median
surviv
group
hour
group
b
hour
logrank
p
nineteen
anim
group
die
compar
eight
anim
group
b
p
four
anim
group
c
die
compar
nil
anim
group
logrank
p
median
serum
tnfa
group
b
sacrific
pgml
respect
p
respect
valu
pgml
pn
liver
bacteri
cell
cfug
pn
lung
bacteri
cell
cfug
pn
conclus
allogen
transplant
pbmc
prolong
surviv
experiment
sepsi
mdrpa
mechan
action
relat
blockad
cell
wall
structur
shown
surviv
experi
heat
kill
isol
b
revers
immunoparalysi
evidenc
increas
serum
tnfa
approach
creat
promis
novel
perspect
immunointervent
sepsi
c
nanni
donati
r
aldini
di
pierro
trespidi
accardo
fanti
r
cevenini
bologna
object
chlamydia
trachomati
one
world
major
caus
sexual
transmit
diseas
cervix
urethra
major
agent
pelvic
inflammatori
diseas
genit
tract
infect
femal
mice
chlamydia
muridarum
close
mimic
acut
genit
tract
infect
women
aim
studi
assess
predict
small
anim
positron
emiss
tomographi
inadequ
statist
power
publish
compar
cohort
studi
ventilatorassoci
pneumonia
detect
mortal
differ
compar
group
v
kourano
michalopoulo
rodopoul
athanasoulia
karageorgopoulo
athen
gr
object
compar
cohort
studi
often
conduct
identifi
novel
therapeut
strategi
prognost
factor
ventilatorassoci
pneumonia
vap
aim
evalu
statist
power
studi
provid
statist
clinic
signific
conclus
method
search
pubm
scopu
compar
cohort
studi
evalu
mortal
patient
vap
calcul
includ
studi
statist
power
detect
observ
differ
mortal
compar
group
observ
power
well
expect
clinic
relev
effect
size
expect
power
identifi
prospect
compar
cohort
studi
vap
elig
inclus
analysi
median
observ
power
studi
interquartil
rang
iqr
median
expect
power
iqr
risk
ratio
mortal
compar
group
iqr
risk
ratio
iqr
reduct
mortal
expect
power
measur
significantli
lower
observ
power
statist
power
cohort
studi
detect
observ
differ
mortal
compar
group
patient
vap
low
power
even
lower
expect
clinic
relev
differ
mortal
consid
wiser
utilis
resourc
alloc
research
favour
conduct
cohort
studi
larger
sampl
size
potenti
differ
compar
group
like
shown
object
clarifi
issu
regard
frequenc
prevent
outcom
treatment
patient
ventilatorassoci
tracheobronch
vat
lower
respiratori
tract
infect
involv
tracheobronchi
tree
spare
lung
parenchyma
method
perform
systemat
review
metaanalysi
relev
avail
data
gather
though
search
pubm
scopu
refer
list
without
time
restrict
conserv
random
effect
model
use
calcul
pool
odd
ratio
confid
interv
ci
result
initi
retriev
articl
paper
includ
frequenc
vat
select
digest
decontamin
prove
effect
prevent
strategi
vat
presenc
oppos
absenc
vat
associ
higher
mortal
ci
administr
system
antimicrobi
without
inhal
one
oppos
placebo
treatment
patient
vat
associ
lower
mortal
ci
studi
provid
relev
data
note
administr
antimicrobi
agent
oppos
placebo
treatment
patient
vat
associ
ventilatorfre
day
lower
frequenc
subsequ
pneumonia
without
shorter
length
intens
care
unit
stay
shorter
durat
mechan
ventil
conclus
approxim
one
tenth
mechan
ventil
patient
suffer
vat
infect
potenti
prevent
implement
select
digest
decontamin
antimicrobi
treatment
patient
vat
may
protect
develop
subsequ
ventilatorassoci
pneumonia
degranul
subsequ
allergen
specif
ige
chlorhexidin
demonstr
skin
prickintraderm
test
posit
chlorhexidin
confirm
diagnosi
chlorhexidineprecipit
anaphylaxi
patient
detail
review
casenot
reveal
patient
manifest
evid
minor
cutan
reaction
preoper
chlorhexidin
use
ascrib
chlorhexidin
time
discuss
fda
issu
public
health
notic
follow
descript
anaphylaxi
chlorhexidin
coat
central
venou
cathet
recent
case
cluster
also
report
anoth
cardiac
centr
uk
period
refer
present
interest
report
chlorhexidin
anaphylaxi
occur
patient
undergo
cardiac
surgeri
patient
receiv
multipl
exposur
chlorhexidin
preoper
investig
prepar
increas
recent
result
drive
reduc
incid
hospitalacquir
infect
wish
postul
patient
sensitis
repeat
topic
exposur
chlorhexidin
exhibit
anaphylaxi
allergen
present
patient
form
chlorhexidin
coat
central
venou
cathet
type
strain
helicobact
pylori
possess
cag
pathogen
island
deliv
virul
factor
cag
specialis
type
iv
secret
machineri
activ
infect
compris
gene
origin
distant
event
horizont
transfer
transloc
effector
protein
caga
phosphoryl
tyrosin
residu
restrict
previous
identifi
repeat
sequenc
call
sequenc
locat
ctermin
half
protein
contain
five
amino
acid
motif
epiya
amplifi
duplic
larg
fraction
clinic
isol
tyrosinephosphoryl
caga
essenti
activ
process
lead
dramat
chang
morpholog
cell
grow
cultur
addit
observ
two
member
src
kinas
famili
csrc
lyn
account
cagaspecif
kinas
activ
ag
cell
lysat
transloc
caga
interact
jam
hostcel
protein
caus
disrupt
apic
junction
complex
transfect
caga
gene
polaris
epitheli
cell
induc
disrupt
celltocel
contact
alter
morpholog
strikingli
cagaexpress
cell
becom
migratori
invas
penetr
collagen
gel
studi
differ
portion
molecul
reveal
presenc
two
distinct
function
domain
necessari
induc
abnorm
cell
differenti
interact
host
cell
morphogen
cell
polar
invas
suggest
contribut
earli
late
stage
cancer
format
result
suggest
mechan
caga
may
act
earli
stage
tumorigen
progress
caus
loss
cell
polar
increas
cell
motil
invas
epitheli
cell
period
year
silenc
diseas
unpronounc
name
chikungunya
chik
recent
becom
medic
realiti
reach
public
throughout
world
conclus
low
mhladr
express
septic
shock
independ
predict
ni
promis
biomark
may
major
interest
identifi
patient
increas
ni
risk
could
benefit
target
tailor
therapi
aim
restor
immun
function
pneumonia
lead
infecti
caus
death
us
kill
peopl
annual
aid
tuberculosi
mening
endocard
combin
wide
rang
observ
studi
communityacquir
pneumonia
cap
half
case
aetiolog
agent
identifi
streptococcu
pneumonia
consist
predomin
bacteri
aetiolog
lectur
primarili
focu
innat
immun
respons
pneumococc
pneumonia
tolllik
receptor
tlr
key
molecul
recogn
pathogen
associ
molecular
pattern
pamp
induc
inflammatori
respons
pneumolysin
intracellular
toxin
found
pneumonia
clinic
isol
import
virul
factor
pneumococcu
recogn
although
consid
import
receptor
gramposit
bacteria
play
decis
role
host
defenc
pneumonia
pneumonia
like
pneumolysininduc
signal
compens
defici
respiratori
tract
infect
pneumonia
besid
contribut
effect
host
defenc
pneumonia
airway
import
tlr
signal
host
defenc
pneumococc
pneumonia
illustr
fact
mice
lack
common
tlr
adaptor
protein
highli
suscept
infect
activ
tlr
result
product
proinflammatori
cytokin
ampl
evid
underlin
import
tumour
necrosi
factor
tnf
interleukin
il
host
defenc
bacteri
pneumonia
murin
pneumonia
pneumonia
model
treatment
neutralis
antitnf
mab
strongli
impair
antibacteri
defenc
addit
receptor
type
defici
mice
infect
pneumonia
display
increas
bacteri
outgrowth
consider
interest
treat
receptor
defici
mice
neutralis
antitnf
antibodi
made
extrem
suscept
pneumococc
pneumonia
infect
lower
airway
pneumonia
associ
complex
interact
pathogen
eg
cell
wall
compon
pneumolysin
host
eg
tlr
cytokin
interact
play
crucial
role
outcom
clinic
import
infect
sever
bacteri
pneumonia
remain
uncommon
unless
specif
condit
exist
tip
balanc
host
pathogen
favour
microorgan
condit
includ
person
extrem
age
exposur
especi
virul
organ
patient
concomit
ill
impair
pulmonari
clearanc
mechan
immunocompromis
host
pathogen
overcom
array
innat
acquir
host
defenc
success
invad
host
known
virul
trait
three
common
respiratori
pathogen
streptococcu
pneumonia
staphylococcu
aureu
pseudomona
aeruginosa
briefli
review
capsular
polysaccharid
pneumococci
major
antiphagocyt
virul
trait
mani
factor
contribut
diseas
pathogenesi
includ
critic
import
exotoxin
known
pneumolysin
bacteriocin
adher
factor
cholin
bind
protein
lipoteicho
acid
iron
manganes
magnesium
transport
pili
compet
biofilm
capac
virul
gene
promot
invas
impair
clearanc
organ
enter
blood
stream
aureu
notori
numer
ab
type
toxin
cytotoxin
superantigen
gener
cours
invas
staphylococci
deploy
complex
seri
quorum
sens
signal
coordin
adhesin
invas
gene
within
biofilm
plankton
organ
like
contribut
success
pathogen
p
aeruginosa
produc
array
extracellular
exotoxin
cytotoxin
deliv
type
iii
secret
system
includ
elastas
phospholipas
c
seri
apoptot
antiphagocyt
exotoxin
along
algin
capsul
unusu
variabl
lp
structur
particip
microbi
invas
pathogen
express
least
three
interact
quorum
sens
system
coordin
virul
biofilm
format
detail
understand
virul
factor
provid
therapeut
option
control
respiratori
pathogen
surfac
express
extracellular
toxin
pneumococci
select
new
vaccin
target
inhibitori
peptid
small
molecul
inhibitor
quorum
sens
biofilm
format
investig
staphylococc
p
aeruginosa
infect
innov
nonantibiot
treatment
strategi
gain
greater
import
progress
antibiot
resist
threaten
manag
sever
bacteri
infect
futur
brucellosi
possibl
commonest
zoonot
infect
worldwid
troubl
human
sinc
antiqu
recent
year
seen
expans
anim
reservoir
diseas
wide
spectrum
wildlif
speci
extend
marin
mammal
recognit
novel
brucella
speci
furthermor
anim
human
diseas
reemerg
numer
countri
brucellosisfre
current
import
endem
foci
includ
near
east
central
asia
complex
socioeconom
polit
factor
may
incrimin
alter
endem
complex
mechan
brucella
evad
immun
respons
surviv
intracellularli
progress
clarifi
novel
diagnost
techniqu
real
time
pcr
may
shed
light
life
cycl
brucella
insid
human
host
preliminari
studi
indic
pathogen
may
persist
latent
form
year
appar
clinic
cure
asymptomat
individu
treatment
principl
evolv
significantli
expert
guidelin
issu
recent
name
ioannina
recommend
support
need
sixweek
combin
treatment
includ
tradit
antibacteri
modifi
accordingli
seriou
complic
spondyl
central
nervou
system
involv
road
develop
vaccin
human
seem
long
though
anthrax
ancient
diseas
rel
forgotten
diseas
western
world
spore
mail
usa
caus
five
death
current
human
anthrax
seen
commonli
agricultur
region
world
anthrax
anim
preval
countri
middl
east
africa
central
asia
south
america
also
endem
diseas
turkey
human
case
may
occur
agricultur
industri
environ
infect
occup
hazard
worker
process
hide
hair
bone
bone
product
wool
veterinarian
agricultur
worker
handl
infect
anim
main
rout
transmiss
contact
ingest
contamin
meal
inhal
bacillu
anthraci
spore
leptospirosi
old
diseas
known
hundr
year
possibl
even
longer
sinc
time
hippocr
remain
major
caus
ill
mani
tropic
subtrop
countri
thu
travel
also
identifi
zoonosi
europ
north
america
diseas
surpris
us
clinic
present
alway
typic
recent
year
pulmonari
atyp
present
wide
recognis
effect
vaccin
chemoprophylaxi
effect
select
popul
prompt
recognit
earli
institut
appropri
treatment
infecti
diseas
appear
critic
ensur
good
outcom
patient
interest
new
develop
diagnost
molecular
epidemiolog
clearli
mani
challeng
remain
field
object
spread
carbapenemas
gene
within
gram
neg
bacteria
great
caus
concern
first
report
gene
outwith
acinetobact
baumannii
report
acinetobact
genospeci
also
identifi
genospeci
isol
encod
gene
aim
studi
examin
genet
environ
gene
investig
mobilis
speci
method
restrict
analysi
rrna
use
confirm
ident
speci
level
suscept
imipenem
meropenem
determin
plate
doubl
dilut
method
screen
pcr
gene
carri
analysi
genet
environ
surround
gene
conduct
sequenc
invers
pcr
product
genewalk
fragment
structur
surround
sequenc
confirm
use
intern
primer
also
use
screen
posit
isol
collect
result
restrict
analysi
confirm
isol
belong
acinetobact
genospeci
isol
show
reduc
suscept
imipenem
meropenem
mic
mgl
antibiot
isol
neg
gene
posit
gene
analysi
genet
environ
gene
reveal
gene
within
novel
genet
structur
upstream
gene
lefthand
end
element
interrupt
element
element
contain
put
promot
sequenc
downstream
lyse
gene
follow
sequenc
similar
element
describ
previous
follow
complex
region
contain
righthand
end
tnpa
gene
interrupt
incomplet
tnpa
gene
similar
interrupt
sequenc
region
follow
second
gene
posit
isol
collect
neg
upstream
studi
first
report
multipl
copi
gene
acinetobact
genospeci
isol
identifi
novel
structur
contain
two
gene
two
sequenc
element
may
respons
duplic
gene
object
acinetobact
baumannii
import
nosocomi
pathogen
wide
intrins
resist
howev
due
dissemin
acquir
resist
mechan
extendedspectrum
betalactamas
esbl
metallo
betalactamas
mbl
product
multidrug
resist
strain
isol
often
first
detect
turkey
found
widespread
among
acinetobact
spp
p
aeruginosa
sinc
discov
countri
recent
found
northern
itali
korea
studi
presenc
type
esbl
investig
caftazidim
resist
baumannii
strain
isol
bloodstream
infect
pcr
also
clonal
related
isol
investig
random
amplifi
polymorph
dna
rapd
puls
field
gel
electrophoresi
pfge
produc
baumannii
strain
method
baumannii
strain
isol
bloodstream
infect
includ
studi
isol
identifi
baumannii
convent
method
phoenix
bd
autom
system
system
becton
dickinson
diagnost
system
spark
ceftazidim
resist
determin
etest
gene
screen
cluster
encod
resist
gene
transport
plausibl
involv
drug
efflux
transport
mf
dmt
abc
rnd
mop
famili
uniqu
drug
resist
strain
absent
suscept
sdf
strain
ii
pili
fimbria
system
relat
biofilm
format
motil
iii
haemolysinand
haemagglutininrel
protein
differ
distribut
among
four
genom
iv
iron
uptak
metabol
gene
conclus
genom
comparison
identifi
uniqu
featur
baumannii
epidem
clone
provid
novel
insight
genet
basi
multidrug
resist
pathogenesi
speci
studi
may
contribut
understand
concept
infect
invas
colonis
emerg
pathogen
baumannii
hard
swallow
emerg
reemerg
issu
foodborn
infect
symposium
arrang
efwisg
mrsa
food
product
caus
concern
case
complac
first
switch
intravenousto
oral
medic
second
educ
program
internsresid
physician
releas
new
antimicrobi
formulari
third
restrict
note
print
laboratori
rapport
fourth
activ
monitor
give
feedback
prescript
suscept
pattern
e
coli
includ
ciprofloxacin
cefuroxim
ceftazidim
cotrimoxazol
tobramycin
hospitalis
patient
analyz
start
statist
analys
perform
use
segment
poisson
regress
model
look
effect
intervent
resist
sudden
stepwis
chang
chang
trend
bayesian
model
averag
use
account
model
uncertainti
result
start
intervent
resist
rate
increas
averag
per
year
intervent
result
signific
reduct
quin
use
averag
prescrib
daili
dose
pdd
per
month
best
fit
poisson
model
resist
data
signific
stepwis
decreas
found
associ
intervent
howev
substanti
uncertainti
model
choic
account
conclus
evid
support
particular
intervent
although
evid
least
one
intervent
associ
observ
reduct
resist
stepwis
decreas
decreas
trend
resist
rate
antimicrobi
studi
period
conclus
mani
md
prescrib
antibiot
often
believ
practic
may
effect
antibiot
resist
result
indic
md
valu
inform
intervent
surveil
order
support
respons
use
antibiot
ongo
effort
germani
address
find
nation
level
eg
establish
surveil
system
antibiot
resist
antibiot
usag
tabl
ir
pn
er
tt
alway
higher
children
ch
adult
ad
signific
differ
found
pn
er
er
er
er
er
tt
tt
gener
cpir
higher
ad
ch
ir
lower
north
n
south
signific
differ
pn
pn
er
er
er
tt
n
knew
deceas
ir
tendenc
pn
n
cp
n
tt
n
er
increas
n
total
outpati
antibiot
use
decreas
increas
pn
fq
increas
ml
stabilis
tt
decreas
conclus
sinc
ir
decreas
note
pn
cp
tt
erir
increas
year
decreas
parallel
start
public
campaign
antibiot
use
ir
rate
remain
higher
ch
ad
ns
differ
becam
less
mark
object
parachlamydia
acanthamoeba
new
recogn
member
order
chlamydial
grow
evid
suggest
bacteria
may
pathogen
role
human
caus
respiratori
diseas
also
recent
identifi
agent
bovin
abort
may
caus
miscarriag
women
contrast
littl
known
pathogen
role
rhabdochlamydia
crassifican
anoth
relat
chlamydial
molecular
diagnost
tool
use
detect
oblig
intracellular
bacteria
inabl
grow
convent
cultur
media
aim
work
develop
realtim
pcr
diagnosi
rhabdochlamydia
infect
ii
studi
respiratori
secret
newborn
presenc
parachlamydia
rhabdochlamydia
dna
method
new
quantit
realtim
taqman
pcr
qpcr
use
abi
prism
develop
qpcr
blindli
appli
consecut
respiratori
sampl
endotrach
nasopharyng
secret
taken
criticallyil
newborn
admit
neonatolog
ward
univers
hospit
sampl
also
test
use
previous
develop
parachlamydiaspecif
pcr
result
newborn
prematur
median
gestat
age
week
rang
initi
respiratori
distress
syndrom
present
posit
pcr
result
obtain
patient
parachlamydia
rhabdochlamydia
speci
median
day
rang
birth
compar
control
group
patient
neg
pcr
newborn
significantli
wors
primari
adapt
higher
incid
resuscit
maneuv
birth
tabl
durat
noninvas
mechan
ventil
stay
neonatolog
ward
also
significantli
longer
fatal
issu
observ
infect
case
compar
death
control
p
gestat
age
birth
well
incid
pulmonari
system
infect
differ
case
control
conclus
high
preval
parachlamydia
rhabdochlamydia
dna
observ
respiratori
secret
prematur
criticallyil
newborn
presenc
dna
microorgan
associ
wors
primari
adapt
sever
respiratori
distress
syndrom
trend
toward
higher
mortal
pathogen
role
investig
genu
kingella
consist
speci
k
kinga
k
orali
k
denitrifican
gram
neg
sometim
difficult
stain
rod
shape
bacteria
normal
respiratori
genitourinari
flora
slowgrow
fastidi
although
improv
recoveri
shown
use
fan
pedsf
blood
cultur
bottl
major
infect
remain
undetect
especi
pretreat
patient
report
use
real
time
polymeras
chain
reaction
rtpcr
assay
detect
k
kinga
aureu
paediatr
osteoarticular
infect
method
synovi
fluid
sampl
patient
month
year
age
collect
month
sampl
knee
hip
ankl
elbow
shoulder
wrist
femur
abscess
autom
dnarna
extract
specimen
subject
hour
pathogenspecif
rtpcr
sampl
inocul
onto
sheep
blood
chocol
agar
well
pedsf
bottl
final
speci
identif
antimicrobi
suscept
determin
phoenix
tm
result
patient
specimen
posit
cultur
andor
rtpcr
result
overal
posit
rate
aureu
predomin
pathogen
account
specimen
patient
mrsa
mssa
posit
specimen
patient
due
k
kinga
n
among
children
year
n
k
kinga
predomin
pathogen
account
posit
patient
follow
mssa
patient
posit
rate
age
group
children
year
year
posit
k
kinga
mrsa
predomin
pathogen
year
old
mssa
evenli
distribut
among
children
year
old
cultur
detect
specimen
posit
k
kinga
aureu
pathogen
detect
cultur
use
molecular
assay
enhanc
detect
organ
especi
k
kinga
vs
cultur
addit
faster
identif
tat
hr
allow
rapid
target
therapi
improv
tat
could
lead
shorter
hospit
stay
case
result
genotyp
reveal
high
degre
divers
indic
panmict
bacteri
popul
associ
genotyp
colonis
frequenc
year
isol
pcr
screen
virul
gene
reveal
incid
hag
signific
differ
observ
preval
virulenceassoci
gene
isol
origin
children
colonis
children
colonis
occas
p
pcrrflp
analysi
hag
show
mani
gene
variant
associ
pcrrflp
pattern
colonis
frequenc
year
isol
conclus
even
rel
localis
geograph
set
genotyp
divers
catarrhali
isol
colonis
children
larg
yearli
pattern
genotyp
predomin
children
serial
colonis
catarrhali
isol
appear
clear
particular
genotyp
becom
subsequ
colonis
differ
genotyp
incid
virul
gene
rel
localis
studi
group
remark
similar
report
global
catarrhali
isol
possibl
indic
similar
select
pressur
exist
catarrhali
local
global
level
virul
gene
variat
appear
high
even
rel
restrict
geograph
group
result
could
consequ
vaccin
design
virul
gene
foulon
casteel
w
foulon
brussel
object
evalu
epidemiolog
cytomegaloviru
pregnanc
evalu
risk
deliv
child
congenit
cmv
ccmv
method
unselect
motherinf
pair
includ
mother
serolog
screen
perform
consist
detect
cmv
igg
igm
antibodi
first
prenat
visit
birth
neonat
cmv
urin
cultur
perform
diagnos
congenit
infect
pregnant
woman
found
second
trimest
spontan
abort
death
utero
investig
possibl
congenit
cmv
infect
carri
result
serolog
screen
first
prenat
visit
show
immun
women
evid
past
infect
igg
posit
igm
neg
women
women
igg
igm
antibodi
detect
investig
store
follow
sampl
patient
could
classifi
primari
cmv
infect
pregnanc
patient
previou
immun
current
pregnanc
patient
type
matern
cmv
infect
could
determin
followup
serolog
women
without
immun
reveal
seroconvers
total
congenit
infect
ccmv
diagnos
incid
ccmv
among
differ
group
women
summaris
tabl
conclus
ccmv
infect
occur
popul
pregnant
women
ccmv
consid
due
primari
matern
cmv
infect
infant
due
recurr
matern
cmv
infect
type
matern
infect
could
determin
risk
seroneg
pregnant
woman
acquir
cmv
pregnanc
transmiss
risk
matern
primari
infect
women
prior
immun
low
risk
ccmv
risk
increas
igm
find
women
know
prior
immun
risk
women
undetermin
infecti
statu
earli
pregnanc
give
birth
congenit
infect
neonat
report
provid
first
data
rotaviru
epidemiolog
diseas
burden
norway
studi
need
assess
econom
impact
rotaviru
diseas
costeffect
vaccin
inform
decis
introduct
rotaviru
vaccin
nation
program
childhood
immunis
pseudomona
aeruginosa
may
colonis
lung
cystic
fibrosi
patient
year
may
also
caus
acut
infect
mechan
ventil
patient
immunocompromis
host
within
matter
day
despit
aggress
antibiot
treatment
organ
rare
erad
instead
p
aeruginosa
adapt
host
environ
develop
resist
mechan
chang
lifestyl
virul
properti
focus
mechan
ventil
patient
detail
dynam
resist
emerg
persist
p
aeruginosa
lung
popul
antibiot
therapi
discuss
p
aeruginosa
popul
evolv
natur
absenc
antimicrobi
treatment
within
lung
intub
patient
chang
virul
properti
relev
find
respect
concept
social
evolut
develop
novel
antiinfect
strategi
highlight
genom
p
aeruginosa
encod
mani
potenti
efflux
system
howev
appear
play
signific
role
antibiot
resist
respect
mex
multipl
efflux
system
particular
interest
abil
extrud
wide
rang
antimicrobi
polyspecif
machineri
result
assembl
drugproton
antiport
ii
periplasm
adaptor
protein
iii
outer
membran
gate
channel
well
establish
constitut
express
tripartit
pump
mexaboprm
provid
p
aeruginosa
rel
high
intrins
resist
quinolon
blactam
except
imipenem
tetracyclin
macrolid
chloramphenicol
trimethoprim
novobiocin
protect
mechan
potenti
poor
permeabl
outer
membran
activ
anoth
pump
mexxyoprm
whose
express
induc
substrat
target
ribosom
eg
tetracyclin
macrolid
aminoglycosid
accumul
report
indic
multidrug
resist
mutant
upregul
one
system
quit
common
clinic
set
mutant
readili
select
suboptim
treatment
fluoroquinolon
blactam
aminoglycosid
tend
accumul
variou
resist
mechan
without
loos
wildtyp
pathogen
p
aeruginosa
whether
low
resist
level
mic
x
confer
efflux
may
promot
secondstep
mutant
alter
drug
target
gyra
gyrb
parc
derepress
ampc
blactamas
confirm
vitro
specif
context
cystic
fibrosi
cf
recent
studi
laboratori
show
mexxyoprm
pump
respons
much
higher
resist
level
aminoglycosid
increas
efficaci
system
partial
result
adapt
mutat
mexi
gene
contrast
subpopul
defici
mexaboprm
tend
emerg
longterm
colonis
cf
airway
easili
select
vitro
select
media
mutant
overexpress
mex
system
mexcdoprj
mexefoprn
mexghiopmd
mexjkoprm
mexvwoprm
rare
describ
cf
noncf
patient
data
support
notion
upregul
mexcdoprj
mexefoprn
might
detriment
virul
p
aeruginosa
conclus
therapeut
strategi
base
efflux
inhibitor
target
mexaboprm
mexxyoprm
system
prioriti
european
aspect
malaria
rapid
diagnost
test
malaria
twenti
year
convinc
prompt
diagnosi
treatment
malaria
critic
factor
reduc
morbid
mortal
microscopi
long
gold
standard
malaria
diagnosi
newer
rapid
diagnost
test
rdt
offer
consider
advantag
especi
endem
countri
close
twenti
year
develop
oper
research
diagnost
perform
rdt
establish
set
metaanalys
clearli
demonstr
equival
rdt
expert
microscopi
detect
parasit
clear
superior
routin
microscopi
actual
one
major
reason
delay
success
implement
rdt
endem
area
use
poor
qualiti
microscopi
imped
reliabl
measur
sensit
specif
undermin
confid
health
worker
rdt
factor
poor
product
perform
inadequ
method
determin
qualiti
product
lack
emphasi
capac
deal
issu
potenti
rdt
realis
crucial
highqual
product
perform
reliabl
accur
field
condit
made
avail
qualiti
insur
perform
step
procedur
achiev
goal
shift
symptombas
diagnosi
parasitebas
manag
malaria
bring
signific
improv
manag
fever
endem
area
travel
return
temper
climat
fever
rdt
also
potenti
improv
diagnost
procedur
especi
hospit
reliabl
microscopi
avail
hour
patient
danger
sign
signific
thrombopenia
neg
rdt
suffici
exclud
malaria
allow
wait
hour
perform
read
microscopi
slide
rdt
repeat
everi
hour
three
consecut
day
fever
persist
absenc
altern
diagnosi
rdt
repres
revolut
fight
malaria
tremend
help
manag
appropri
patient
fever
especi
malaria
declin
henc
caus
fever
increas
ambiti
deploy
foreseen
come
year
africa
larg
grant
global
fund
contribut
achiev
millennium
goal
fever
key
symptom
malaria
among
return
travel
headach
chill
myalgia
sweat
lack
focu
frequent
record
nonspecif
nausea
vomit
often
seen
children
differenti
diagnosi
infect
mainli
viral
origin
difficult
dri
cough
mild
diarrhoea
often
present
laboratori
find
thrombocytopenia
low
normal
leucocyt
count
help
assess
mild
moder
malaria
clinic
sign
symptom
eg
fever
may
mitig
semiimmun
patient
visit
friend
rel
foreign
visitor
seen
nonendem
countri
repres
major
case
diagnos
industrialis
countri
caution
warrant
assess
patient
mani
may
longer
expos
malaria
countri
origin
thu
longer
partial
protect
also
risk
suffer
sever
complic
import
malaria
case
may
sever
present
jaundic
impair
conscious
coma
acut
renal
failur
cours
event
acut
respiratori
failur
delay
diagnosi
start
treatment
partli
respons
fatal
rate
countri
nt
look
wo
nt
find
anaerob
revisit
anaerob
microbiota
mouth
friend
foe
anaerob
form
major
part
commens
microbiota
digest
tract
constitut
integr
compon
function
mucos
surfac
mouth
teeth
creat
uniqu
nonshed
environ
bacteria
attach
form
biofilm
agerel
success
order
speci
bacteri
colonis
mouth
establish
individu
anaerob
speci
tend
remain
member
oral
microbiota
agerel
pattern
colonis
anaerob
bacteria
partli
connect
develop
loss
dentit
interact
differ
bacteria
resid
microenviron
influenc
composit
microbiota
develop
patholog
condit
although
commens
bacteria
regard
benefici
host
anaerob
member
oral
microbiota
contain
characterist
potenti
detriment
health
statu
individu
molecular
mean
characteris
result
increas
knowledg
normal
microbiota
mouth
detect
new
speci
genera
well
phylotyp
associ
infecti
situat
mouth
oral
infect
multifactori
polymicrobi
natur
aetiolog
organ
origin
mainli
oral
resid
microbiota
involv
anaerob
obviou
infect
root
canal
periodont
tissu
tissu
surround
erupt
wisdom
teeth
typic
anaerob
find
gramneg
rod
addit
gramposit
anaerob
cocci
nonsporeform
gramposit
anaerob
rod
common
odontogen
infect
occas
anaerob
localis
dentoalveolar
infect
spread
adjac
tissu
even
bloodstream
result
sever
complic
extraor
site
interestingli
rel
limit
number
anaerob
speci
involv
clinic
sever
infect
howev
microbi
find
seem
vari
depend
geographi
concomit
increas
number
immunosuppress
patient
number
opportunist
infect
caus
commens
anaerob
may
increas
identif
speci
level
help
establish
associ
individu
anaerob
speci
specif
diseas
state
studi
bacteriolog
diabet
foot
infect
dfi
yield
vari
often
contradictori
result
role
anaerob
particularli
unclear
often
type
sever
infect
poorli
defin
recent
antibiot
therapi
unknown
specimen
collect
cultur
techniqu
inadequ
optim
collect
transport
cultur
techniqu
use
multipl
organ
includ
aerob
anaerob
usual
recov
sever
dfi
interact
within
polymicrobi
soup
lead
product
virul
factor
haemolysin
proteas
collagenas
short
chain
fatti
acid
promot
inflamm
imped
heal
contribut
chronic
infect
better
defin
bacteriolog
diabet
foot
infect
analyz
data
larg
prospect
us
multicentr
trial
patient
moder
sever
infect
requir
initi
parenter
antibiot
therapi
use
optim
postdebrid
sampl
collect
transport
cultur
procedur
cultureposit
specimen
total
pure
cultur
yield
organ
total
anaerob
rang
averag
per
specimen
recov
patient
gramposit
cocci
gpc
account
anaerob
strain
cultur
still
gold
standard
realli
tremend
technolog
advanc
made
cultureindepend
method
detect
identif
human
bacteri
pathogen
pcr
hybridis
genom
dna
yet
time
honour
pastorian
bacteri
cultur
liquid
solid
nutrit
media
still
remain
gold
standard
laboratori
diagnosi
major
bacteri
infect
unusu
robust
centuri
technolog
stem
unmatch
oper
characterist
broad
rang
detect
agent
depend
adequ
combin
mediaincub
condit
unlimit
sourc
clonal
popul
individu
isol
allow
versatil
characteris
antibiot
suscept
andor
pathogen
factor
product
andor
epidemiolog
subtyp
possibl
storagebiobank
cell
complementari
clinic
test
research
diseas
surveil
collect
proof
pathogen
role
agent
time
viabl
cell
isol
site
infect
contrast
falseposit
result
molecular
test
tissu
transloc
persist
bacteri
dna
solubl
antigen
major
drawback
bacteriolog
cultur
includ
long
turnaround
time
cost
labourskil
intens
partli
allevi
new
technolog
includ
autom
process
physicalchem
growth
detect
rapid
molecular
fingerprint
malditof
raman
spectrometri
rdna
snp
detect
like
next
decad
see
complet
redefinit
place
direct
detect
method
culturebas
confirm
method
clinic
bacteriolog
enabl
rejuven
rather
elimin
cultur
daili
diagnost
tool
advent
realtim
pcr
reveal
instrument
success
implement
molecular
method
routin
clinic
microbiolog
laboratori
autom
nucleic
extract
platform
coupl
robot
handl
largescal
detect
quantif
purpos
mostli
virolog
review
attempt
implement
homebrew
commerci
nucleicacid
base
detect
method
directli
blood
sampl
highlight
hope
pitfal
expand
two
promis
nucleic
acid
amplif
method
lamp
loop
mediat
isotherm
amplif
proteinfre
method
call
dnazym
isotherm
amplif
method
share
sever
strength
robust
across
highli
diversifi
physicochem
condit
versatil
assay
develop
minim
requir
sampl
prepar
definit
compet
current
realtim
pcr
assay
might
becom
novel
standard
due
lower
cost
improv
perform
ribosom
rna
rrna
approach
microbi
evolut
ecolog
becom
integr
part
microbiolog
rapidli
grow
databas
exist
encompass
besid
rrna
sequenc
almost
validli
describ
bacteria
archaea
also
numer
rrna
sequenc
far
uncultiv
microb
directli
retriev
environ
pcr
metagenom
base
patchi
evolutionari
conserv
rrna
gene
oligonucleotid
probe
design
direct
way
specif
rang
speci
larg
evolutionari
entiti
like
phyla
even
domain
probe
label
fluoresc
dye
enzym
horseradish
peroxidas
use
identifi
singl
microbi
cell
fluoresc
situ
hybridis
fish
directli
complex
environment
sampl
updat
recent
applic
methodolog
improv
given
includ
identif
small
bacteri
cell
catalyz
report
deposit
card
fish
optimis
method
proper
control
fish
yield
exact
cell
number
spatial
distribut
defin
bacteri
popul
also
highli
complex
mix
microbi
commun
r
amann
bm
fuch
natur
review
microbiolog
quick
reliabl
speci
identif
microorgan
great
import
medic
microbiolog
sever
bacteri
fungal
speci
identifi
use
labori
timeconsum
method
furthermor
mani
case
misidentif
occur
due
eg
limit
biochem
reactiv
differ
morphotyp
limit
inform
refer
panel
talk
matrixassist
laser
desorptionionis
timeofflight
malditof
mass
spectrometri
present
method
speci
identif
technolog
appli
protein
pattern
match
base
mass
spectrometri
identif
process
mass
pattern
gener
organ
subsequ
comparison
pattern
databas
compris
refer
pattern
deriv
wellcharacteris
refer
strain
lead
speci
identif
exampl
identif
variou
nonfer
bacteri
strain
isol
clinic
specimen
comparison
partial
rdna
sequenc
shown
moreov
speed
accuraci
comparison
method
interand
intralaboratori
reproduc
malditof
msbase
speci
identif
discuss
trend
invas
streptococcu
pneumonia
serogroup
sequenc
type
belgium
goegebu
k
van
pelt
j
verhaegen
j
van
leuven
object
pneumonia
serogroup
isol
frequent
caus
invas
pneumococc
diseas
particularli
children
onward
mark
increas
isol
observ
overal
preval
increas
determin
sequenc
type
st
isol
order
better
understand
trend
resist
spread
method
nation
refer
centr
receiv
invas
isol
laboratori
belgium
randomli
chosen
isol
age
analys
via
multilocu
sequenc
type
mlst
describ
enright
spratt
microbiol
also
includ
data
strain
characterist
patient
characterist
result
differ
sequenc
type
st
identifi
n
n
n
n
n
n
n
n
n
mutat
usual
increas
mic
slightli
enhanc
probabl
mutat
efflux
pump
like
pmra
reduc
antibiot
concentr
bacteri
cell
enabl
longer
surviv
hypothesis
efflux
posit
bacteria
like
develop
resist
efflux
neg
bacteria
follow
question
address
efflux
pump
inhibitor
reserpin
verapamil
reduc
mutat
frequenc
fluoroquinolonesuscept
efflux
posit
pneumococci
exhibit
higher
parc
gyra
qrdr
mutat
frequenc
efflux
neg
isol
efflux
phenotyp
impos
fit
cost
method
match
efflux
posit
neg
pneumococc
isol
ident
similar
genotyp
accord
multilocu
sequenc
type
collect
german
commun
acquir
pneumonia
network
capnetz
analys
n
strain
includ
efflux
neg
control
ciprofloxacin
cip
mic
efflux
phenotyp
measur
agar
dilut
method
efflux
detect
reserpin
mgl
ad
fourfold
decreas
mic
consid
efflux
posit
mutat
frequenc
determin
plate
bacteri
suspens
onto
agar
without
cip
incub
coloni
count
ratio
cfuml
yield
mutat
frequenc
equal
mutat
frequenc
determin
ad
differ
concentr
verapamil
mgl
reserpin
mgl
biolog
fit
calcul
maximum
slope
growth
curv
record
microtitr
plate
reader
result
even
low
concentr
reserpin
clearli
reduc
mutat
frequenc
efflux
posit
lesser
extent
efflux
neg
pneumococci
expos
cip
figur
verapamil
exhibit
effect
mere
high
concentr
efflux
posit
isol
produc
frequent
mutant
efflux
neg
isol
p
fisher
exact
test
efflux
phenotyp
measur
impact
biolog
fit
conclus
posit
efflux
phenotyp
increas
qrdr
mutat
frequenc
presenc
fluoroquinolon
effect
inhibit
low
concentr
reserpin
matter
concern
efflux
associ
decreas
biolog
fit
background
use
fluoroquinolon
fq
associ
increas
fq
resist
pneumonia
respiratori
fq
levofloxacin
levo
moxifloxacin
moxi
first
line
therapi
seriou
respiratori
infect
increas
fq
resist
fqr
sp
concern
levo
target
parc
moxi
target
gyra
may
permit
differenti
degre
select
pressur
examin
fq
use
chang
preval
fqr
qrdr
mutat
canadian
isol
sp
method
cbsn
canadian
collabor
network
microbiolog
laboratori
perform
surveil
antibiot
resist
sp
sinc
antimicrobi
resist
perform
central
lab
clsi
standard
sequenc
qrdr
region
fqr
isol
stratifi
sampl
fq
suscept
isol
popul
fq
use
obtain
im
canada
result
fq
use
increas
rx
levo
use
moxi
use
isol
avail
test
levo
r
rate
increas
remain
stabl
moxi
r
rate
increas
stabilis
preval
parc
mutat
increas
significantli
last
decad
see
tabl
preval
isol
parc
gyra
mutat
increas
decreas
first
gyra
mutant
detect
preval
gyra
mutant
sinc
increas
remain
low
conclus
despit
increas
use
respiratori
fq
fqr
pneumococci
low
increas
canada
preval
isol
parc
mutat
decreas
isol
mutat
gyra
alon
remain
extrem
rare
suggest
moxi
exert
minim
select
pressur
resist
streptococci
two
well
characteris
macrolid
resist
describ
target
modif
activ
drug
efflux
target
site
modif
mediat
erm
gene
erm
b
erm
erm
c
confer
mlsb
phenotyp
target
modif
mutat
rrna
well
mutat
ribosom
protein
also
report
express
mef
gene
activ
efflux
mechan
respons
mtype
resist
characteris
clinic
isol
agalactia
exhibit
mlsb
phenotyp
tetracyclin
resist
studi
determin
resist
gene
associ
localis
mobil
conjug
method
macrolid
tetracyclin
resist
gene
confirm
pcr
associ
macrolid
tetracyclin
gene
investig
longpcr
sequenc
conjug
experi
perform
filter
mate
genet
localis
resist
gene
determin
endonucleas
ceui
follow
pfge
southern
blot
hybridis
studi
perform
use
three
specif
probe
rrna
gene
erm
b
tet
gene
result
agalactia
carri
erm
b
tet
gene
amplicon
kb
size
nucleotid
sequenc
analysi
entir
product
ident
kb
pediococcu
acidilactici
contain
four
orf
encod
put
resolvas
topoisomeras
type
respect
endonucleas
ceui
method
easili
distinguish
plasmid
chromosom
localis
iceui
cut
chromosom
dna
reveal
localis
resist
gene
plasmid
attempt
transfer
erm
b
tet
structur
conjug
agalactia
e
faecali
recipi
fail
conclus
result
show
first
case
associ
erm
b
tet
gene
uniqu
mosaic
structur
agalactia
probabl
plasmid
demonstr
ceuiassay
studi
go
characteris
entir
genet
element
carri
resist
gene
improv
influenza
preanalyt
collect
system
altern
collect
system
inactiv
preserv
extract
influenza
rapid
test
k
luinstra
ackerman
petrich
smieja
brescia
hamilton
ca
object
studi
altern
influenza
sampl
collect
system
evalu
potenti
use
pandem
situat
object
develop
nontemperatur
depend
swab
collect
transport
system
inactiv
influenza
viru
infect
preserv
cell
morpholog
nucleic
acid
na
detect
suspect
influenza
infect
andor
system
compat
direct
na
test
without
need
purif
prior
detect
rapid
realtim
rtpcr
method
flock
nasopharyng
swab
np
collect
utm
u
compar
np
collect
cymol
c
mswab
dri
flock
swab
collect
system
copan
italia
cymol
alcoholbas
medium
preserv
cell
dfa
test
mswab
contain
ul
medium
ul
glass
bead
requir
na
purif
step
shell
vial
cultur
use
assess
influenza
viru
inactiv
minut
exposur
collect
media
mockinfect
influenza
viru
sampl
absorb
duplic
swab
place
collect
system
infect
collect
media
held
rt
minut
inocul
duplic
shell
vial
cultur
stain
hour
influenza
stabil
na
recoveri
mock
infect
collect
system
assess
day
room
temperatur
rt
aliquot
infect
collect
media
extract
easymag
ul
purifi
na
test
quantit
influenza
rtpcr
roch
lightcycl
mswab
collect
sampl
also
test
directli
boil
without
na
purif
result
shell
vial
cultur
found
influenza
viru
inactiv
minut
exposur
c
medium
expos
u
media
influenza
detect
dfa
u
c
cell
smear
quantit
influenza
rna
constant
u
c
collect
system
rt
quantiti
rna
recov
declin
significantli
collect
system
boil
yield
data
compar
easymag
extract
copan
cymol
medium
inactiv
influenza
infect
preserv
cell
stabilis
rna
day
rt
cymol
medium
potenti
altern
safe
sampl
collect
pandem
influenza
situat
mswab
present
rapid
test
altern
luminex
respiratori
viral
panel
respiratori
specimen
children
r
selvaraju
baker
k
est
l
hay
abel
hiraki
kansa
citi
us
object
luminex
respiratori
viral
panel
rvp
multiplex
pcr
capabl
detect
differenti
twelv
differ
respiratori
virus
subtyp
influenza
flu
subtyp
influenza
b
flu
b
respiratori
syncyti
viru
rsv
subtyp
b
adenoviru
adv
parainfluenza
piv
parainfluenza
piv
parainfluenza
piv
human
metapneumoviru
hmpv
rhinoviru
rhv
aim
studi
evalu
analyt
perform
characterist
rvp
assay
evalu
abil
detect
respiratori
virus
nasopharyng
aspir
obtain
children
method
analyt
sensit
specif
accuraci
precis
luminex
rvp
assay
determin
use
control
viral
stock
respiratori
specimen
previous
test
rmix
shell
vial
cultur
result
luminex
rvp
assay
reliabl
detect
atcc
viral
stock
flu
flu
b
rsvb
rhv
rang
cross
reactiv
note
cmv
hsv
ebv
vzv
cornoaviru
among
respiratori
specimen
previous
characteris
cultur
specimen
accur
detect
overal
accuraci
median
coeffici
variat
mean
fluoresc
index
valu
signal
replic
analys
influenza
b
rsv
clinic
specimen
test
rvp
assay
includ
cultur
posit
cultur
neg
specimen
respiratori
virus
isol
cultur
posit
specimen
includ
follow
adv
flu
flu
b
rsv
hmpv
rhv
rvp
assay
detect
respiratori
virus
except
one
rsv
viru
overal
sensit
rang
differ
respiratori
viral
group
among
cultur
neg
specimen
respiratori
virus
detect
rvp
subsequ
confirm
repeat
analys
conclus
luminex
rvp
assay
highli
sensit
specif
test
use
detect
commonli
encount
respiratori
virus
respiratori
specimen
addit
rvp
assay
viral
test
algorithm
respiratori
infect
children
provid
rapid
result
improv
diagnost
yield
may
result
decreas
antibiot
usag
reduc
diagnost
test
reduc
hospit
stay
savvala
daniil
berberid
koutsibiri
stambolidi
papachristodoul
n
spanaki
tsakri
athen
gr
object
develop
countri
virus
particularli
norovirus
recogn
lead
caus
acut
gastroenter
determin
aetiolog
preval
season
distribut
viral
gastrointestin
infect
hospitalis
patient
acut
diarrhoea
method
oneyear
period
novemb
total
faecal
specimen
collect
children
prematur
neonat
adult
hospitalis
symptom
sign
acut
gastroenter
stool
sampl
test
presenc
rotaviru
adenoviru
astroviru
noroviru
rotaviru
adenoviru
astroviru
antigen
detect
perform
chromatograph
immunoassay
rotaviru
adenoviru
vikia
biomerieux
franc
h
r
astrovirusveg
farmaceutica
spain
norovirus
detect
enzym
immunoassay
ridascreen
rbiopharm
germani
confirm
revers
transcriptionpcr
data
analyz
season
infect
possibl
transmiss
mode
overal
incid
viral
identif
acut
diarrhoeal
stool
patient
fifti
one
viral
antigen
detect
one
patient
posit
antigen
detect
suffer
diseas
unclear
aetiolog
associ
replic
diseas
might
consid
contrast
patient
show
symptom
time
antigen
detect
patient
show
special
mode
acquisit
bmt
possibl
result
differ
immunolog
prime
respons
addit
latter
patient
restrict
blood
cell
two
patient
show
antigen
express
unclear
transcript
translat
viral
gene
influenc
furthermor
pathophysiolog
impact
viral
replic
individu
object
sever
case
studi
report
meningoenceph
caus
primari
epsteinbarr
viru
ebv
infect
aim
investig
viral
load
inflammatori
characterist
thu
far
poorli
defin
diseas
entiti
evalu
case
ebv
polymeras
chain
reaction
test
pcr
request
cerebro
spinal
fluid
csf
sampl
primari
infect
defin
clinic
present
sore
throatpharyngitismalais
combin
lymphocytosi
detect
heterophil
antibodi
posit
ebv
igm
antibodi
patient
proven
neuroborreliosi
serv
control
group
leukocyt
respons
ebv
viral
load
csf
serum
compar
primari
ebv
neuroborreliosi
case
result
identifi
six
case
primari
ebv
infect
median
age
male
neurolog
symptom
rang
mening
sign
enceph
compar
patient
neuroborreliosi
median
age
male
four
six
patient
primari
ebv
infect
neurolog
symptom
ebv
dna
detect
csf
serum
wherea
neuroborreliosi
case
ebv
pcr
neg
compart
viral
load
lower
csf
compar
serum
blood
leukocyt
lymphocyt
monocyt
count
significantli
increas
compar
neuroborreliosi
case
see
tabl
specif
gene
use
pool
g
p
type
specif
primer
strain
typeabl
gene
purif
qiaquick
gel
extract
kit
qiagen
germani
first
amplicon
borva
strain
subject
sequenc
analysi
autom
sequenc
abi
xl
dna
analyz
appli
biosystem
usa
phylogenet
analysi
perform
use
mega
version
object
dengu
flaviviru
among
widelyspread
viral
diseas
previou
report
demonstr
exist
live
dengu
viru
blood
urin
even
convalesc
postfebril
period
case
excret
patient
urin
detect
late
day
onset
ill
goe
along
model
west
nile
viru
anoth
type
flaviviru
excret
urin
month
acut
infect
anim
studi
human
case
report
report
pilot
studi
address
magnitud
find
method
april
octob
paediatr
adult
febril
patient
suspect
dengu
infect
enrol
diagnosi
dengu
base
standard
specif
serolog
pair
sera
patient
neg
serolog
serv
control
blood
urin
specimen
collect
sever
time
point
whole
blood
separ
plasma
peripher
blood
mononuclear
cell
pbmc
aliquot
use
earlier
studi
store
freezer
avail
plasma
pbmc
urin
process
inocul
aed
aegypti
surviv
mosquito
day
inocul
employ
viral
detect
denguespecif
rtpcr
indirect
fluoresc
antibodi
ifa
stain
mosquito
head
perform
posit
rtpcr
specimen
except
one
pbmc
await
ifa
result
result
case
primari
secondari
infect
respect
neg
control
includ
translat
earli
late
dengu
specimen
earli
late
negativecontrol
counterpart
respect
dengu
viru
isol
blood
urin
specimen
late
day
onset
ill
viru
isol
control
specimen
posit
rtpcr
specimen
also
demonstr
posit
ifa
neg
earlyphas
specimen
conclus
studi
demonstr
prolong
surviv
dengu
viru
clinic
recoveri
find
patholog
epidemiolog
signific
ad
potenti
role
urin
transmiss
diseas
spread
viru
human
might
occur
infecti
urin
help
arthropod
vector
research
could
provid
new
insight
understand
pathogenesi
denv
infect
isol
dengu
viru
blood
urin
specimen
earli
day
onset
ill
late
day
phase
infect
specimen
dengu
isolatedtot
specimen
mosquito
inocul
earli
phase
late
phase
plasma
pbmc
perform
urin
specimen
